PO001

Assessing the Impact of Factor IX Pharmacokinetics on Hemophilia B: A Comparative Study of Measurement Methods

B. Koc[1,*], F. Aydın[2], G. Gunver[3], B. Zulfikar[1]
[1]Hereditary Bleeding Disorders Unit, Istanbul University Oncology Institu, [2] Department of Medical Biochemistry, [3]Department of Biostatistics, Istanbul University Istanbul Medical Faculty, Istanbul, Türkiye

PO002

Intrinsic Activated Thrombin Generation for Efficacy and Monitoring of Factor VIII Replacements and Mimetics

E. Urlings[1,2], R. Van Oerle[1,3], F. Heubel-Moenen[4,*], D. Hellenbrand[2], A. Monard[2], P. Van der Meijden[1], T. Hackeng[1,3], H. Ten Cate[1,3], Y. Henskens[2], H. Spronk[1,3]
[1]Biochemistry, Maastricht University, [2]Central Diagnostic Laboratory, Maastricht University Medical Center, [3]Coagulation Profile B.V., [4]Department of Hematology, Maastricht University Medical Center, Maastricht, Netherlands

PO003

APTT Mixing Studies-Pilot survey: Results and analysis from the UK NEQAS BC Haemophilia programmes 2024

A. Williams[1,*], C. Reilly-Stitt[1], S. Kitchen[1], I. Jennings[1], W. Lester[2]
[1]UK NEQAS BC, Sheffield, [2]University Hospitals Birmingham, Birmingham, United Kingdom

PO004

NEQAS BC and ECAT collaborative exercise with Efanesoctocog alfa spiked plasma for FVIIIC testing by One Stage and Chromogenic assays.

C. Reilly-Stitt[1,*], I. Jennings[1], A. Williams[1], P. Meijer[2], A. Bowyer[3], S. Kitchen[1]
[1]NEQAS BC, Sheffield, United Kingdom, [2]ECAT, Voorschoten, Netherlands, [3]Royal Hallamshire Hospital, Sheffield, United Kingdom

PO005

Ex vivo Comparison of Mim8 Combined with Activated Factor XI Versus Tissue Factor in Thrombin Generation Assays

W. H. Ong Clausen[1], T. Latendorf[2], R. Stehr[2], D. Bausch-Fluck[3,*], J. Lund[4]
[1]Biostatistics, Novo Nordisk, Søborg, Denmark, [2]Laboratorium für Klinische Forschung (LKF) GmbH, Kiel, Germany, [3]Global Medical Affairs, Novo Nordisk, Zurich, Switzerland, [4]4 Global Drug Discovery, Novo Nordisk, Søborg, Denmark

PO006

Access to Fidanacogene Elaparvovec: Hemophilia B Gene Therapy Directed by a First-in-Class Companion Diagnostic

P. Patel[1], J. Sperinde[2], M. Díaz-Muñoz[3,*], O. Glass[1], L. J. Wilcox[4], S. des Etages-Wong[5], C. J. Petropoulos[2]
[1]Pfizer Inc, New York, NY, [2]Labcorp-Monogram Biosciences, South San Francisco, CA, United States, [3]Pfizer Inc, Madrid, Spain, [4]Pfizer Inc, Toronto, Canada, [5]Pfizer Inc, Groton, CT, United States

PO007

nAbCyte Anti-AAVRh74var HB-FE Assay for Detection of Neutralizing Antibodies to Adeno-Associated Virus: Clinical Validation

F. Plonski[1], K. A. Fader[2], D. Agathon[3], G. Wilson[4], P. Sun[5], L. J. Wilcox[6], M. Díaz-Muñoz[7,*], J. Sperinde[8], W. Huang[8], L. Corral[8], A. Wakeel[8], C. J. Petropoulos[8], S. des Etages-Wong[2]
[1]Pfizer Inc, Collegeville, PA, [2]Pfizer Inc, Groton, CT, United States, [3]Pfizer Inc, Paris, France, [4]Pfizer Inc, New York, NY, [5]Pfizer Inc, Cambridge, MA, United States, [6]Pfizer Inc, Toronto, ON, Canada, [7]Pfizer Inc, Madrid, Spain, [8]Labcorp-Monogram, South San Francisco, CA, United States

PO008

Current coagulation testing in hemophilia A and perceived usefulness of the EnzySystem

A. Bavinck[1,2,*], K. Davis[3], L. van Engelshoven[2], A. Sijbers[2], T. Hamacher[4], M. van Lier[4], A. Shapiro[3], S. Schols[1,5], W. van Heerde[2,5]
[1]Department of Hematology, Radboudumc, [2]Enzyre, Nijmegen, Netherlands, [3]Indiana Hemophilia & Thrombosis Center, Indianapolis, United States, [4]Holland Innovative, Eindhoven, [5]Hemophilia Treatment Center Nijmegen-Eindhoven-Maastricht, Nijmegen, Netherlands

PO009

Resolution at nucleotide level of an abnormal pattern of intron 22 inversion using nanopore sequencing in a patient with severe haemophilia A

Y. Jourdy[1], N. Chatron[2], M. Fretigny[1,*], A. Labalme[2], Q. testard[3], D. Sanlaville[2], C. vinciguerra[1]
[1]Service d'hématologie Biologique, [2]Service de génétique, [3]Service Bioinformatique, Hospices Civils de Lyon, BRON, France

PO010

Accurate evaluation of factor VIII activity of efanesoctocog alfa in the presence of emicizumab

C. Nougier[1], S. Pipe[2], I. Pabinger[3], C. Pouplard[4], R. Schutgens[5], C. Hermans[6], G. Young[7], E. Sexton[2], P. Quehenberger[3], A. Guery[4], A. Huisman[5], M. A. Van Dievoet[6], E. Marquez[7], Y. Dargaud[1,*]
[1]French Reference Center for Hemophilia, Lyon University Hospitals, Lyon, France, [2]Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor Michigan, United States, [3]Hematology and Hemostaseology, Department , Medical University of Vienna, Vienna, Austria, [4]Department of Haemostasis, University Hospital of Tours, Tours, France, [5]Center for Benign Haematology,, Van Creveldkliniek, University Medical Center , Utrecht, Netherlands, [6]Hematology, Saint-Luc University Hospital, Catholic University of Louvain, Brussels, Belgium, [7]Hemostasis and Thrombosis Center, Children's Hospital Los Angeles, Los Angeles, United States

PO011

A rare case of hemophilia A in a female with X chromosome mosaicism

O. Pshenichnikova[1,*], V. Salomashkina[1], O. Yastrubinetskaya[1], V. Surin [1], O. Mishina[1], G. Alimova [1], T. Obukhova[1], N. Zozulya[1]
[1]National Medical Research Center for Hematology, Moscow, Russian Federation

PO012

Neutralizing anti-drug antibodies against emicizumab in severe hemophilia A – preliminary results of a single center study

L. Van Stam[1,*], M. van der Beijlevelt[1], M. Coppens[2], N. van Es[2], K. Fijnvandraat[1,3], W. F. Kopatz[4], J. C. Meijers[4], B. Pezeshkpoor[5], S. C. Gouw[1]
[1]Department of Pediatric Hematology, [2]Department of Vascular Medicine, Amsterdam UMC location University of Amsterdam, [3]Department of Molecular Cellular Hemostasis, Sanquin Research and Landsteiner Laboratory,

[4]Department of Experimental Vascular Medicine, Amsterdam UMC location University of Amsterdam, Amsterdam, Netherlands, [5]Medical Faculty, University of Bonn, Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Bonn, Germany

PO013

Procoagulant platelets: A potential compensatory mechanism in hemophilia A and its impact on bleeding severity in patients with hemophilia A

K. Althaus[1,2,*], A. Bäuerle[1], S. Kieninger[1], S. Hammer[1,2], S. Halimeh[3], T. Bakchoul[1,2]
[1]Institute for Clinical and Experimental Transfusion Medicine , [2]Center for Clinical Transfusion Medicine, Universitity Hospital Tuebingen, Tuebingen, [3]Gerinnungszentrum Rhein Ruhr, Duisburg, Germany

PO014

In vitro adsorption of direct oral anticoagulants from patient plasma samples

M. Pikta[1,2,*], L. Örd[3], T. Titova[1], M. Viigimaa[2,4], K. Krause[5], L. J. Mettis[6], V. Banys[7]
[1] Department of Laboratory Medicine, North Estonia Medical Centre, [2]Department of Health Technologies, Tallinn University of Technology, [3]Department of Emergency Medicine, [4]Department of Cardiology, North Estonia Medical Centre, [5]Mediq Eesti OÜ, [6]Department of Hematology, North Estonia Medical Centre, Tallinn, Estonia, [7]JSC Medicina practica laboratorija, Vilnius, Lithuania

PO015

Diagnosis of assay discrepancy in mild haemophilia A using chromogenic FVIII:C with extended incubation time

A. Bowyer[1,*], V. Uppal[1], F. Shepherd[1], S. Guy[1], S. Kitchen[1]
[1]Coagulation, Sheffield Teaching Hospitals, Sheffield, United Kingdom

PO016

High-quality standardised ELISA to manage dose adjustments during concizumab prophylaxis in patients with haemophilia A/B with and without inhibitors in the routine clinical setting: Test access model description

N. Shridhar[1,*], M. Conway[2], P. FitzGerald[2], J. Gjørret[3], C. Huguet[2], T. Porstmann[4], C. Ruzanski[3], C. Fortugno[2]
[1]Novo Nordisk Service Centre India Private Ltd, Bangalore, India, [2]Randox Laboratories Ltd., Crumlin, United Kingdom, [3]Novo Nordisk, Søborg, Denmark, [4]Novo Nordisk Health Care AG, Zurich, Switzerland

PO017

Lipoprotein (a) in hemophilia A and B patients

T. Helin[1,2,*], T. Szanto[3], A.-E. Lehtinen[3], R. Lassila[3,4]
[1]Coagulation Laboratory, Clinical Chemistry, HUS Diagnostic Center, Helsinki University Hospital, [2]University of Helsinki, [3]Coagulation Disorders Unit, Helsinki University Hospital, [4]ONCOSYS Systems Oncology, University of Helsinki, Helsinki, Finland

PO018

Progress and Challenges in Hemophilia Management at BDTH-KASU Hemophilia Treatment Center, Kaduna

L. G. Dogara[1,*], M. S. Stephen[1], G. Y. Bahago[1], F. Ibrahim[1], M. Foluke-Achi[1], J. N. Mahlangu[2]
[1]Haematology, Barau Dikko Teaching Hospital (BDTH) - Kaduna State University (KASU), Kaduna, Nigeria, [2]Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand and NHLS, Johannesburg, South Africa

PO019

Relationship between mutations in severe hemophilia A and risk of inhibitor development: A large single-center study

A. Ahmadfard Moghadam[1], A. R. Manafzadeh[2,*], M. R. Nikoonia[3], S. S. Moazezi[3], D. Bashash[1], F. Ramezan[3], M. Hamidpour[4], S. Tabibian[5]
[1]1. Department of Hematology and Blood Banking, Shahid Beheshti University of Medical Science , Tehran , Iran, Islamic Republic Of, [2]2. Department of Internal Medicine, Albert Szent-Györgyi Health Centre, University of Szeged, Szeged, Hungary, [3]Blood and Viral Research Center, Iranian Comprehensive Hemophilia Care Center, Iran University of Medical Sciences (IUMS), [4]Department of Hematology and Blood Banking, Shahid Beheshti University of Medical Science , [5]Blood Diseases Research Center, Iranian Comprehensive Hemophilia Care Center, Iran University of Medical Sciences (IUMS), Tehran , Iran, Islamic Republic Of

PO020

Pharmacokinetically guided dose adjustment of anti -haemophilic prophylaxis in Pediatric Population with sever and mild Haemophilia A

I. LAROUS[1], M. MESSASSET[2,*]
[1]LABORATORY, [2] PEDIATRIC CENTRE, UHC, Setif, Algeria

PO021

Prevalence of factor VIII and IX inhibitors in Pediatric Population with Haemophilia A and B in Eastern Algeria

I. LAROUS[1], M. MESSASSET[2,*]
[1]LABORATORY OF THE PEDIATRIC CENTRE, [2]THE PEDIATRIC CENTRE, UHC, SETIF, Algeria

PO022

nAbCyte Anti-AAVRh74var HB-FE Assay for Detection of Neutralizing Antibodies to Adeno-Associated Virus: Analytical Validation

J. Sperinde[1], T. Wrin[1], B. Milne-Davies[1], M. Takeda[1], W. Zhang[1], L. Corral[1], W. Huang[1], F. Plonski[2], K. A. Fader[3], D. Agathon[4], G. Wilson[5], M. Díaz-Muñoz[6,*], L. J. Wilcox[7], S. des Etages-Wong[3], C. J. Petropoulos[1]
[1]Labcorp-Monogram Biosciences, South San Francisco, CA, [2]Pfizer Inc, Collegeville, PA, [3]Pfizer Inc, Groton, CT, United States, [4]Pfizer Inc, Paris, France, [5]Pfizer Inc, New York, NY, United States, [6]Pfizer Inc, Madrid, Spain, [7]Pfizer Inc, Toronto, ON, Canada

PO023

Pharmacokinetic evaluation of extended half-life versus standard half-life factor VIII: Real-life conditions

Y. Toloza[1], A. Escobar[1], I. Perdomo[2], S. Prasca[1], M. Castillo[3], S. Garces[2], C. Becerra[1], J. Donado[1], N. Duque-Zapata[1], S. Parra[1], A. F. Escobar Gonzalez[4,*]
[1]Antioquia, Medicarte, Medellin, [2]Cundinamarca, Medicarte, Bogota, [3]Atlantico, Medicarte, Barranquilla, [4]Pediatric Hematology, Medicarte, Medellin, Colombia

PO024

D-dimers levels in patients with haemophilia A and B

B. Tardy[1,2,3,*], A. Montmartin[3], P. Noyel[4], C. Legendre[4], A. Boban[5]
[1]Centre de Ressources et de Comptétentes Hémophilie et Maladies Hémorragiques , [2]CIC1408, Centre Hospitalier Universitaire de Saint-Etienne, [3]Sainbiose DVH Hemostase U1059, Université Jean Monnet, [4]Laboratoire biologie hémostase, Centre Hospitalier Universitaire de Saint-Etienne, Saint-Etienne, France, [5]Department of Hematology, University Hospital Center Zagreb, School of Medicine, University of Zagreb, Zagreb, Zagreb, Croatia

PO025

Natural history of AAV5 neutralising antibodies in adults with haemophilia B during ≥6-month screening and lead-in to the HOPE-B trial with etranacogene dezaparvovec gene therapy

R. Klamroth[1,*], M. Recht[2], N. Key[3], W. Miesbach[4], S. W. Pipe[5], P. van der Valk[6], R. Kaczmarek[7], D. Drelich[8], N. Galante[8], S. LeQuellec[9], P. E. Monahan[8], B. Salazar[8], J. M. Tarrant[8]
[1]Vivantes Klinikum, Berlin, Germany, [2]Yale University School of Medicine, New Haven, CT, [3]UNC Blood Research Center and Department of Medicine, Chapel Hill, NC, United States, [4]University Hospital Frankfurt, Frankfurt, Germany, [5]University of Michigan, Ann Arbor, MI, United States, [6]Center for Benign Haematology, Thrombosis and Haemostasis, University Medical Center Utrecht, University Utrecht, Van Creveldkliniek, Utrecht, Netherlands, [7]IU School of Medicine, Indianapolis, IN, [8]CSL Behring, King of Prussia, PA, United States, [9]CSL Behring Europe, Hattersheim am Main, Germany

PO026

PROSPECTIVE VIEW OF EMICIZUMAB TREATMENT ACCORDING THROMBIN GENERATION TIME

N. Vilalta[1,*], M. Triquell[1], D. Llobet[1], M. Simón[1], N. Cerdà[1], M. Carrasco[1], J. Mateo[1]
[1]Hemostasis and Thrombosis Unit , Hospital de la Santa Creu i Sant Pau, Barcelona , Spain

PO028

Role of Factor VIII in Promoting Endothelial Cell Function and Membrane Stability

C. Olgasi[1], A. Cucci[1], S. Assanelli[1], C. Sgromo[1], C. Borsotti[1], G. Venturin[2], S. Winge[3], R. Santi[4], A. Follenzi[1,5,*]
[1]Department of Translational Medicine, [2]Department of Health Sciences, University of Piemonte Orientale, Novara, Italy, [3]Octapharma AB, Stockholm, Sweden, [4]Dipartimento Attività Integrate Ricerca Innovazione, Azienda Ospedaliera SS. Antonio e Biagio e C. Arrigo,, [5]Dipartimento Attività Integrate Ricerca Innovazione, Azienda Ospedaliera SS. Antonio e Biagio e C. Arrigo, SSD Medicina Traslazionale, Alessandria, Italy

PO029

Role of factor VIII in the regulation of endothelial cell function and extracellular matrix protein expression

C. Olgasi[1], A. Cucci[2], I. Molineris[3,4], S. Assanelli[2], C. Borsotti[2], C. Sgromo[2], A. Lauria[3,4], M. Manfredi[1], S. Oliviero[3,4], A. Follenzi[2,5,*]
[1]Department of Translational Medicine, [2]Department of Health Sciences, Università del Piemonte Orientale, Novara, [3]Università degli Studi di Torino, Torino, [4]Italian Institute for Genomic Medicine (IIGM), Candiolo, [5]Dipartimento Attività Integrate Ricerca Innovazione, Azienda Ospedaliera SS. Antonio e Biagio e C. Arrigo, SSD Medicina Traslazionale, Alessandria, Italy

PO030

Impact of variable recombinant factor VIII binding on platelet functions

A. Strebel[1], F. A. Pennacchio[1,*], S. Lickert[1], R. Klamroth[2], V. Vogel[1]
[1]Department of Health Sciences and Technology, Laboratory of Applied Mechanobiology, Zurich, Switzerland, [2]Vivantes Klinikum im Friedrichshain, Zentrum für Hämophilie und Hämostaseologie, Berlin, Germany

PO031

Characterization of a F8-/-IgH-/- double knockout mouse model of hemophilia A for long-term exposure to factor VIII products

L. Monica[1,2,*], O. Oleshko[1], A. Klingberg[1], B. Haarmeijer[1], D. Varnholt[1], S. Wuschko[3], H. Paul[3], L. Aires[4], J. Füner[2], N. Franke[2], P. Schauerte[5], D. Starberg Jespersen[6], L. Belyanskaya[4], A. Tiede[1], S. Werwitzke[1]
[1]Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, [2]preclinics GmbH, Potsdam, Germany, [3]Octapharma Pharmazeutika Produktionsges.m.b.H., Vienna, Austria,

[4]Octapharma AG, Lachen, Switzerland, [5]Taconic Biosciences GmbH, Leverkusen, Germany, [6]Taconic Biosciences A/S, Lille Skensved, Denmark

PO032

Preclinical development of NVG-444, a first-in-class next-generation FVIII mimetic antibody with Autoregulation for improved efficacy and safety

J.-P. Bukowski[1], D. Fernando[1], A. Baccaro[1], P. Henne[1], S. Anand[1], Z. Yan[1], K. O'Donovan[1], D. Granger[1], A. C. Nathwani[1,2,3], V. Muczynski[1,2,*]
[1]NovalGen Ltd, [2]Cancer Institute , University College London , [3]Katharine Dormandy Haemophilia and Thrombosis Unit , Royal Free London NHS Foundation Trust, London, United Kingdom

PO033

In Vitro Effects of Mim8 and Combined Mim8-Bypassing Therapy on Thrombin Generation, Thromboelastography and Fibrin Clot Ultrastructure

L. Josset[1], H. Rezigue[1], J. Lund[2], Y. Dargaud[1,*]
[1]UR4609 Hemostasis & Thrombosis, University of Lyon 1, Lyon, France, [2]Rare Disease Research, Research & Early Development, NovoNordisk A/S, Maaloev, Denmark

PO034

THE ROLE OF miRNA IN MODULATING PHENOTYPIC VARIABILITY IN PATIENTS SHARING THE SAME F8 GENE VARIANT

I. Garagiola[1,*], A. Cairo[1], M. Mortarino[1], H. E. Torghabehei[1], C. Suffritti[1], R. Gualtierotti[2], L. D. Notarangelo[3], F. Peyvandi[2]
[1]Angelo Bianchi Bonomi Haemophilia and Thrombosis Center and Fondazione Luigi Villa, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico , [2]Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, [3]Medical Direction, Children's Hospital, ASST-Spedali Civili, Brescia, Italy

PO035

Efficacy and safety of concizumab prophylaxis in patients with haemophilia and inhibitors: Results from the Early Access Program in France

A. Butelet[1,*], N. Béranger[2], V. Cussac[2], R. d'Oiron[3,4,5,6], Y. Dargaud[5,7], V. Delerue[2], S. Desage[5], C. Galeotti[3], S. Susen[8], V. Chamouard[4,5]
[1]Center for Constitutional Bleeding Disorders, Reims University Hospital, Reims, [2]Novo Nordisk, [3]Reference Centre for Haemophilia and Rare Bleeding Disorders, Hôpital Bicêtre AP-HP Université Paris-Saclay, Paris, [4]Haemostasis and Thrombosis Department, University Lyon 1, [5]National Coordination Centre for French Haemophilia Reference Centres, Lyon, [6]INSERM Hémostase Inflammation Thrombose HITH U1176, Université Paris-Saclay, Paris, [7]University Lyon 1, Lyon, [8]Hemostasis and Transfusion Department and French Network for Rare Bleeding Disorders, Lille University Hospital, Lille, France

PO036

Spinal Stenosis: An Emerging Complication of Aging in People with Haemophilia

C. Kelly[1,2,*], M. Mc Gowan[1,3], N. Larkin[1], J. M. Mc Donnell[4,5], M. Byrne[1], C. Bergin[1], Á. O' Gara[6], K. Ryan[1], M. O' Donovan[1], N. O' Connell[1], K. Synnott[4], J. S. Butler[4,7], S. Darwish[4], B. O' Mahony[8], M. Kennedy[9], P. L. Turecek[10], J. S. O' Donnell[1,2], J. Gormley[9], M. Lavin[1,2]
[1]National Coagulation Centre, St James Hospital, [2]Irish Centre for Vascular Biology, School of Pharmacy & Biomedical Sciences, Royal College of Surgeons Ireland, [3]Department of Physiotherapy, St James Hospital, [4]National Spinal Injuries Unit, Department of Trauma and Orthopaedic Surgery, Mater Misericordiae University Hospital, [5]Royal College of Surgeons Ireland, [6]Department of Anaesthetics, St James Hospital, [7]School of

Medicine, University College Dublin, [8]Cathedral Court, Irish Haemophilia Society, [9]Discipline of Physiotherapy, School of Medicine, Trinity College Dublin, The University of Dublin, Dublin, Ireland, [10]A Takeda Company, Baxalta Innovations GmbH, Vienna, Austria

PO037

Four-year results of etranacogene dezaparvovec in haemophilia B patients with pre-existing AAV5 neutralising antibodies: Phase 3 HOPE-B trial

R. Klamroth[1,*], P. Van der Valk[2], D. Quon[3], R. S. Kazmi[4], F. Wang[5], S. Le Quellec[5], P. E. Monahan[5], C. Hermans[6]
[1]Internal Medicine, Vascular Medicine and Coagulation Disorders, Vivantes Clinic Friedrichshain, Berlin, Germany, [2]Centre for Benign Haematology, Thrombosis and Haemostasis, Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands, [3]The Luskin Orthopedic Institute for Children, Los Angeles, United States, [4]University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, [5]CSL Behring, King of Prussia, United States, [6]Cliniques Universitaires Saint-Luc, Brussels, Belgium

PO038

PedNet real world experience of emicizumab prophylaxis started in PUPs and MTPs (<1 year old) with severe hemophilia A

G. Kenet[1], K. Fischer[2,3], J. Motawani[4], N. G. Andersson[5,6,7], J. Blatny[8], G. Castaman[9], M. Carcao[10], C. Escuriola-Ettingshausen[11], C. Konigs[12], M. de Kovel[3,*], B. Nolan[13], M. Olivieri[14], C. Oudot[15], H. Pergantou[16], S. Ranta,[17] on behalf of PedNet Haemophilia Research Foundation, Baarn, The Netherlands
[1]National Hemophilia Center, Sheba Medical Center, Ramat Gan, Israel, [2]Center for Benign Haematology, Thrombosis and Haemostasis, University Medical Center Utrecht, Utrecht, [3]PedNetHaemophilia Research Foundation, Baarn, Netherlands, [4]Haematology, Birmingham Children's Hospital, Birmingham, United Kingdom, [5]Center for Thrombosis and Haemostasis, Skane University Hospital, Malmo, [6]Paediatric Haematologu and Oncology, Skane University Hospital, [7]Clinical Sciences and Paediatrics, Lund University, Lund, Sweden, [8]Paediatric Haematology and Biochemisty, Children's University Hospital and Masaryk University, Brno, Czech Republic, [9]Oncology, Careggi University Hospital, Florence, Italy, [10]division of Haematology/Oncology, The Hospital for Sick children and University of Toronto, Toronto, Canada, [11]Hamophilie, HZRM, [12]Paediatrics and Adolescent Medicine, Clinical and Molecular Haemostasis, University Hospital Frankfurt, Frankfurt, Germany, [13]Paediatric Haematology, Our Lady's Children's Hospital for Sick Children, Dublin, Ireland, [14]Paediatric Thrombosis and haemostasis Unit, Paediatric Haemophilia Center, Dr. von Hauner children's Hospital, Munich, Germany, [15]Centre regional d'Hemophilie, Centre Hospitalo Universitaire de Toulouse, Toulouse Cedex, France, [16]Haemophilia Centre for children/Haemostasis and Thrombosis Unit, Aghia Sophia Children's Hospital, Athens, Greece, [17]Pediatric Coagulation Unit, Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden

PO039

Circulating miRNA Landscape in Hemophilic Arthropathy: Distinguishing Disease Conditions and Identifying Potential Biomarkers

R. Gualtierotti[1,2,*], A. Cairo[2], C. Suffritti[2], S. Spena[2], H. Eidgah Torghabehei [2], A. Giachi[1], S. Mascetti[3], F. Peyvandi[1,2]
[1]Department of Pathophysiology and Transplantation, Università degli Studi di Milano, [2]Angelo Bianchi Bonomi Haemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico , [3]Department of Computer Science Giovanni Degli Antoni, Università degli Studi di Milano, Milan, Italy

PO040

Four-year results of etranacogene dezaparvovec in haemophilia B patients without AAV5 neutralising antibodies: Phase 3 HOPE-B trial

P. Raheja[1,*], N. O'Connell[2], P. Verhamme[3], P. Kampmann[4], R. S. Lemons[5], F. Wang[6], P. E. Monahan[6], S. Le Quellec[6], F. W. G. Leebeek[7]

[1]The Royal London Hospital Haemophilia Centre, Bart Health NHS Trust, London, United Kingdom, [2]National Coagulation Centre, St James's Hospital, Dublin, Ireland, [3]University Hospitals Leuven, Leuven, Belgium, [4]Rigshospitalet, Copenhagen, Denmark, [5]University of Utah, Salt Lake City, [6]CSL Behring, King of Prussia, United States, [7]Department of Haematology, Erasmus University Medical Center-Erasmus MC, Rotterdam, Netherlands

PO041

Growing up with N9-GP: Safety and efficacy of prophylaxis for up to eleven years in children with haemophilia B

M. Carcao[1,*], K. Walsh[2], C. Mrakotsky[3], A. Landorph[4], A. KC Chan[5]

[1]Division of Haematology/Oncology, Department of Paediatrics, The Hospital for Sick Children, Toronto, Canada, [2]Center for Neuroscience and Behavioral Medicine, Children's National Hospital and the George Washington University School of Medicine and Health Sciences, Washington, DC, [3]Departments of Neurology & Psychiatry, Boston Children's Hospital, Harvard Medical School, Boston, United States, [4]Novo Nordisk A/S, Copenhagen, Denmark, [5]Department of Paediatrics, McMaster Centre for Transfusion Research, McMaster Children's Hospital, McMaster University, Hamilton, Canada

PO042

Evaluation of the risk factor for developing cardiovascular diseases in adult Japanese hemophiliacs

Y. Chikasawa[1,*], H. Kosuge[2], M. Yoshimura[3], M. Ishikura[1], R. Miyashita[1], T. Yamaguchi[1], A. Ichiki[1], M. Bingo[1], T. Muramatsu[1], M. Yotsumoto[1], T. Hagiwara[1], K. Amano[1], T. Sato[4], Y. Araki[3], E. Arizono[3], S. Shimizu[4], S. Hida[2], K. Satomi[2], E. Kinai[1]

[1]Department of Laboratory Medicine, [2]Department of Cardiology, [3]Department of Radiology, [4]Department of Geriatric Medicine, Tokyo Medical University, Tokyo, Japan

PO043

Five-Year Follow-up of the Phase 1/2 Alta Study of Giroctocogene Fitelparvovec in Adults With Severe Hemophilia A

B. A. Konkle[1], A. D. Leavitt[2], N. Visweshwar[3], T. J. Harrington[4], K. Stine[5], A. Giermasz[6], D. Chiu[7], M. de los Angeles Resa[8], L.-J. Tseng[8], F. Biondo[9], D. Agathon[10,*], F. Plonski[11]

[1]Washington Center for Bleeding Disorders and the University of Washington, Seattle, WA, [2]Department of Medicine and Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, [3]Department of Hematology, University of South Florida, Tampa, FL, [4]Department of Internal Medicine and Hematology, University of Miami Miller School of Medicine, Miami, FL, [5]Department of Pediatrics, Hematology/Oncology, UAMS at Arkansas Children's Hospital, Little Rock, AR, [6]Hemophilia Treatment Center, University of California Davis, Sacramento, CA, United States, [7]Pfizer Ltd, London, United Kingdom, [8]Pfizer Inc, New York, NY, United States, [9]Pfizer Srl, Rome, Italy, [10]Pfizer Inc, Paris, France, [11]Pfizer Inc, Collegeville, PA, United States

PO044

Vector Clearance Following Administration of Giroctocogene Fitelparvovec in Adults With Hemophilia A in the Phase 3 AFFINE Trial

H. Alzahrani[1,*], K. Kavakli[2], L. Frenzel[3], Y.-S. Park[4], L.-J. Tseng[5], D. Chiu[6], F. Biondo[7], J. Smith[8], D. Agathon[9], F. Plonski[10]

[1]King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia, [2]Division of Hematology, Department of Pediatrics, Ege University Faculty of Medicine, Ege, Türkiye, [3]Department of Hematology, Hemophilia Care and Research, Necker Hospital, Institut Imagine, Paris, France, [4]Department of Pediatrics, Kyung Hee University College of Medicine, Kyung Hee University Hospital at Gangdong, Seoul, Korea, Republic Of, [5]Pfizer Inc, New York, NY, United States, [6]Pfizer Ltd, London, United Kingdom, [7]Pfizer Srl, Rome, Italy, [8]Pfizer Inc, Groton, CT, United States, [9]Pfizer Inc, Paris, France, [10]Pfizer Inc, Collegeville, PA, United States

PO045

Bleed Protection After Giroctocogene Fitelparvovec Infusion in Adults With Moderately Severe to Severe Hemophilia A in the Phase 3 AFFINE Trial

M. Ozelo[1,*], K. Kavakli[2], L. Frenzel[3], Y. Miyakawa[4], Y.-S. Park[5], J. Astermark[6,7], F. Sahin[8], C. Berube[9], L.-J. Tseng[10], D. Chiu[11], P. Klaus[12], J. Healy[13], F. Plonski[14], D. Agathon[15]
[1]Hemocentro UNICAMP, Department of Internal Medicine, School of Medical Sciences, University of Campinas, Campinas, Brazil, [2]Division of Hematology, Department of Pediatrics, Ege University Faculty of Medicine, Ege, Türkiye, [3]Department of Hematology, Hemophilia Care and Research, Necker Hospital, Institut Imagine, Paris, France, [4]Department of Hematology, Saitama Medical University, Saitama, Japan, [5]Department of Pediatrics, Kyung Hee University College of Medicine, Kyung Hee University Hospital at Gangdong, Seoul, Korea, Republic Of, [6]Department of Translational Medicine, Lund University, Lund, [7]Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Malmö, Sweden, [8]Ege University Medical Faculty Hospital, Izmir, Türkiye, [9]Division of Hematology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, [10]Pfizer Inc, New York, NY, United States, [11]Pfizer Ltd, London, United Kingdom, [12]Pfizer Pharma GmbH, Berlin, Germany, [13]Pfizer Canada ULC, Kirkland, QC, Canada, [14]Pfizer Inc, Collegeville, PA, United States, [15]Pfizer Inc, Paris, France

PO046

Real-world use of emicizumab in surgery: a systematic review

S. Arcudi[1,*], S. Pasca[2], F. Peyvandi[1]
[1]Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, [2]Transfusion and Immunohematology Department, Azienda Provinciale Servizi Sanitari, Trento, Italy

PO047

Patient characteristics in FREEDOM, a study evaluating physical activity and joint health in patients with haemophilia A receiving efanesoctocog alfa prophylaxis

J. Astermark[1,*], R. Berrueco[2], G. Castaman[3], S. Shapiro[4], H. Ahlin[5], J. Björkqvist[5], M. Fusser[5], P. A. Holme[6]
[1]Department of Haematology, Oncology, and Radiation Physics, Skåne University Hospital and Department of Translational Medicine, Lund University, Malmö, Sweden, [2]Paediatric Haematology Department, Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain, [3]Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, Florence, Italy, [4]Oxford University Hospitals National Health Service Foundation Trust, Oxford, United Kingdom; Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom, [5]Sobi, Stockholm, Sweden, [6]Department of Haematology, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway

PO048

Surgical and Medical Procedures in Participants With Hemophilia A or B Without Inhibitors Receiving Marstacimab in the BASIS and Open-Label Extension Trials

O. Benitez[1,*], H. K. Kim[2], C. T. Taylor[3], R. McDonald[3], B. McComb[3], P. Sun[4], A. Palladino[5]

[1]Departamento de Hematología Experimental, VHIO Vall d'Hebron Instituto de Oncología, Hospital Universitario Vall d'Hebron, Barcelona, [2]Pfizer SLU, Madrid, Spain, [3]Pfizer Inc, New York, [4]Pfizer Inc, Cambridge, [5]Pfizer Inc, Collegeville, United States

PO049

Safety and Efficacy of Mim8 Prophylaxis Once Every Two Weeks in Haemophilia A: A FRONTIER4 Interim Analysis

T. Matsushita[1], P. Chowdary[2], A. M. Banchev[3], K. Kavakli[4], J. A. Kremer Hovinga[5], J. Windyga[6], V. Jiménez-Yuste[7], J. Bovet[8], L. M. G. Fernández[9], G. Young[10,*]
[1]Nagoya University Hospital, Nagoya, Japan, [2]Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, United Kingdom, [3]Paediatric Haematology and Oncology Department, University Hospital Tsaritsa Giovanna – ISUL, Sofia, Bulgaria, [4]Department of Pediatric Hematology, Ege University Children's Hospital, Izmir, Türkiye, [5]Department of Hematology and Central Hematology Laboratory, Bern University Hospital, Bern, Switzerland, [6]Department of Hemostasis Disorders and Internal Medicine, Institute of Hematology and Transfusion Medicine, Warsaw, Poland, [7]Hospital Universitario La Paz, Universidad Autónoma de Madrid, Madrid, Spain, [8]Novo Nordisk, Paris, France, [9]Novo Nordisk, Madrid, Spain, [10]Cancer and Blood Disease Institute, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California, United States

PO050

Investigating the risk of intravenous ferric carboxymaltose (FCM)-induced hypophosphatemia in patients with inherited bleeding disorders at Sheffield Teaching Hospitals (STH).

G. Deakin[1,*], N. Hamilton[2]
[1]Haemophilia & Thrombosis Centre, [2]Clinical pharmacy, Royal Hallamshire Hospital, Sheffield, United Kingdom

PO051

RECLASSIFICATION OF HEMOPHILIA CARRIERS AND ANALYSIS OF THEIR HEMORRHAGIC PHENOTYPE: EXPERIENCE FROM A CENTER IN BRAZIL

A. L. Prezotti[1,*], D. M. do Carmo Rocha[1], J. Souza Mario Duarte[1], A. Rocha Neto[1], S. Soraya Marcondes[2], V. Correa Peixoto[1], M. do Perpetuo Socorro Vendramini Orletti[1]
[1]HEMOES, [2]HUCAM, VITORIA, Brazil

PO052

Impact of Age, Race, and Geographic Region on Efficacy Outcomes Following Gene Therapy for Hemophilia B With Fidanacogene Elaparvovec: Results From the Phase 3 BENEGENE-2 Trial

K. Kavakli[1,*], A. Cuker[2], J. McKay[3], B. Hutter[4], F. Biondo[5], P. Sun[6], J. Rupon[7], F. Plonski[7]
[1]Ege University Faculty of Medicine, Izmir, Türkiye, [2]Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, [3]Pfizer Inc, Pearl River, NY, United States, [4]Pfizer Inc, London, United Kingdom, [5]Pfizer Srl, Rome, Italy, [6]Pfizer Inc, Cambridge, MA, [7]Pfizer Inc, Collegeville, PA, United States

PO053

Assessing health related quality of life in haemophilia patients on Emicizumab in St Thomas' Hospital London

C. Cox[1,*], S. Classey[1], B. Madan[1], U. Faruqi[1], L. Neave[1], G. Dolan[1], P.-L. Luo[1]
[1]Guy's and St Thomas' NHS Trust, London, United Kingdom

PO054

A real-world study of haemophilia treatment satisfaction, bleeds, health related quality of life as reported by patients and physicians to demonstrate gaps.

S. Thakkar[1,*], V. Merla[2], L. Wilcox[3], A. Sohn[2], R. Sahar[4], C. Blazos[4], S. Lai[4], E. Morton[4], K. Wynne-Cattanach[4], N. Ball[4]
[1]Pfizer Inc, Cambridge, MA, [2]Pfizer Inc, New York, United States, [3]Pfizer Inc, Kirkland, QC, Canada, [4]Adelphi Real World, Bollington, United Kingdom

PO055

Bleeding events in children with Haemophilia A on emicizumab: a comparison between an older and a younger cohort

S. Best[1,*], B. Nolan[1,2], P. Loughnane[1], M. Kavanagh[1], I. Kelly[1], C. Ferry[1], B. Brady[1], B. Mullen[1], R. Hunter Nolan[1], S. Ahmed[1,2]
[1]Paediatric Coagulation Centre, Children's Health Ireland, [2]School of Medicine, Trinity College, Dublin, Ireland

PO056

An update on rIX-FP prophylaxis use in paediatric patients with haemophilia B: French real-world data

F. Volot[1,*], A. Harroche[2], Y. Dargaud[3], Y. Huguenin[4], A. Hassoun[5], A. Fournel[6], C. Berger[7], B. Frotscher[8], C. Oudot-Challard[9], M. Pondrom[10], H. Catovic[11], C. Martin[11], A. Rauch[12]
[1]HTC, Dijon Bourgogne University Hospital, Dijon, [2]HTC, Department of Hematology, University Hospital Necker Enfants Malades, Paris, [3]Clinical Hemostasis Unit, National Reference Center of Hemophilia, Louis Pradel Hospital-Ur 4609 Hemostasis and Thrombosis, Claude Bernard University, Lyon, [4]HTC, Pellegrin Hospital, Bordeaux, [5]HTC, Simone Veil Hospital, Gh Eaubonne-Montmorency, Eaubonne, [6]HTC, University Hospital, Besançon, [7]HTC, University Hospital-Hospital-Lyon University, Jean Monnet University, Inserm, U 1059, Sainbiose, Saint-Etienne, [8]HTC, University Hospital, Nancy, [9]HTC, University Hospital, Toulouse, [10]HTC, University Hospital, Nice, [11]CSL Behring, Paris, [12]HTC, National Reference Willebrand Centre, University Hospital, Lille, France

PO057

Mim8 Prophylaxis Beyond Bleeding: Multifaceted, Patient-reported Outcomes for Haemophilia A in FRONTIER2

C. Escuriola-Ettingshausen[1,*], C. Ay[2], C. Hermans[3], P. Kampmann[4], R. M. Meldgaard[5], I. Rakhmatullin[5], C. Tomuleasa[6], L. Fie Ditteke van Vulpen[7], M. Wang[8], I. Woznica Karczmarz[9], S. Susen[10]
[1]Haemophilie-Zentrum Rhein Main, HZRM, Frankfurt, Germany, [2]Division of Hematology and Hemostaseology, Department of Medicine, Medical University of Vienna, Vienna, Austria, [3]Division of Hematology, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), Brussels, Belgium, [4]Rigshospitalet, Copenhagen, [5]Novo Nordisk A/S, Søborg, Denmark, [6]Department of Haematology – Medfuture Research Center, Iuliu Hatieganu University of Medicine and Pharmacy, Ion Chiricuta Institute of Oncology, Cluj-Napoca, Romania, [7]Center for Benign Haematology, Thrombosis and Haemostasis, Van Creveldkliniek, University Medical Center Utrecht, Utrecht University,, Utrecht, Netherlands, [8]University of Colorado Hemophilia and Thrombosis Center, Aurora, Colorado, United States, [9]Department of Transfusion Medicine, Children's University Hospital, Lublin, Poland, [10]Hemostasis and Transfusion Department, University of Lille, Lille University Hospital, Lille, France

PO058

Exogenous Factor Consumption in Participants With Hemophilia A or B Without Inhibitors Receiving Marstacimab in the BASIS Trial

H. K. Kim[1,*], C. T. Taylor[2], R. McDonald[2], P. Sun[3], T. Gould[2], A. Palladino[4]
[1]Pfizer SLU, Madrid, Spain, [2]Pfizer Inc, New York, [3]Pfizer Inc, Cambridge, [4]Pfizer Inc, Collegeville, United States

PO059

Intra-articular injection of mesenchymal stem cell (MSCs) for the management of hemophilic arthropathy . Evaluation of a novel treatment modality based on a small case series

D. Kalatzis[1,*], A. Kouramba[2], S.-D. Christidi[1], K. Kaoullas[1], M. Papadatou[2], G. Thevaeos[1]
[1]Trauma and Orthopaedics Department, Laiko General Hospital of Athens, [2]Blood Transfusion Service and National Reference Center for Congenital Bleeding Disorders, ''Laiko'' General Hospital, Athens, Greece

PO060

Treatment of Bleeding Episodes with Efanesoctocog Alfa in Adults and Adolescents with Severe Haemophilia A: Second Interim Analysis of the XTEND-ed Long-term Extension Study

J. Oldenburg[1,*], S. Meunier[2], N. Suzuki[3], L. Bystrická[4], G. Neill[5], L. Abad-Franch[4], L. Mamikonian[6], A. Weyand[7]
[1]Institute of Experimental Haematology and Transfusions Medicine, University of Bonn, Bonn, Germany, [2]Hospices Civils de Lyon, Groupement Hospitalier Universitaire Est, Unité Hémostase Clinique, Bron, France, [3]Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan, [4]Sobi, Basel, Switzerland, [5]Sanofi, Reading, United Kingdom, [6]Sanofi, Cambridge, MA, [7]Division of Hematology/Oncology, Department of Pediatrics, University of Michigan, Ann Arbor, MI, United States

PO061

Moderate hemophilia A and FVIII prophylaxis: real-world data from the FranceCoag cohort

B. Guillet[1,2,*], H. Chambost[3,4], A. Lebreton[5], D. Pau[6], J. Vercruyssen[6], S. Pibre[6], A. Gaude[7], R. d'Oiron[8,9] on behalf of Francecoag collaborators
[1]Center for Hemophilia and Rare Bleeding Disorders, University hospital, [2]Univ Rennes, CHU Rennes, Inserm, Ehesp, Irset-Umr_s 1085, Rennes, [3]Department of Pediatric Hematology and Oncology, AP-HM, La Timone Children's Hospital, [4]Aix Marseille University, Inserm, Inra, C2vn, Marseille, [5]University Hospital of Clermont-Ferrand, Clermont-Ferrand, [6]Medical Evidence & Data Science Unit, Roche S.A.S, Boulogne-Billancourt , [7]Medical affairs, Chugai Pharma France, Puteaux, [8]AP-HP, Bicêtre Hospital, Center for Hemophilia and Rare Bleeding Disorders, [9]University Paris-Saclay, and UMR S1176 INSERM, Le Kremlin-Bicêtre, France

PO062

DISCREPANCY BETWEEN ONE STAGE CLOTTING AND CHROMOGENIC FACTOR VIII ACTIVITY IN WOMEN WITH HEMOPHILIA A AND HEMOPHILIA A CARRIERS: A retrospective clinical study

S. Desage[1], A. Lienhart[1], M. Janbain[2], H. Rezigue[1], A. Leuci[1], Y. Dargaud[1,*]
[1]Hemosatsis & Thrombosis, Hospices Civils de Lyon, Lyon, France, [2]Hematology, Tulane School of Medicine, New Orleans, United States

PO063

Valoctocogene roxaparvovec estimated long-term durability of treatment effect: An extrapolation of the most recent clinical data

S. Santos[1], T. M. Robinson[2], S. Harris[1,*], D. Trueman[3]
[1]BioMarin UK Ltd., London, United Kingdom, [2]BioMarin Pharmaceutical Inc., Novato, United States, [3]Source HEOR, London, United Kingdom

PO064

Number needed to scan with Point-of-care Ultrasonography for screening hemarthrosis in hemophilia patients

F. Yepes[1], C. Becerra[2], I. Perdomo[3], J. Donado[3], Y. Toloza[3], N. Duque-Zapata[3], A. F. Escobar Gonzalez[4,*]
[1]Medicarte, Medellin, Colombia, [2]Santander, [3]Antioquia, [4]Pediatric Hematology, Medicarte, Medellin, Colombia

PO065

Health-Related Quality of Life Outcomes for Marstacimab in Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B Without Inhibitors: Results From the Phase 3 BASIS Trial

V. Jiménez-Yuste[1,*], I. Mazar[2], C. Khanji[3], J. C. Cappelleri[4], A. G. Bushmakin[4], A. Palladino[5], R. McDonald[3], E. Hwang[5], C. Turich Taylor[3], J. Teeter[4]
[1]Servicio de Hematología, Hospital Universitario La Paz-IdiPAZ, Universidad Autónoma de Madrid, Madrid, Spain, [2]Pfizer Inc, Cambridge, [3]Pfizer Inc, New York, [4]Pfizer Inc, Groton, [5]Pfizer Inc, Collegeville, United States

PO066

Unmet needs in sexual health education for adolescents with bleeding disorders: Addressing knowledge gaps

M. Hetman[1,*], G. Dobaczewski[1], E. Latos-Grazynska[1]
[1]Department of Paediatric Bone Marrow Transplantation, Oncology and Haematology, Wroclaw Medical University, Wrocław, Poland

PO067

Unmet Needs of Patients With Haemophilia A/B With or Without Inhibitors: Real-World End-of-Study Results From the explorer6 Non-Interventional Study

G. Castaman[1,*], A. Abraham[2], C. Barnes[3], R. Brown Frandsen[4], K. Hampton[5], F. Lopez-Jaime [6], C. Martins Mazini Tavares[4], K. Nogami[7], J. Windyga[8], A. Wheeler[9,10]
[1]Department of Oncology, Careggi University Hospital, Florence, Italy, [2]Department of Haematology, Christian Medical College, Vellore, India, [3]The Royal Children's Hospital, Melbourne, Australia, [4]Novo Nordisk A/S, Søborg, Denmark, [5]Department of Cardiovascular Science, University of Sheffield, Sheffield, United Kingdom, [6]Haemostasis and Thrombosis Unit, Málaga Regional University Hospital, Málaga, Spain, [7]Department of Pediatrics, Nara Medical University, Nara, Japan, [8]Department of Haemostasis Disorders and Internal Medicine, Institute of Haematology and Transfusion Medicine, Warsaw, Poland, [9]Washington Centre for Bleeding Disorders, [10]University of Washington Department of Haematology, Seattle, United States

PO069

How to increase joint disease assessment in patient with haemophilia: from theory to practice

M. N. D. Di Minno[1,*], R. C. Santoro[2], M. E. Mancuso[3], C. Biasoli[4], I. Cantori[5], L. Cara[6], F. Daniele[7], A. Guida[8], L. A. Mameli[9], E. Marchesini[10], P. S. Preti[11], R. Marino[12], A. C. Molinari[13], E. Zanon[14], G. Pasta[15]
[1]Hub Centre for thrombotic and hemorrhagic disorders, Federico II University Hospital, Naples, [2]Hemostasis and thrombosis Unit, Regional reference centre for haemophilia and inherited bleeding disorders, AOUD, Catanzaro, [3]Center for Thrombosis and hemorrhagic diseases, IRCCS Humanitas Research Hospital, Rozzano, Milan, [4]Interdepartmental Simple Structure for the management of hemorrhagic and thromboembolic diseases, M.Bufalini Hospital, Cesena, [5]Haemophilia Center, Department of Transfusion Medicine, Hospital of Macerata, Macerata, [6]Pediatric Onco-Haematology Center, Microcitemico Hospital of Cagliari, Cagliari, [7]Haemostasis and Thrombosis Service, Ospedale Civile dell'Annunziata, Cosenza, [8]Congenital Diseases Center , University Hospital OO. RR. San Giovanni e Ruggi d'Aragona, Salerno, [9]Coagulation Diseases Unit, S. Annunziata University Hospital, Sassari, [10]Hemophilia Centre - SC Vascular and Emergency Department, University of Perugia , Perugia, [11]11Thrombosis and Haemostasis Centre, Department of Internal Medicine, IRCCS S. Matteo Foundation, University of Pavia, Pavia, [12]Haemophila and Thrombosis Center, University Hospital Policlinico-Giovanni XXIII, Bari, [13]Regional Reference Center for Inherited Bleeding Disorders, IRCCS Istituto Giannina Gaslini, Genova, [14]Haemophilia Centre-First Chair of Internal Medicine, Padua University Hospital, Padua, [15]IRCCS San Matteo Hospital, Pavia, Italy

PO070

Patient- and caregiver-reported outcomes with subcutaneous Mim8 prophylaxis in paediatric patients with haemophilia A with or without factor VIII inhibitors: phase 3 FRONTIER3 study

G. Kenet[1,*], M. Luciani[2], P. Kjöllerström[3], R. Berrueco[4], A. R. Høgh Nielsen[5], J. J. Thaung Zaw[5], K. Fijnvandraat[6]
[1]National Hemophilia Center and Institute of Thrombosis & Hemostasis, Sheba Medical Center, Tel Aviv, Israel, [2]Onco-Hematology, Cell and Gene Therapy and Bone Marrow Transplant Clinic Area, Bambino Gesù Children's Hospital, Rome, Italy, [3]Pediatric Hematology Unit, Hospital Dona Estefânia, ULS São José, Lisbon, Portugal, [4]Pediatric Hematology Department, Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain, [5]Novo Nordisk A/S, Søborg, Denmark, [6]Department of Paediatric Haematology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands

PO071

Developing Evidence-Based Guidelines for AAV Gene Therapy in Hemophilia

G. F. Pierce[1], E. Gouider[2], G. E. Kaeser[3], J. Frantsve-Hawley[4], D. Coffin[1,*]
[1]World Federation of Hemophilia, Montreal, Canada, [2]World Federation of Hemophilia, Tunis, Tunisia, [3]Gwen Kaeser Consulting, Bend, [4]EBQ Consulting Corp, Chicago, United States

PO072

MAPTO survey, Mapping Approaches to Tolerance in Haemophilia Treatment for PUPs/MTPs in the Non-Replacement Era

L. E. Van Stam[1,*], B. J. Horstman[1], P. Angchaisuksiri[2], M. D. Carcao[3], G. Kenet[4], C. Königs[5], J. Mahlangu[6], M. E. Mancuso[7], S. M. Rezende[8], R. F. Sidonio Jr.[9], S. Sivapalaratnam[10], A. Srivastava[11], G. Young[12], K. Fijnvandraat[1,13], S. C. Gouw[1]
[1]Department of Pediatric Hematology, Amsterdam UMC location University of Amsterdam, Amsterdam, Netherlands, [2]Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, [3]Division of Hematology/Oncology, Department of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, Canada, [4]Tel Hashomer & Thrombosis Reserach Instituite, Tel Aviv University, National Hemophilia Center, Sheba, Tel Aviv, Israel, [5]Department of Pediatrics and Adolescent Medicine, Clinical and Molecular Hemostasis, University Hospital Frankfurt, Goethe University, Frankfurt, Germany, [6], Department of Molecular Medicine and Hematology, Faculty of Health Sciences, Hemophilia Comprehensive Care Centre, University of the Witwatersrand and National Health Laboratory Service, Johannesburg, South Africa, [7]Humanitas University, Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Milan, Italy, [8]Faculty of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, [9]Department of Pediatrics, Emory University and Children's Healthcare of Atlanta, Atlanta, United States, [10]Blizard Institute, Queen Mary University London, London, United Kingdom, [11]Haematology Research Unit , St. Johns Research Institute & Department of Clinical Haematology, St. John's Medical College Hospital, Bengaluru, India, [12]University of Southern California Keck School of Medicine, Children's Hospital Los Angeles, Los Angeles, United States, [13]Department of Molecular Cellular Hemostasis, Sanquin Research and Landsteiner Laboratory, Amsterdam, Netherlands

PO073

Characterization of Early-Phase Clinical Trials for Gene Therapies in Hemophilia A: review study

M. F. Almutairi[1,*], T. H. Al-Quresheh[1]
[1]hematology and oncology efficacy and safety assessment , SFDA, Riyadh, Saudi Arabia

PO074

Understanding Parental Awareness and Educational Needs on Sexual Health in Pediatric Bleeding Disorders

M. Hetman[1,*], G. Dobaczewski[1], E. Latos-Grazynska[1]

[1]Department of Paediatric Bone Marrow Transplantation, Oncology and Haematology, Wroclaw Medical University, Wrocław, Poland

PO075

Subclinical Joint bleeding in Patients with Hemophilia: A Systematic Review

F. Alabbas[1,*] on behalf of Yes, S. Ramakrishnan[2], L. Henrique de Assis[3] on behalf of Yes
[1]Pediatric Hematology, Prince Sultan Medical Military City, Riyadh, Saudi Arabia, [2]Haematology, Norfolk and Norwich University Hospital, Norwich, United Kingdom, [3]Internal Medicine and Hematology, MedCenter-CDR Group, Eunápolis, Brazil

PO076

Factors influencing the efficacy of radiosynoviorthesis on joint-related pain in patients with haemophilia

A. Schmidt[1,*], P. Ransmann[1], B. Boddenberg-Pätzold[2], H. Eichler[3], G. Goldmann[4], B. Habermann[5], S. Halimeh[6], J. Oldenburg[4], H. Richter[7], T. Hilberg[1], A. Strauss[8]
[1]Department of Sports Medicine, University of Wuppertal, Wuppertal, [2]Nuramed, Köln, [3]Institute of Clinical Haemostaseology and Transfusion Medicine, Saarland University and University Hospital, Homburg, [4]Institute for Experimental Haematology and Transfusion Medicine, University Hospital Bonn, Bonn, [5]Orthopaedic Institution Fürstenhof, Frankfurt/Main, [6]Centre for Coagulation Rhein-Ruhr, Duisburg, [7]Haemophilia Care Centre, Münster, [8]Department of Orthopaedics and Trauma Surgery , University Hospital Bonn, Bonn, Germany

PO077

How is bleeding tendency and bleeding pattern in female carriers of hemophilia A and B in Norway, and what's the impact of the genetic mutation?

H. Knudsen[1,*], S. Grønhaug[1], C. E. Henriksson[2], H. Sundvold[3], H. Glosli[1]
[1]Center for Rare Disorders, [2]Department of Medical Biochemiestry, [3]Department of Medical Genetics, Oslo University Hospital, Oslo, Norway

PO078

Interim results of a new examination protocol for women and girls with inherited bleeding disorders (WGBD)

S. Halimeh[1,*], B. Habermann[2]
[1]GZRR, Duisburg, [2]Praxis Orthopädie am Fürstenhof, Frankfurt, Germany

PO079

Real-World Effectiveness and Usage of a Recombinant Factor VIII Fc: Interim Analysis in Children and Adolescents from the 48-Month Prospective, Observational A-MORE Study

M. Olivieri[1,*], P. Huttunen[2], C. Biasoli[3], C. Königs[4], B. Faganel Kotnik[5], A. Schoenenberger López[6], M. Fusser[7], S. Lethagen[7,8]
[1]Pediatric Thrombosis and Hemostasis Unit, Dr Von Hauner Children's Hospital, LMU Klinikum, Munich, Germany, [2]Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, New Children's Hospital, Helsinki University Hospital, Helsinki, Finland, [3]Centro Emofilia, Struttura Semplice Interdipartimentale Malattie Emorragiche e Tromboemboliche, Ospedale M. Bufalini, Cesena, Italy, [4]Department of Pediatrics and Adolescent Medicine, Goethe University Frankfurt, University Hospital, Frankfurt, Germany, [5]Department of Hematology and Oncology, University Children's Hospital, University Medical Center Ljubljana, Ljubljana, Slovenia, [6]Observational Research, Sobi, Basel, Switzerland, [7]Global Medical Affairs and Clinical Development, Sobi, Stockholm, Sweden, [8]Haemostasis and Thrombosis Centre, Copenhagen University, Copenhagen, Denmark

PO080

Association of Bleeding Rate and ABO Blood Group with Prophylaxis in Non-Severe Hemophilia A

D. E. Schmidt[1,2,*], K. Fischer[3,4], M. S. de Kovel[4], N. Gretenkort Andersson[5,6], S. Ranta[1,2] on behalf of PedNet Study Group

[1]Department of Women's and Children's Health, Karolinska Institutet, [2]Pediatric Coagulation, Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden, [3]Van Creveldkliniek, University Medial Center Utrecht, Utrecht, [4]PedNet Haemophilia Research Foundation, Baarn, Netherlands, [5]Department of Clinical Sciences, Pediatrics, Lund University, Lund, [6]Department for Thrombosis and Hemostasis, Skåne University Hospital, Malmö, Sweden

PO081

Health-related quality of life (HRQoL), physical activity (PA) and joint health in people with severe haemophilia A (PwSHA) and a bleeding phenotype receiving emicizumab – results from the HemiNorth 2 study

J. Astermark[1,2,*], S. Ranta[3], L. M. Westesson[4,5], M. Hoffmann[6], S. Quere[7], A. Y. Castro Sanchez[7], S. Robson[7], T. Czirok[7], R. Lassila[8], P. André Holme[9,10]

[1]Department of Translational Medicine, Lund University, [2]Department of Haematology Oncology and Radiation Physics, Skåne University Hospital, Malmö, [3]Astrid Lindgren's Children's Hospital, Karolinska University Hospital, Stockholm, [4]Region Västra Götaland, Sahlgrenska University Hospital, Department of Medicine, [5]Sahlgrenska Academy, Institution for Nursing Science and Health at Gothenburg University, Gothenburg, Sweden, [6]Department of Paediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark, [7]F. Hoffmann-La Roche Ltd, Basel, Switzerland, [8]Department of Haematology, Coagulation Disorders Unit, and Research Programme Unit in Systems Oncology Oncosys, Medical Faculty, University of Helsinki, Helsinki, Finland, [9]Institute of Clinical Medicine, Oslo University Hospital, [10]Department of Haematology, University of Oslo, Oslo, Norway

PO082

Final analysis of the phase 1/2 trial of valoctocogene roxaparvovec for severe hemophilia A

P. Raheja[1,*], S. Rangarajan[2], W. Lester[3], B. Madan[4], G. F. Pierce[5], E. Symington[6], C. Millar[7], D. Osmond[8], M. Li[8], K.-M. Chavele[8]

[1]Haemophilia Centre Royal London Hospital, Barts Health NHS Trust, London, [2]Faculty of Medicine, University of Southampton, Southampton, [3]University Hospitals Birmingham NHS Foundation Trust, Birmingham, [4]Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, [5]Independent Consultant, La Jolla, United States, [6]Cambridge University Hospitals NHS Foundation Trust, Cambridge, [7]Imperial College Healthcare NHS Trust and Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom, [8]BioMarin Pharmaceutical Inc., Novato, United States

PO083

Annualised Bleeding Rates in Patients with Haemophilia A or B and Inhibitors with and without Target Joints at Baseline: Results from the Concizumab Phase 3 explorer7 Study

S. Linari[1,*], S. Apte[2], A. Boban[3], R. Brown Frandsen[4], J. Mahlangu[5], C. Martins Mazini Tavares[4], T. Matsushita[6], M. S. Nekkal[7], J. Sathar[8], A. Chan[9], A. Shapiro[10]

[1]Department of Oncology, Careggi University Hospital, Florence, Italy, [2]Sahyadri Specialty Hospital, Pune, India, [3]Department of Haematology, University Hospital Centre Zagreb, Zagreb, Croatia, [4]Novo Nordisk, Søborg, Denmark, [5]Haemophilia Comprehensive Care Centre, University of the Witwatersrand and National Health Laboratory Service, Johannesburg, South Africa, [6]Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan, [7]Blood Transfusion Centre, University Hospital Medical Centre Beni Messous, Algiers,

Algeria, [8]Department of Haematology, Ampang Hospital, Kuala Lumpur, Malaysia, [9]McMaster University, Ontario, Canada, [10]Indiana Hemophilia and Thrombosis Center, Indianapolis, United States

PO084

Efficacy and Safety of Fidanacogene Elaparvovec by BMI: Results From the BENEGENE-2 Trial

K. Kavakli[1,*], L. Frenzel[2], A. Cuker[3], J.-D. Wang[4], L. J. Wilcox[5], P. Gaitonde[6], P. Sun[6], J. McKay[7], D. Agathon[8], F. Plonski[9]

[1]Division of Hematology, Department of Pediatrics, Ege University Faculty of Medicine, Izmir, Türkiye, [2]Department of Hematology, Hemophilia Care and Research, Necker Hospital, Institut Imagine, Paris, France, [3]Department of Medicine and Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States, [4]Center for Rare Disease and Hemophilia, Taichung Veterans General Hospital, Taichung, Taiwan, Province of China, [5]Pfizer Inc, Toronto, Canada, [6]Pfizer Inc, Cambridge, [7]Pfizer Inc, Pearl River, United States, [8]Pfizer Inc, Paris, France, [9]Pfizer Inc, Collegeville, United States

PO085

Efficacy and Safety of Fidanacogene Elaparvovec by Hepatitis History: Results From the BENEGENE-2 Trial

L. Frenzel[1,*], A. Cuker[2], K. Kavakli[3], J.-D. Wang[4], D. Agathon[5], F. Biondo[6], P. Klaus[7], J. McKay[8], P. Sun[9], L. J. Wilcox[10], F. Plonski[11]

[1]Department of Hematology, Hemophilia Care and Research, Necker Hospital, Institut Imagine, Paris, France, [2]Department of Medicine and Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States, [3]Division of Hematology, Department of Pediatrics, Ege University Faculty of Medicine, Izmir, Türkiye, [4]Center for Rare Disease and Hemophilia, Taichung Veterans General Hospital, Taichung, Taiwan, Province of China, [5]Pfizer Inc, Paris, France, [6]Pfizer Srl, Rome, Italy, [7]Pfizer Pharma GmbH, Berlin, Germany, [8]Pfizer Inc, Pearl River, [9]Pfizer Inc, Cambridge, United States, [10]Pfizer Inc, Toronto, Canada, [11]Pfizer Inc, Collegeville, United States

PO086

Patient Burden and Preferences for Hemophilia Treatments: A Multi-Country Discrete-Choice Experiment with Hemo-TEM

H. Lu[1], J. Whitty[1], C. Colavecchia[2,*], T. Gould[2], J. Coulter[2], N. Dunn[3], P. Chowdary[4], L. J. Wilcox[5], J. C. Cappelleri[6], S. A. Christopher[2], A. Sohn[2], B. Hauber[2]

[1]Evidera, London, United Kingdom, [2]Pfizer Inc, New York, United States, [3]Independent Consultant, [4]Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, United Kingdom, [5]Pfizer Inc, Toronto, Canada, [6]Pfizer Inc, Groton, United States

PO087

Indirect Treatment Comparison of Marstacimab versus Emicizumab in Haemophilia A

A. Sohn[1], T. Gould[1,*], J. C. Cappelleri[1], M. Ines[1], Y. Wang[2], A. Nevo[2], H. Jin[2], J. Uyei[2], K. Lindsley[2], D. J. Boyne[2]

[1]Pfizer Inc, New York, [2]IQVIA, Inc., San Mateo, United States

PO088

Real-world bleeding rates of people with severe haemophilia A on emicizumab treatment in the Netherlands with and without a history of an inhibitor

L. M. Taal[1,*], C. M. vanVeen[1], M. R. Brands[2], M. Beijlevelt-van der Zande[3], M. H. Driessens[4], C. L. Eckhardt[5], P. L. den Exter[6], M. J. Kruip[7], B. A. Laros[8,9], S. Meijer[4], M. Stein-Wit[10], K. Meijer[11], S. C. Gouw[3]

[1]HemoNed Foundation, Leiden, [2]Erasmus MC, Erasmus University Medical Center Rotterdam, Rotterdam, [3]Department of Pediatric Hematology, Amsterdam UMC location University of Amsterdam, Amsterdam, [4]Netherlands Hemophilia Patient Society (NVHP), Nijkerk, [5]Center for Benign Haematology, Thrombosis and

Haemostasis, Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, [6]Department of Medicine, Thrombosis and Hemostasis, Leids Universitair Medisch Centrum, Leiden, [7]Department of Hematology, Erasmus University Medical Center Rotterdam, Rotterdam, [8]Department of Hematology, Radboud University Medical Center, [9]Hemophilia Treatment Center Nijmegen-Eindhoven-Maastricht, Nijmegen, [10]Department of Pediatrics, University Medical Center Groningen, [11]Department of Hematology, , University Medical Center Groningen, University of Groningen, Groningen, Netherlands

PO089

Improved Overall Quality of Life and Treatment Satisfaction in Patients with Haemophilia Receiving Fitusiran: Analyses of Qualitative Semi-Structured Interviews of Participants in the ATLAS-OLE Trial

A. Srivastava[1], S. Rangarajan[2,3], C. Ross[4], S. Ali[5], S. Andersson[5], L. Menapace[5], M. Puurunen[5], M. Afonso[6,*]
[1]Haematology Research Unit, St. Johns Research Institute & Department of Clinical Haematology, St. John's Medical College Hospital, Bengaluru, India, [2]Faculty of Medicine, University of Southampton, Southampton, United Kingdom, [3]Clinical Trials Research Unit, K.J Somaiya Hospital and Research Centre, Mumbai, [4]Department of General Medicine & Hematology, St. John's Medical College, Bangalore, India, [5]Sanofi, Cambridge, MA, United States, [6]Sanofi, Gentilly, France

PO090

Health-Related Quality of Life and Joint Health Results From a Phase 1/2 Study of Giroctocogene Fitelparvovec Gene Therapy in Adults With Severe Hemophilia A

T. J. Harrington[1], A. Leavitt[2], N. Visweshwar[3], B. Konkle[4], K. Stine[5], A. Giermasz[6], D. Chiu[7], M. D. L. A. Resa[8], L.-J. Tseng[8], F. Biondo[9], J. Healy[10], D. Agathon[11,*], F. Plonski[12]
[1]University of Miami Miller School of Medicine, Miami, FL, [2]University of California San Francisco, San Francisco, CA, [3]University of South Florida, Tampa, FL, [4]Washington Center for Bleeding Disorders and the University of Washington, Seattle, WA, [5]UAMS at Arkansas Children's Hospital, Little Rock, AR, [6]Hemophilia Treatment Center, University of California Davis, Sacramento, CA, United States, [7]Pfizer Inc, London, United Kingdom, [8]Pfizer Inc, New York, NY, United States, [9]Pfizer Srl, Rome, Italy, [10]Pfizer Canada ULC, Kirkland, Canada, [11]Pfizer Inc, Paris, France, [12]Pfizer Inc, Collegeville, PA, United States

PO091

Socio-economic burden of being a hemophilia carrier in 2024 - a survey

M. Reschke[1,*], I. Wieland[2], M. Krause[3], C. Escuriola[4], S. Halimeh[5], R. S. Alesci[6] on behalf of Kommission Hämophilie der Gesellschaft für Thrombose und Hämophilie
[1]Hemostaseology, Universitätsmedizin Berlin, Berlin, [2]Pediatric hemostaseology, Medizinische Hochschule Hannover, Hannover, [3]Hemostaseology, DKD, Wiesbaden, [4]Hemostaseology, Hemophilia Center Rhein Main , Frankfurt/M, [5]Hemostaseology, Gerinnungszentrum Rhein Ruhr, Duisburg, [6]Hemostaseology, Gerinnungszentrum Hochtaunus, Bad Homburg, Germany

PO092

BLEEDING RELATED TO REPRODUCTIVE HEALTH IN CARRIERS OF HEMOPHILIA: SINGLE CENTER EXPERIENCE

N. Fernandez Mosteirin[1,*], J. M. Calvo villas[1]
[1]Haematology and Haemotherapy, Miguel Servet University Hospital , Zaragoza, Spain

PO093

Long-term data of the effect of ankle joint distraction in hemophilic arthropathy

L. F. van Vulpen[1,*], M. A. Timmer[1], H. M. de Visser[2], R. E. Schutgens[1], S. C. Mastbergen[3]
[1]Center for Benign Haematology, Thrombosis and Haemostasis, Van Creveldkliniek, [2]Orthopaedic surgery, [3]Rheumatology and Cinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands

PO094

A 6-year single centre experience on the use of Emicizumab prophylaxis in children with severe haemophilia A with and without FVIII inhibitors

K. Reynolds[1,*], N. Lawson[1], J. Lancashire[1], J. Patel[1], J. Motwani[1]
[1]Haemostasis Department, Birmingham Children's Hospital, Birmingham , United Kingdom

PO095

Joint health in women with hemophilia- reality in 2024- a survey

R. S. Alesci[1,*], M. Reschke[2], C. Escuriola Ettinghausen[3], I. Wieland[4], M. Krause[5], N. Davut[6], S. Halimeh[7,8] on behalf of Ständige Kommission Hämophilie der GTH Germany
[1]IMD Blood coagulation centre Hochtaunus, Bad Homburg, [2]Pediatric Dept of Hematology, Charite University Hospital, Berlin, [3]Haemophilia Centre Rhine Main, Frankfurt, [4]Pediatric Dept of Hematology, Medical University Hospital Hannover, Hannover, [5]Internal Med. Dept, DKD Helios Hospital Wiesbaden, Wiesbaden, [6]Hematology Research Center, [7]Blood coagulation centre Rhine Rhur, Duisburg, [8]University Hospital Essen, Essen, Germany

PO096

TSUBASA: A prospective study evaluating association between physical activity and bleeding events, quality of life, and safety in people with haemophilia A without factor VIII inhibitors

K. Nogami[1,*], T. Fujii [2], A. Sawada[3], A. Nagao[4], C. Nagae[5], M. Nojima[6], N. Suzuki[7], D. Nosaka[8], T. Shimura[8], Y. Sugao[8], K. Amano[9]
[1]Department of Pediatrics, Nara Medical University, Nara, [2]Division of Transfusion Medicine/Hemophilia Treatment Center, Hiroshima University Hospital, Hiroshima, [3]Department of Respiratory Medicine and Hematology, Hyogo Medical University, Hyogo, [4]Department of Blood Coagulation, Ogikubo Hospital, Tokyo, [5]Department of Pediatrics, St Marianna University School of Medicine, Kanagawa, [6]Center for Translational Research/Division of Advanced Medicine Promotion, Institute of Medical Science, The University of Tokyo, Tokyo, [7]Department of Transfusion Medicine, Nagoya University Hospital, Aichi, [8]Chugai Pharmaceutical Co., Ltd, [9]Department of Laboratory Medicine, Tokyo Medical University, Tokyo, Japan

PO097

Application of Generative AI to the Efficiency Analysis of MAIC between Factor VIII Concentrates: Help or Not?

M. R, Lopez[1,*], R. N.Vazquez[2], R. Iglesias Varela[1], R. Ocampo Martinez[1]
[1]Hematology and Hemotherapy Department, Hospital Universitario Alvaro Cunqueiro, Vigo, [2]Thrombosis and Haemostasis Unit, Hospital Universitario Virgen del Rocio, Seville, Spain

PO098

SURGICAL OUTCOME IN PATIENTS WITH EMICIZUMAD FOLLOWED IN A GREEK HAEMOPHILIA CENTRE

A. Kouramba[1,*], G. Thivaios[2], P. Christoforou[1], S. Christidi[2], D. Kalatzis[2], M. Papadatou[1], A. Chanos[1], O. Katsarou[1]
[1]Blood Transfusion Service and National Reference Center for Congenital Bleeding Disorders, ''Laiko'' General Hospital, Athens, Greece, [2]Trauma and Orthopaedics Department, Laiko General Hospital of Athens, Greece, Athens, Greece

PO099

Initial clinical experience with Efanesoctocog alfa in orthopedic surgery at University Hospital Ostrava, Czech Republic

R. Hrdličková[1,*], Š. Blahutová[1], M. Mohyla[2], Z. Čermáková[1], R. Kašpárek[2]
[1]Blood Centre, [2]Clinic of Trauma Surgery and Orthopaedics, University Hospital Ostrava, Ostrava, Czech Republic

PO100

Surgical use of rIX-FP in patients with haemophilia B: French real-world data

M. Fouassier[1], F. Volot[2], A. Fournel[3], B. Tardy[4,5], C. Reynes[6], R. d'Oiron[7,8], A. Rauch[9], C. Biron-Andreani[10], Y. Huguenin[11], D. Desprez[12], B. Gillet[13], B. Frotscher[14], J.-B. Valentin[15], C. Berger[4,16], H. Catovic[17], C. Martin[17], B. Guillet[18,19,*]
[1]HTC, Hôtel-Dieu University Hospital, Nantes, [2]HTC Centre, Dijon Bourgogne University Hospital, Dijon, [3]HTC, University Hospital, Besançon, [4]HTC, University Hospital, [5]Inserm CIC 1408, Saint-Etienne University Hospital Center, Saint-Etienne, [6]HTC, University Hospital Annecy, Annecy, [7]CRH, CRC-MHC (Centre de Référence de l'Hémophilie, Centre de Ressource et de Compétence des Maladies Hémorragiques Constitutionnelles), Hôpital Bicêtre, AP-HP, Université Paris-Saclay, [8]HITh, UMR_S1176, INSERM, Université Paris-Saclay, Le Kremlin Bicêtre, Paris, [9]HTC, National Reference Willebrand Centre, University Hospital - Lille, Lille, [10]HTC, University Hospital, Montpellier, [11]HTC, Pellegrin Hospital, Bordeaux, [12]HTC, University Hospital – Strasbourg, Strasbourg, [13]HTC and Hematology Laboratory, University Hospital, Caen, [14]HTC, University Hospital, Nancy, [15]HTC, University Hospital, Tours, [16]Lyon University, Jean Monnet University, INSERM, U 1059, Sainbiose, [17]CSL Behring, Paris, [18]HTC, University Hospital, [19]Univ Rennes, CHU Rennes, Inserm, EHESP, Irset - UMR_S 1085, F-35000, Rennes, France

PO101

Intensive FVIII replacement in haemophilia patients with hypertrophic synovium: a randomized study

M. Di Minno[1], I. Calcaterra[1,*], E. Baldacci[2], R. Marino[3], F. Valeri[4], R. C. Santoro[5], G. Pasta[6], C. Martinoli[7]
[1]Clinical Medicine and Surgery, Federico II University of Napoli, Napoli, [2]Haematology, University Hospital Policlinico Umberto I, Rome, [3]Bari University Hospital, Bari, [4]Regional Centre for Haemorrhagic and Thrombotic Diseases, AOU Città Della Salute e Della Scienza, Torino, [5]Centre for Hemorrhagic and Thrombotic Disorders, Pugliese Ciaccio Hospital, Catanzaro, [6]Fondazione IRCCS San Matteo Hospital, Pavia, [7]University of Genova, Genova, Italy

PO102

Shared Decision Making Around Emicizumab Dosing Frequency to Support Compliance

N. Longsmith[1], L. Johnson[1], C. Harrison[1,1], C. Lockley[1], J. Voyse[1], I. E. Skytterholm[1,*], G. Wild[1], C. Woodhead[1]
[1]Sheffield Haemophilia Centre, Sheffield Teaching Hospitals, Sheffield, United Kingdom

PO103

Evaluation of Omfiloctocog alfa (SCT800) Efficacy in Real-World Treatment of Severe or Moderate Hemophilia A in China: Final Analysis from the SURPASS Study

F. Xue[1,*], P. Lei[2], S. Lian[3], M. Jia[4], R. Zhou[5], H. Dang[6], L. Cai[7], Q. Hu[8], L. Wang[9], H. Wang[10], J. Sun[11], Z. Yan[12], X. Suo[13], Y. Guo[14], B. Xie[15], L. Yang[16], Y. Yang[17], R. Yang[1]

[1]Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, [2]Henan provincial People's Hospital, Zhengzhou, [3]Dalian Municipal Central Hospital, Dalian, [4]The First Hospital of Lanzhou University, Lanzhou, [5]Nanjing Drum Tower Hospital, Nanjing, [6]Nanyang Medical College Affiliated Hospita, Nanyang, [7]The Second People's Hospital of Shenzhen, Shenzhen, [8]Huazhong University of Science and Technology Tongji Medical College Tongji Hospital, Wuhan, [9]The First People's Hospital of Jinzhong, Jinzhong, [10]Weifang Medical College School Hospital, Weifang, [11]Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, [12]North China University of Science and Technology Affiliated Hospital, Tangshan, [13]Handan Central Hospital, HAndan, [14]Peking University People's Hospital, Beijing, [15]Wenzhou People's Hospital, Wenzhou, [16]Dazhou Central Hospital, Dazhou, [17]The First Bethune Hospital of Jilin University, Changchun, China

PO104

Real-World Effectiveness of Eptacog Beta [Coagulation Factor VIIa (Recombinant)] in the USA

R. F. Sidonio, Jr.[1,*], A. H. Al-Huniti[2], V. Balasa[3], A. Cuker[4], A. Dvorak[5], D. V. Quon[6], M. H. White[7], A. Robertson[8], B. Sohier[9], E. Sauty[9]

[1]Hemophilia, Georgia Center for Bleeding and Clotting Disorders, Atlanta, [2]Pediatric Hematology-Oncology, Mayo Clinic, Rochester, [3]Cancer and Blood Disorder Center, Valley Children's Hospital, Stanford University School of Medicine, Madera, [4]Medicine and Department of Pathology & Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, [5]State University of New York Upstate, Syracuse, [6] Luskin Orthopaedic Institute for Children, Los Angeles, [7]Aflac Cancer and Blood Disorders Center at Children's Healthcare of Atlanta and Emory University School of Medicine, Atlanta, [8]LFB USA, Framingham, United States, [9]LFB, Les Ulis, France

PO105

Joint health and physical activity in people with haemophilia A without factor VIII inhibitors before switching to emicizumab prophylaxis: Beyond ABR study interim analysis

G. Castaman[1,*], M. N. Dario Di Minno[2], R. Kruse-Jarres[3,4], D. Stephensen[5], S. Lobet[6,7,8], S. Robson[9], C. Brocchieri[9], V. Jiménez-Yuste[10]

[1]Department of Oncology, Centre for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, [2]Department of Clinical Medicine and Surgery, Unit of Thrombosis and Haemostasis, Federico II University, Naples, Italy, [3]Washington Center for Bleeding Disorders, [4]Division of Hematology, Department of Medicine, University of Washington, Seattle, United States, [5]Faculty of Medicine, Health and Social Care, Canterbury Christ Church University, Canterbury, United Kingdom, [6]Service d'Hématologie, [7]Service d'Ergothérapie et de Kinésithérapie, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (UCLouvain), Brussels, [8]Neuromusculoskeletal Lab (NMSK), Secteur des Sciences de la Santé, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain (UCLouvain), Ottignies-Louvain-la-Neuve, Belgium, [9]F. Hoffmann-La Roche Ltd, Basel, Switzerland, [10]Department of Hematology, Hospital Universitario La Paz-IdiPAZ, Autónoma University, Madrid, Spain

PO106

Emicizumab Treatment for Acquired Haemophilia A: Imperial College Healthcare NHS Trust Haemophilia Centre Experience.

O. Tatarinova[1,*], N. Karawitage[1], S. Vinayagam[1], K. Logan[1], C. Ryu[1], D. J. Arachchillage[1], P. Woolley[1], G. Adams[1], F. Alwan[1]

[1]Department of Haematology, Imperial College Healthcare NHS Trust, London, United Kingdom

PO107

UK survey of patient perspectives of dental care when living with a bleeding disorder.

L. Nanayakkara[1], D. Morgan[2,*], C. Boyle[3]
[1]Department of Restorative Dentistry, Barts Health NHS Trust, [2]Public Affairs and Policy, The Haemophilia Society, [3]UK Medical Affairs, Nordic Pharma , London, United Kingdom

PO108

Expedited learning and enhanced usability of a pre-filled Mim8 pen injector for the management of haemophilia A

L. Shastri[1,*], G. Mulders[2], T. Sparre[1], K. C. Bellm[3], G. Ter-Borch[1], R. Sidonio Jr[4]
[1]Novo Nordisk A/S, Søborg, Denmark, [2]Department of Hematology, Erasmus University Medical Centre, Rotterdam, Netherlands, [3]Department of Pediatrics, Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, [4]Emory University and Children's Healthcare of Atlanta, Atlanta, Georgia, United States

PO109

Clinical outcomes over 3 years of efanesoctocog alfa in adults and adolescents with severe haemophilia A: European results from the second interim analysis of XTEND-ed

R. Klamroth[1,*], P. Chowdary[2], T. Lissitchkov[3], M. T. Alvarez-Román[4], U. Khan[5], L. Bystricka[6], E. Santagostino[6], S. Susen[7]
[1]Vivantes Hospital, Friedrichshain, Berlin, Germany, [2]Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, United Kingdom, [3]Department of Chemotherapy, Hemotherapy and Hereditary Blood Diseases at Clinical Hematology Clinic, Specialized Hospital for Active Treatment of Hematological Diseases, Sofia, Bulgaria, [4]Department of Hematology, University Hospital La Paz, Autonomous University of Madrid, Madrid, Spain, [5]Sanofi, Cambridge, MA, United States, [6]Sobi, Basel, Switzerland, [7]Lille University Hospital, Lille University, Lille, France

PO110

Retrospective Analysis of Pregnancy and Birth Outcomes in Hemophilia Carriers: A 10-Year Review of Known and Undiagnosed Cases from Southern Italy

M. Napolitano[1,*], M. Mattana[2], S. Raso[3], C. Cammarata[1], M. G. Ingrascì[4], R. Tomasello[1], S. Siragusa[4], M. Leotta[5], A. Strangio[5], A. Ierardi[5], R. C. Santoro[5]
[1]Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE, [2]Department of precision medicine in medical, surgical and critical care (Me.Pre.Cc), University of Palermo, [3]Department of Hematology and Rare Diseases, Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello, [4]Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University of Palermo, Palermo, [5]Haemostasis and Thrombosis Unit Dpt Haemato-Oncology, Azienda Ospedaliero Universitaria Renato Dulbecco, Catanzaro, Italy

PO111

Gastrointestinal Bleeding in patients with hemophilia

M. Charfi[1,*], H. Gdoura[2], F. Kallel[1], I. Ben Amor[1], R. Mallek[1], O. Kassar[1], A. Koubaa[1], I. Frikha[1], M. Medhaffar[1], N. Tahri[2], M. Elloumi[1]
[1]clinical hematology department, [2]gastrology department, Hedi Chaker Hospital, Sfax, Tunisia

PO112

Bleeding outcomes and quality of life after optimization of prophylaxis in hemophilia

E. Cruz[1,*], M. Coutinho[1], A. Barros[1], M. J. Vaz[1], J. Ribeiro[1], F. Felícia[1], P. Gonçalves[1], S. Morais[1]
[1]Congenital Coagulopathies Centre , Unidade de Saude Local de Santo António, Porto, Portugal

PO113

Sleep quality in patients with haemophilia and its predictors

A. Schmidt[1,*], P. Ransmann[1], M. Brühl[1,2], F. Tomschi[1], G. Goldmann[3], A. Strauss[2], T. Hilberg[1]
[1]Department of Sports Medicine, University of Wuppertal, Wuppertal, [2]Department of Orthopaedics and Trauma Surgery , [3]Institute for Experimental Haematology and Transfusion Medicine, University Hospital Bonn, Bonn, Germany

PO114

Fifth interim analysis of the HEM-POWR study: A post hoc analysis of real-world effectiveness of damoctocog alfa pegol in patients with severe and nonsevere haemophilia A

M. T. Reding[1], M. T. Alvarez-Román[2,*], G. Castaman[3], M. Janbain[4], T. Matsushita[5], K. Meijer[6], K. Schmidt[7], J. Oldenburg[8]
[1]University of Minnesota Medical Center, Minneapolis, Minnesota, United States, [2]Hospital Universitario La Paz, Madrid, Spain, [3]Careggi University Hospital, Florence, Italy, [4]Tulane School of Medicine, New Orleans, Louisiana, United States, [5]Nagoya University Hospital, Nagoya, Japan, [6]University Medical Center Groningen, Groningen, Netherlands, [7]Bayer, Berlin, [8]Institute of Experimental Hematology and Transfusion Medicine, Medical Faculty, University Hospital Bonn, Bonn, Germany

PO115

Assessment of treatment schedule, factor VIII trough level, and area under the curve for efanesoctocog alfa vs an extended half-life FVIII comparator: a modelling approach

S. Brighton[1], N. Kragh[2], J. Thanner[2,*], N. Martone[3], T. Burke[1,4], E. Ferri Grazzi[1]
[1]HCD Economics Ltd, Knutsford, United Kingdom, [2]Sobi, Stockholm, Sweden, [3]Sobi, Milan, Italy, [4]Faculty of Health and Social Care, University of Chester, Chester, United Kingdom

PO118

Acquired Hemophilia-management strategies: A single center experience

L. Waldman Radinsky[1,*], M. Sivan[2,3], A. Lubetsky[1,4], M. M. Misgav[1,4], S. Lalezari[1], O. Cohen[4,5], T. Barhod[1], G. Kenet[1,4], O. Efros[1,4,6]
[1]National Hemophilia Center, [2]Sheba Medical Center, Ramat-Gan, Israel, [3]University of Nicossia, Nicossia, Cyprus, [4]Tel-Aviv University, Tel-Aviv, [5]Blood Bank, Kaplan Medical Center, [6]Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel

PO119

Advocacy to improve the quality of educational initiatives for patients with rare bleeding disorders: proposed methodology

T. Sannié[1,*], C. Galeotti[2], A. Borel-Derlon[1], C. Artu-Dumont[1], V. Dumez[3], M. Jourdain[1], Y. Collé[1], R. d'Oiron[2]
[1]Association française des hémophiles, Paris, [2]Centre de Référence de l'Hémophilie et des maladies hémorragiques constitutionnelles rares, Hôpital Bicêtre AP-HP, Université Paris-Saclay, Kremlin-Bicêtre, France, [3] Centre d'Excellence sur le Partenariat avec les Patients et le Public (CEPPP), Montréal, Canada

PO120

Real-World Effectiveness and Usage of a Recombinant Factor VIII Fc: Interim Analysis in Adults from the 48-Month Prospective, Observational A-MORE Study

O. Benitez Hidalgo[1,*], A. Olsson[2,3], K. Meijer[4], C. Escuriola-Ettingshausen[5], F. Peyvandi[6,7], A. Schoenenberger López[8], M. Fusser[9], S. Lethagen[9,10]

[1]Haemophilia Unit, Haematology Department , Vall d'Hebron Hospital, Barcelona, Spain, [2]Department of Medicine, Region Västra Götaland, Sahlgrenska University Hospital, [3]Department of Internal Medicine, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, [4]Department of Haematology, University Medical Center Groningen, Groningen, Netherlands, [5]Haemophilia Center Rhein Main, Frankfurt, Germany, [6]Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, [7]Department of Pathophysiology and Transplantation, University of Milan, Milano, Italy, [8]Observational Research, Sobi, Basel, Switzerland, [9]Global Medical Affairs and Clinical Development, Sobi, Stockholm, Sweden, [10]Haemostasis and Thrombosis Centre, Copenhagen University, Copenhagen, Denmark

PO121

Safety profile of damoctocog alfa pegol: Fifth interim analysis of the real-world HEM-POWR study for previously treated patients with severe and nonsevere haemophilia A

M. T. Reding[1], M. T. Alvarez Román[2], G. Castaman[3], M. Janbain[4], T. Matsushita[5], K. Meijer[6], K. Schmidt[7], J. Oldenburg[8,*]
[1]University of Minnesota Medical Center, Minneapolis, Minnesota, United States, [2]Hospital Universitario La Paz, Madrid, Spain, [3]Careggi University Hospital, Florence, Italy, [4]Tulane School of Medicine, New Orleans, Louisiana, United States, [5]Nagoya University Hospital, Nagoya, Japan, [6]University Medical Center Groningen, Groningen, Netherlands, [7]Bayer, Berlin, [8]Institute of Experimental Hematology and Transfusion Medicine, Medical Faculty, University Hospital Bonn, Bonn, Germany

PO122

Evaluation of safety and efficacy of Emicizumab prophylaxis in Egyptian pediatric patients with Hemophilia A: Single center cross sectional Study.

M. Zakaria[1,*], T. Hassan[1]
[1]pediatrics, zagazig university, zagazig, Egypt

PO123

Cost-Efficacy Analysis of Rurioctocog Alfa Pegol (PROPEL) vs. Efanesoctocog in Haemophilia A using Artificial Intelligence (AI)

M. R, Lopez[1,*], R. N.Vazquez[2], M. Calviño[3], R. Ocampo Martinez[1]
[1]Hematology and hemotherapy , Hospital Universitario Alvaro Cunqueiro, Vigo, [2]Thrombosis and Haemostasis Unir, Hospital Universitario Virgen del Rocio, Sevilla, [3]Hematology and hemotherapy , Complejo Universitario Hospitalario de Santiago, Santiago, Spain

PO124

Do value perceptions on the contribution of etranacogene dezaparvovec for the treatment of severe and moderately severe Haemophilia B vary between clinicians and hospital pharmacists? A Multicriteria Decision Analysis study

O. Benítez Hidalgo[1], V. Jiménez-Yuste[2], J. C. Juarez Giménez[1], R. J. Núñez Vázquez[3], J. L. Poveda Andrés[4], X. Badia[5], I. Cortés[6,*]
[1]Hospital universitario Vall d'Hebrón, Barcelona, [2]Hospital Universitario La Paz, Madrid, [3]Hospital Universitario Virgen del Rocío, Sevilla, [4]Hospital Universitari i Politècnic La Fe,, valencia, [5]omakase consulting, S.L, [6]CSL Behring S.A, Barcelona, Spain

PO125

Discrepancies between MAIC and IA Analysis in the evaluation of treatments in Hemophilia A (HA)

M. R, Lopez[1,*], R. N. Vazquez[2], M. Calviño[3], R. Ocampo Martinez[1]

[1]Hematology and hemotherapy, Hospital Universitario Alvaro Cunqueiro, Vigo, [2]Thrombosis and Haemostasis Unit, Hospital Universitario Virgen del Rocio , Sevilla, [3]Hematology and hemotherapy, Complexo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain

PO126

COMPARISON BETWEEN TWO GENE THERAPY PLATFORMS IN HAEMOPHILIA B (HB) USING BASIC GENERATIVE IA

M. R, Lopez[1,*], R. N.Vazquez[2], R. Ocampo Martinez[1], C. Albo Lopez[1]
[1]Hematologia y hemoterapia, Hospital Universitario Alvaro Cunqueiro, Vigo, [2]Thrombosis and Haemostasis Unit, Hospital Universitario Virgen del Rocio, Sevilla, Spain

PO127

Impact of a hypothetical switch to efanesoctocog alfa prophylaxis on bleeding, treatment burden and area under the curve in severe haemophilia A: Italian CHESS III cohort analysis

E. Ferri Grazzi[1,*], S. Brighton[1], N. Kragh[2], J. Thanner[2], N. Martone[3], T. Burke[1,4]
[1]HCD Economics Ltd, Knutsford, United Kingdom, [2]Sobi, Stockholm, Sweden, [3]Sobi, Milan, Italy, [4]Faculty of Health And Social Care, University of Chester, Chester, United Kingdom

PO128

Long term follow up of cerebral bleeding in Egyptian Haemophilia A and B patients with and without inhibitors

M. Abdelwahab[1,*]
[1]Pediatric Hematology, Cairo University Pediatric Hospital, kasr Alainy Hospital, Cairo, Egypt

PO129

Are There Still Benefits in Immune Tolerance Induction? The Experience of a Center in Brazil

L. S. Oliveira[1,*], A. L. L. D. Morais[1], C. C. S. D. Oliveira[1], G. F. D. Reis[1], M. G. Sisdelli[1], R. A. Franca[1], L. C. Oliveira[1]
[1]Hemocentro de Ribeirão Preto da Universidade de São Paulo, Ribeirão Preto, Brazil

PO130

Long-term, real-world use of rIX-FP in adult patients with haemophilia B in Italy: outcomes of more than 4 years of retrospective-prospective follow-up (IDEAL Part A+B)

G. Castaman[1,*], A. Coppola[2], F. Peyvandi[3], L. Banov[4], D. Cultrera[5], M. Margaglione[6], A. Tosetto[7], L. Valdré[8], I. Schiavetti[9,10], A. Loraschi[11]
[1]Centre for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, Firenze, [2]Regional Hub Centre for Haemophilia and Congenital Bleeding Disorders, University Hospital of Parma, Parma, [3]Haemophilia and Thrombosis Centre, and Università degli Studi di Milano, Department of Pathophysiology and Transplantation, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi, Milano, [4]Regional Reference Centre for Haemorrhagic Diseases, IRCCS Istituto Giannina Gaslini, Genova, [5]Haemophilia Regional Reference Centre, Haematology Unit, Policlinico "G. Rodolico" - S. Marco Hospital, Catania, [6]Department of Clinical and Experimental Medicine, University of Foggia, Foggia, [7]Haemostasis and Thrombosis Unit, Haematology Department, San Bortolo Hospital, Vicenza, [8]Inherited Bleeding Disorders Unit, IRCCS AOUBO, Bologna, [9]Department of Health Sciences, University of Genoa, [10]Hippocrates Research, Genova, [11]CSL Behring, Milano, Italy

PO131

Year 3 interim results from HA-SAFE: an observational study evaluating long-term safety of treatment with damoctocog alfa pegol

J. Oldenburg[1], M. T. Alvarez Román[2], H. Pergantou[3], S. Wenning[4,*], M. E. Mancuso[5,6]
[1]University Clinic Bonn, Bonn, Germany, [2]Hospital Universitario La Paz, Madrid, Spain, [3]Haemophilia Centre/Haemostasis and Thrombosis Unit, Aghia Sophia General Children's Hospital of Athens, Athens, Greece, [4]SRH Kurpfalzkrankenhaus Heidelberg, Heidelberg, Germany, [5]Center for Thrombosis and Haemorrhagic Disease, IRCCS Humanitas Research Hospital, Rozzano, [6]Humanitas University, Pieve Emanuele, Milan, Italy

PO132

An Unusual Adverse Effect of a Pegylated Extended Half-Life FVIII – A Case Report

S. R. D. Silva[1,*], L. R. Gonçalves[1], M. Carvalho[1], I. Moreira[1], D. C. Gonçalves[1], S. Fernandes[1], F. Araújo[1]
[1]Reference Center of Congenital Coagulopathies, Local Health Unit of São João,, Porto, Portugal

PO133

Feasibility of tests for motor skills (general fitness, proprioception and balance) in patients with hemophilia and association with pain and orthopedic joint status

K. Holstein[1,2,*], K. Glismann[3], M. Tetzlaff[2], S. Patra[3], P. Iken[3], T. Hilberg[4], F. Tomschi[4], C. Rolling[2], C. Bokemeyer[2], G. Welsch[3], F. Langer[2]
[1]Coagulation Center, Institute for clinical chemistry, University Hospital Schleswig-Holstein, Kiel, [2]II. Medical Department, [3]Athleticum, Orthopaedic Sports Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, [4]Department of Sports Medicine, University of Wuppertal, Wuppertal, Germany

PO134

Assessment Of The Health-Related Quality Of Life In A Cohort Of Hemophilia Patients With Joint Arthropathies Before And After The Era Of Non- Factor prophylaxis (Emicizumab) Therapy (Single Egyptian Center Study)

G. L. Abdel Hakeem[1,2,*] on behalf of Minia Hemophillia treatment center on behalf of minia hemophillia treatment center
[1]pediatric department, Minia University, [2]pediatric department, Minia insurance hospital, Al Minya, Egypt

PO135

Management of pregnancy in women with inherited bleeding disorders; 10 years of experience in managing haemophilia carriers and von Willebrands disease within 2 Haemophilia comprehensive care centres within the UK

E. Millen[1,*], A. Webster[2], G. Swallow[3]
[1]Nottingham Haemophilia Comprehensive Care Centre, Nottingham, [2]University Hospitals of Leicester, Leicester, [3]Nottingham University Hospitals, Nottingham, United Kingdom

PO136

Intracranial hemorrhage in children and adolescents with hemophilia A and B : The experience in hospitals of Çukurova Region

I. Sasmaz[1,2,*], A. B. Antmen[1], D. A. Tuncel[3], D. M. Yılmaz[4]
[1]Pediatric Hematology, Acibadem Adana Hospital, [2]PediatricHematology, Cukurova University, [3]Pediatric Hematology, Adana City Hospital, [4]Neuorosurgery, Cukurova University, Adana, Türkiye

PO137

Real-world data on the use of emicizumab in children with hemophilia A with inhibitors in Colombia.

N. Builes[1,2], W. Pardo[1,*], J. G. Duque[1]
[1]Neurum IPS, [2]Hospital Pablo Tobon Uribe, Medellin, Colombia

PO138

EFFECTIVENESS OF LOW - DOSE PROPHYLAXIS WITH STANDARD FACTOR CONCENTRATED IN HEMOPHILIA PATIENTS MANAGED AT THE NATIONAL INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION 2019 – 2023

M. Nguyen[1,*], P. T. Tran[1], Q. T. Tran[1], B. D. Vu[1,1], T. H. Nguyen[1]
[1]Hemophilia Center, National Institute of Hematology and Blood Transfusion, Hanoi, Viet Nam

PO139

Innovative tool as part of educational workshops for reporting on learning by teenagers living with hemophilia

T. Sannié[1,*], M. Séné-Bourgeois[1], E. Hamelin[1], G. Janin[1], T. Lambert[2], H. Maynadié[2], G. Morelle[2], R. d'Oiron[2], C. Galeotti[2]
[1]Association française des hémophiles, Paris, [2]Centre de Référence de l'Hémophilie et des maladies hémorragiques constitutionnelles rares, Hôpital Bicêtre AP-HP, Université Paris-Saclay, Kremlin-Bicêtre, France

PO140

Are Women Welcome in Haemophilia Clinical Trials?

M. O'Donnell[1,*], R. Abdul-Kadir[2], R. D'Oiron[3], P. Elfvinge[4], G. Golan[5], K. Gomez[6], S. C. Gouw[7], L. Quintas[8], K. P. M. van Galen[9], M. Lavin[10] on behalf of EAHAD Women and Girls with Bleeding Disorders Working Group
[1]Irish Centre for Vascular Biology, School of Pharmacy & Biomedical Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland, [2]Katharine Dormandy Haemophilia and Thrombosis Unit, Department of Obstetrics and Gynaecology, Royal Free Foundation Hospital and Institute for Women's Health, University College London, London, United Kingdom, [3]Reference Centre for Hemophilia and Rare Bleeding Disorders, AP-HP, Bicêtre Hospital, University Paris-Saclay and UMR S1176 INSERM, Le Kremlin-Bicêtre, France, [4]Department of Haematology, Karolinska University, Stockholm, Sweden, [5]Israel National Hemophilia Center, Sheba Medical Center, Ramat Gan, Israel, [6]Haemophilia Centre and Thrombosis Unit, Royal Free London NHS Foundation Trust, London, United Kingdom, [7]Department of Pediatric Hematology, Amsterdam UMC location University of Amsterdam, Meibergdreef 9, Amsterdam, Netherlands, [8]European Haemophilia Consortium, Brussels, Belgium, [9]Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands, [10]National Coagulation Centre, St. James's Hospital, Dublin 8, Ireland

PO141

Switching from standard to extended half-life coagulation factor replacement in hemophilia: clinical outcomes and costs of care in Finland

T. Szanto[1,*], M. Koivusalo[2], T. Kovalainen[2], A. Vesikansa[2], O. Laine[3], A. Partanen[4], T. Siitonen[5], M. Vesanen[6], J. Mehtälä[2], N. Sarnesto[7], J. Haapkylä[7], A.-E. Lehtinen[1], R. Lassila[1]
[1]Coagulation Disorders Unit, Department of Hematology, Comprehensive Cancer Center, Helsinki University Hospital, [2]MedEngine Oy, Helsinki, [3]Department of Internal Medicine, Tampere University Hospital, Tampere, [4]Department of Medicine, Kuopio University Hospital, Kuopio, [5]Department of Medicine, Oulu University Hospital, Oulu, [6]Department of Internal Medicine, Turku University Hospital, Turku, [7]Novo Nordisk Farma Oy, Helsinki, Finland

PO142

Enhancing Global Collaboration: The Role of Data Governance in the WFH Gene Therapy Registry

B. A. Konkle[1], F. Peyvandi[2], M. Naccache[3,*], T. Youttananukorn[3], V. Newman[4], D. Coffin[3], G. F. Pierce[3]
[1]University of Washington, Seattle, United States, [2]Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy, [3]World Federation of Hemophilia, Montreal, Canada, [4]Garthorne Medical and Clinical Limited, Witheridge, United Kingdom

PO143

Shaping the Hemophilia B Pathway to Gene Therapy integration in Spain – The Bhemogen project

S. Bonanad[1,*], M. T. Alvarez[2], S. Garcia-Barcenilla[2], D. A. Garcia-Diego[3], C. Herrera[4], J. B. Montoro[5], J. L. Poveda[1], J. P. Quintero[6], M. R. Lopez[7], I. Cortes[8], I. Gomez[8]
[1]HU La Fe, Valencia, [2]HU La Paz, [3]Spanish Hemophilia Federation, Madrid, [4]HU General Reina Sofia, Cordoba, [5]HU Vall d'Hebron, Barcelona, [6]HU Virgen del Rocio, Sevilla, [7]HU Alvaro Cunqueiro, Vigo, [8]CSL Behring España S.A., Madrid, Spain

PO144

Single center experience of efanesoctocog alfa in adult and pediatric patients with hemophilia A.

K. Schafer[1,*], A. Parekh[1], N. H. Doan[1], C. Angerman[1], M. Sanchez[1], A. Mahajan[1], A. Giermasz[1]
[1]Hematology, University of California, Davis , Sacramento, United States

PO145

Efficacy and safety of rVIII-SingleChain in the perioperative management: experience of two hospitals

B. Pedrote Amador[1,*], R. Núñez Vazquez[1], C. Garcia Diaz[2], T. González López[2]
[1]Hospital Universitario Virgen del Rocio, Seville, [2]Hospital Universitario de Burgos., Burgos, Spain

PO146

SURGERY ON HEMOPHILIACS

F. Kherbache[1,*], N. ZATOUT[2], F. Z. TOUIL[1], R. BELLAL[1], H. HAMOUDA[1]
[1]HEMATOLOGIE, [2]UHC, Setif, Algeria

PO147

The Role of Physical Medicine & Rehabilitation in Ultrasound and Functionality Evaluation in a Reference Centre for Congenital Bleeding Disorders

A. M. Santos Pires[1,*], P. Kjollerstrom[2], R. Maia[2], S. Batalha[2], M. Oliveira[2], D. Caires[3], I. Camarinha[1] on behalf of Reference Centre for congenital Bleeding Disorders Unidade Local de Saúde de S.José
[1]PMR, [2]Hematology, ULSSJosé, [3]PMR, Centro Hospitalar Funchal, Lisbon, Portugal

PO148

Clinical outcomes over 2 years of efanesoctocog alfa in children with severe haemophilia A: European results from the second interim analysis of XTEND-ed

K. Fijnvandraat[1,*], M. Albisetti[2], B. Zülfikar[3], U. Khan[4], H. Palmborg[5], L. Abad-Franch[6], B. Nolan[7]
[1]Emma Children's Hospital/AMC, University of Amsterdam, Amsterdam, Netherlands, [2]University Children's Hospital Zurich, Zurich, Switzerland, [3]Department of Pediatric Hematology, Istanbul University Oncology Institute, Inherited Bleeding Disorders Center, Istanbul, Türkiye, [4]Sanofi, Cambridge, MA, United States, [5]Sobi, Stockholm, Sweden, [6]Sobi, Basel, Switzerland, [7]Children's Health Ireland at Crumlin, Dublin, Ireland

PO149

Survey for the development of an application for the improvement of treatment adherence

R. Gualtierotti[1,2,*], F. Franco[3], L. Bedogni[3], F. Poggi[4], S. Mascetti[5], M. Colussi[1], A. Giachi[1], C. Suffritti[2], F. Peyvandi[1,2]
[1]Department of Pathophysiology and Transplantation, Università degli Studi di Milano, [2]Angelo Bianchi Bonomi Haemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico , Milan, [3]Dipartimento di Scienze Fisiche, Informatiche e Matematiche, Università degli Studi di Modena e Reggio Emilia, Modena, [4]Institute for Cognitive Sciences and Technologies (ISTC), National Research Council (CNR), Bologna, [5]Department of Computer Science Giovanni Degli Antoni, Università degli Studi di Milano, Milan, Italy

PO150

Joint health and quality of life: a one-year evaluation after switching to emicizumab

S. Arcudi[1,*], R. Gualtierotti[1], V. Begnozzi[1], E. Boccalandro[1], S. M. Siboni[1], F. Peyvandi[1]
[1]Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

PO151

Deciding type of prophylaxis in previously untreated / minimally treated infants with hemophilia: Report from a pediatric center

A. Adramerina[1], M. Tritou[1], A. Theodoridou[1], M. Economou[1,*]
[1]1st Pediatric Department, Aristotle University of Thessaloniki, Thessaloniki, Greece

PO152

Developing a Prioritized Set of Advocacy Indicators for Enhanced Hemophilia Care in Africa Using WBDR and AGS Data

S. Diop[1], L. Adiat[2], E. Alafo[3], I. Andrianjafiarinoa[4], O. Awodu[5], I. Bana[6], U. Chirwa[7], M. Coetzee[8], A.-L. Cruickshank[9], D. Dwuma-Badu[10], W. Fowles[11], S. Grobler[12], D. Gwarzo[13], A. Imamba[14], I. Kamara[15], T. Kotila[16], C. Martey[17], F. Mkwenembera[18], N. Midiwo[19], D. Munube[20], V. N. Mabopda Kuate [21], A. B. Nwako[22], T. Nwagha[23], B. Rayner[24], B. Santos[25], T. Tiiti[8], S. A. Toure[26], C. Udo[27], L. Yao[28], S. Yuguda[29], T. Gowa[30], C. Niang[31], P. Dakik[32], E. Tootoonchian[33], D. Coffin[32,*], E. Gouider[34]
[1]Université Cheikh Anta Diop, Dakar, Senegal, [2]LUTH, Lagos, Nigeria, [3]Hospital Central de Maputo, maputo, Mozambique, [4]Hemophilia Treatment Center, Madagascar, Antananarivo, Madagascar, [5]University of Benin, Benin, Nigeria, [6]NHLS Universitas Hospital, Bloemfontein, South Africa, [7]University Teaching Hospitals (UTHs), lusaka, Zambia, [8]University of the Free State, Bloemfontein, [9]UCT/SAHF, cape town, South Africa, [10]Korle-Bu teaching Hospital, accra, Ghana, [11]South Africa Haemophilia Foundation, Durban, [12]NHLS, Bloemfontein, South Africa, [13]Aminu Kano Teaching Hospital, Kano, Nigeria, [14]Lewanika Hospital, mongu, Zambia, [15]CHU de Cocody Abidjan, abidjan, Côte d'Ivoire, [16]University of Ibadan, ibadan, Nigeria, [17]Komfo Anokye Teaching hospital, khumasi, Ghana, [18]Kamuzu Central Hospital, Lilongwe, Malawi, [19]AMPATH MTRH, eldoret, Kenya, [20]Mulago National Referral Hospital, Kampala, Uganda, [21]Centre Hospitalier Universitaire de , Yaoundé, Cameroon, [22]Maseru District Hospital, Maseru, Lesotho, [23]UNTH, Enugu, Nigeria, [24]SAHF, cape town, South Africa, [25]Victória do Espírito Santo, Luanda, Angola, [26]HTC of Dakar, Dakar, Senegal, [27]National Hospital Abuja, Abuja, Nigeria, [28]CHU Sylvanus Olympio, lome, Togo, [29]Gombe State University, Gombe, Nigeria, [30]WFH, Nairobi, Kenya, [31]WFH, Dakar, Senegal, [32]WFH, Montreael, [33]WFH, Montreal, Canada, [34]University Tunis El Manar, tunis, Tunisia

PO154

ARTIFICIAL INTELLIGENCE IN OUR CLINICAL PRACTICE: ABOUT FIX EXTENDED HALF-LIFE CONCENTRATES

M. R, Lopez[1,*], M. Calviño Suarez[2], R. N.Vazquez[3], R. Ocampo Martinez[1]
[1]Hematology and Hemotherapy, Hospital Universitario Alvaro Cunqueiro, Vigo, [2]Hematology and Hemotherapy, Complexo Hospitalario Universitario de Santiago, Santiago de Compostela, [3]Thrombosis and Haemostasis Unit, Hospital Universitario Virgen del Rocio, Sevilla, Spain

PO155

Critical role of Ultrasonography in hemophilia patients (pWH) in developing countries: Revealing the inconspicuous.

M. Bafna[1,2,3,*]
[1]Radiology, Core Diagnostic center, [2]Volunteer, Hemophilia society Kolhapur, [3]consultant radiologist, Star hospital, kolhapur, India

PO156

Pharmacokinetic Study of Emicizumab in a Population of Severe Hemophiliac Patients with and without Inhibitors

O. Benítez Hidalgo[1,*], V. Cortina Gener[1], J. C. Juarez Giménez[2]
[1]Hemophilia Unit, [2]Pharmacy Department, Hospital Vall d'Hebron, Barcelona, Spain

PO157

The relationship between vitamin D deficiency and bone metabolism in adult patients with haemophilia A

M. M. Biernat[1,*], J. Rupa-Matysek[2], D. Jędrzejuk[3], D. Urbaniak-Kujda[1], P. Biernat[4], M. Podolak-Dawidziak[1], T. Wróbel[1]
[1]Department and Clinic of Hematology, Cellular Therapies and Internal Medicine, Wroclaw Medical University, Wroclaw, [2]Department of Haematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, [3]Department and Clinic of Endocrinology, Diabetology, and Isotope Therapy, [4]Chair and Department of Drug Forms Technology, Wroclaw Medical University, Wroclaw, Poland

PO158

Economic Impact of First Gene Therapy (GT) Approval for Hemophilia B (HB) in Spain: A Simulation Study

M. R, Lopez[1,*], R. N.Vazquez[2], R. Ocampo Martinez[1], C. Albo Lopez[1]
[1]Hematology and Hemotherapy, Hospital Universitario Alvaro Cunqueiro, Vigo, [2]Thrombosis and Haemostasis Unit, Hospital Universitario Virgen del Rocio, Sevilla, Spain

PO159

Clinical Implications of Emicizumab in Hemophilia A Management

A. R. Sawal[1,*]
[1]HTC, Hemophilia Patients Welfare Society, Rawalpindi, Pakistan

PO160

Regarding Non Factor Therapies (NFTs); suitable or security? That's the question

M. R, Lopez[1,*], R. N.Vazquez[2], M. Calviño Suarez[3], R. Ocampo Martinez[1], C. Albo Lopez[1]
[1]Hematology and Hemotherapy, Hospital Universitario Alvaro Cunqueiro, Vigo, [2]Thrombosis and Haemostasis Unit, Hospital Universitario Virgen del Rocio, Sevilla, [3]Hematology and Hemotherapy, Complexo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain

PO161

BLEEDING EVENTS IN CHILDREN WITH HAEMOPHILIA A ON EMICIZUMAB: A SINGLE CENTRE EXPERIENCE

A. Michalopoulou[1,*], A. Dettoraki[1], H. Pergantou[1], I. Stamati[1], S. Psoma[1], S. Thymianou[1], E. Karelioti[1], H. Pergantou[1]
[1]Hemophilia Centre/Hemostasis and Thrombosis Unit, "Aghia Sophia" Children's Hospital, Athens, Greece

PO162

Emicizumab Prophylactic Therapy: A Clinical and Laboratory Overview from a Single-Center Perspective

C. E. Ursu[1,*], M. Serban[1], D. Savescu[2], A. Pavlova[3], A. Traila[4], J. M. Patrascu Jr.[5], I. Ionita[6], C. Jinca[7], E. Boeriu[7], F. Ghilezan[8], I. Vaide[9], T. S. Arghirescu[7]
[1]Onco-Hematology Research Unit, Romanian Academy of Medical Sciences, Children Emergency Hospital “Louis Turcanu” Timisoara, European Hemophilia Treatment Centre, [2]Laboratory Department, Children Emergency Hospital “Louis Turcanu” Timisoara, European Hemophilia Treatment Centre, Timisoara, Romania, [3]University Clinic Bonn AöR Institute of Experimental Haematology and Transfusion Medicine, Bonn, Germany, [4]Medical Centre for Evaluation Therapy, Medical Education and Rehabilitation of Children and Young Adults, European Hemophilia Comprehensive Treatment Centre, Buzias, [5]Department of Orthopaedics, “ Victor Babes ” University of Medicine and Pharmacy Timisoara, [6]Department of Hematology, “Victor Babes” University of Medicine and Pharmacy Timisoara, [7]Department of Pediatrics, Division of Onco-Hematology, “ Victor Babes ” University of Medicine and Pharmacy Timisoara, [8]Hematology Clinic, Timisoara Municipal Emergency Clinical Hospital , Timisoara, Romania, [9]Institute of Clinical Medicine, University of Tartu, Tartu, Estonia

PO163

Patient Views on Transitioning from Emicizumab to Efanesoctocog Alfa Prophylaxis: Results from an Online Survey

E. Krumb[1,*], C. Lambert[1], C. Hermans[1]
[1]Hematology, Cliniques universitaires Saint-Luc, Brussels, Belgium

PO164

Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Switching From Emicizumab to Marstacimab: In Vitro Data and Phase 1b Study Design

D. Matino[1,2,*], C. T. Taylor[3], A. Iorio[2,4], D. D. Pittman[5], S. Rakhe[5], J. Teeter[3], S. Kazani[5], F. Biondo[6], B. McComb[7], S. Raje[8], T. Gould[7], A. Palladino[8]
[1]Thrombosis and Atherosclerosis Research Institute, [2]Department of Medicine, McMaster University, Hamilton, ON, Canada, [3]Pfizer Inc, Groton, CT, United States, [4]Department of Health Research Methods, Evidence, and Impact (HEI), McMaster University, Hamilton, ON, Canada, [5]Pfizer Inc, Cambridge, MA, United States, [6]Pfizer Srl, Rome, Italy, [7]Pfizer Inc, New York, NY, [8]Pfizer Inc, Collegeville, PA, United States

PO165

Outcome of Emicizumab in Management of Egyptian Hemophilia A Patients with and without inhibitors: A single center prospective study

M. Abdelwahab[1,*], M. ElGhamrawy[1], H. Seifeldeen [2], N. Fathy[3]
[1]Pediatric Hematology, [2]Pediatric radiology, [3]Pediatrics, Cairo University Pediatric Hospital, Cairo, Egypt

PO166

Evolution and challenges in treatment of hemophilia in South Tunisia

M. Charfi[1,*], O. Kassar[1], F. Kallel[1], H. Charfi[1], R. Kammoun[1], I. Frikha[1], I. Ben Amor[1], R. Mallek[1], A. Koubaa[1], M. Medhaffar[1], M. Elloumi[1]
[1]clinical hematology department, Hedi Chaker Hospital, Sfax, Tunisia

PO167

Self/Home-Infusion of Clotting Factors Prophylaxis In Patients With Severe Hemophilia

B. Habibpanah[1,*], P. Eshghi[1], N. shams[1], Z. Shormeij[1], L. Khanali[1]
[1]Pediatric Congenital Hematologic Disorders Research Center, Research Institute for Children's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran., Tehran, Iran, Islamic Republic Of

PO168

Effectiveness and safety of damoctocog alfa pegol in the fifth interim analysis of the HEM-POWR study: A post hoc analysis of patients with severe and nonsevere haemophilia A from Nordic study sites

P. A. Holme[1,2,*], F. Baghaei[3,4], L. H. Poulsen[5], J. Astermark[6,7]
[1]Department of Hematology, Oslo University Hospital, [2]Institute of Clinical Medicine, University of Oslo, Oslo, Norway, [3]Department of Specialist Medicine, Region Västra Götaland, Sahlgrenska University Hospital, [4]Sahlgrenska Academy, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden, [5]The Haemophilia Center Department of Hematology , Aarhus University Hospital, Aarhus, Denmark, [6]Department of Translational Medicine, Lund University, [7]Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Malmö, Sweden

PO169

Platelet function study in acquired hemophilia A

R. Rossio[1,*], A. Lecchi[1], S. La Marca[1], L. Padovan[1], R. Gualtierotti[1,2], C. Novembrino[1], C. Suffritti[1], A. Ciavarella[1], S. Arcudi[1], S. M. Siboni[1], F. Peyvandi[1,2]
[1]Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, [2]Department of Pathophysiology and Transplantation, , Universita degli studi di Millano, Milan, Italy

PO170

Development of a new examination protocol for women and girls with inherited bleeding disorders

S. Halimeh[1,*], B. Habermann[2]
[1]GZRR, Duisburg, [2]Praxis Orthopädie am Fürstenhof, Frankfurt, Germany

PO171

APREND-HEMOS: an educational pathway for hemophilia and congenital coagulopathies based on patient's needs

R. Berrueco[1,*], N. Caballero[1], C. Benedicto[1], A. Cañellas-Mayor[2], P. Canal[2], R. Basurto[2], A. M. Bosque[2], J. Farreras[3], J. Vinyets[3], M. Fortes[2]
[1]Pediatric Hematology, [2]School of health, [3]Patient experience, Sant Joan de Déu, Esplugues Llobregat, Spain

PO172

Orthopedic surgeries in haemophilia: A single center experience in Turkey

A. B. Antmen[1,*], H. I. Sasmaz[1,2], Y. Sarpel[3], C. Ozkan[4], E. Togrul[3], U. Aygunes[1], D. A. Tuncel[5]
[1]Pediatric Hematology, Acibadem Adana Hospital, [2]Pediatric Hematology, Cukurova University, [3]Orthopedic Surgery, Acibadem Adana Hospital, [4]Orthopedic Surgery, Cukurova University, [5]Pediatric Hematology, Adana City Hospital, Adana, Türkiye

PO173

A Retrospective Evaluation of Joint Health in Patients Followed Up at a Hemophilia Comprehensive Care Center

F. Şahin[1,*], Z. Demirci[1], F. Keklik Karadağ[2], A. Arslan[3], N. Soyer[1], G. Saydam[1]

[1]Ege Adult Hemophilia and Thrombosis Center, Ege University , [2]Hematology Department, Izmir City Hospital, Izmir, Türkiye, [3]Hematology Department, Clinical Transfusion Medicine and Immunogenetics,, Ulm, Germany

PO174

Clinical Outcomes and Safety Profile of Emicizumab for the Management of Children with Hemophilia A in UAE: A Retrospective Study at 2 Tertiary Hospitals in UAE

H. Al Rufaye[1,*], M. F. Khanani[1], N. Awan[1], K. Al Habayba[1], L. Al Khouli[2], H. Al Jabour[2], H. Osman[3], N. Alzein[2]
[1]Pediatric Hematology Oncology, Tawam Hospital, Al Ain, [2]Pediatric Hematology Oncology, SKMC, Abu Dhabi, [3]Adult Hematology Oncology, Tawam Hospital, Al Ain, United Arab Emirates

PO175

Real world experience with the use of Emicizumab in hemophilia A patients with and without inhibitors in Morocco :
Insights from a low- and middle-income country.

N. Khoubila[1,*]
[1]Hematology Department, CHU Ibn Rochd, Casablanca, Morocco

PO176

Clinical and Economic Success of Emicizumab in Acquired Hemophilia: Experience from Two Hospitals in a Spanish Province

P. Tejuca-Gonzalez[1], A. Hernandez-Sanchez[2], K. Hurst[1], R. Awol[2], F.-J. Lopez-Jaime[1,*]
[1]Unidad de Hemostasia y Trombosis, Hospital Universitario Regional de Málaga, [2]Hospital Quironsalud Malaga, Malaga, Spain

PO177

"THE NURSE AS A MEMBER OF THE MULTIDISCIPLINARY TEAM IN THE MANAGEMENT OF HAEMOPHILIA"

K. Panagiotopoulou[1,*], E. Vlahioti[1], I. Stamati[2], S. Psoma[2], A.-A. Derdemezi[1], H. Pergantou[2]
[1]Nursing Services Directorate, [2]Haemophilia Centre/Haemostasis and Thrombosis Unit, General Children's Hospital Agia Sophia, Athens, Greece

PO178

The Impact of Extended Half Life Factors on Quality of Life in Surgery

D. A. Tuncel[1,*]
[1]Pediatric Hematology Oncology Department, Health Sciences University Adana City Training and Research Hospital , Adana, Türkiye

PO179

Audit of recombinant factor replacement despite using Emicizumab prophylactically over 12 months for patients with Moderate or severe Haemophilia A in an adult haemophilia treatment centre South Australia

Y.-H. Y. Lin[1,*], Y. Brennan [1], V. Mavrinac-Tiddy[1]
[1]Haematology, SA health Royal adelaide hospital , Adeladie, Australia

PO180

MAPPING HEMOPHILIA IN CENTRAL KAZAKHSTAN: INSIGHTS FROM A REGIONAL PATIENT REGISTRY

A. Akhmetali[1,2,*], A. Altay[1,2], N. Volobuyeva [1], M. Fominykh [1], L. Turgunova[2], A. Klodzinskiy[3]
[1]Outpatient Unit , "Hematology Center" LLP, [2]General Medicine , Karaganda Medical University , [3]Head office , "Hematology Center" LLP, Karaganda , Kazakhstan

PO181

Observational study to explore physical activity and joint health status in non-severe hemophilia in Castilla La Mancha (CLM), Spain

S. Herrero[1,*] on behalf of Thrombosis and Hemostasis Group of the Castilian-Manchegan Hematology Society (SCMHH), A. Rodríguez [2], M. Nebro[3], A. Martín[4], S. Andrés [5], F. Panadero[6], I. Martínez[7], B. L. Díaz[8], A. Martínez[9], J. A. Perez [10], A. Del Rey [11], M. J. García [12], L. Núñez [13], A. Rodriguez[14]
[1]Hematology, HUG, Guadalajara, [2]Hematology, HUT, Toledo, [3]Hematology, HGUCiudad Real, Ciudad Real, [4]Rehabilitation, HGUAlbacete, Albacete, [5]Rehabilitation, HUG, Guadalajara, [6]Hematology, HGUAlbacete, Albacete, [7]Rehabilitation, HUT, Toledo, [8]Hematology, H.Valdepeñas, Valdepeñas, [9]Hematology, H.Santa Bárbara, Puertollano, [10]Radiology, HUG, Guadalajara, [11]Hematology, H.Hellín, Hellín, [12]Hematology, HVirgen del Prado, Talavera, [13]Hematology, H. De la Mancha Centro, Alcazar De San Juan, [14]Rehabilitation, HGUCiudad Real, Ciudad Real, Spain

PO182

HEALTH-RELATED QUALITY OF LIFE IN CHILDREN WITH HEMOPHILIA A IN A DEVELOPING COUNTRY

M. Elshinawy[1,*], N. Elshinawy[2], N. Alansary[3]
[1]Pediatric Hematology, [2]Faculty of Medicine, Alexandria Univesrsity, [3]Hematology, Medical Research Institute, Alexandria University, Alexandria, Egypt

PO183

allergy with rFVIIa: how to manage it?

A. Mohand Oussaid[1,*], L. sekfali[2], N. boukhedouma[3], K. N. Benhalla Djaddoun[3], A. Ladjouze[1]
[1]pediatric A, chu beni messous, [2]chu mustapha, [3]chu beni messous, algiers, Algeria

PO184

Evaluating the Stability and Efficacy of SCT800 in Perioperative Management of Orthopedic Procedures for Patients with Hemophilia A: A Preliminary Analysis

Y. Xu[1,2,*], J. Yang[3], Z. Yu[4], X. Chen[5], P. Tong[6], F. Guo[7], H. Shang[8], R. Lu[9], J. Sun[10], B. Chen[1]
[1]Nanfang Hospital of Southern Medical University, Guangzhou, [2]Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, [3]Xiangya Hospital, Central South University, Changsha, [4]Henan Provincial People's Hospital, Zhengzhou, [5] Second Affiliated Hospital of Chongqing Medical University, Chongqing, [6]Zhejiang Provincial Hospital of Chinese Medicine, Hangzhou, [7]Tongji Hospital, Tongji Medical College, Wuhan, [8]Shenzhen Second People's Hospital, Shenzhen, [9]Jiangsu Provincial People's Hospital, Nanjing, [10]Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China

PO185

EFFECTIVENESS OF PROPHYLAXIS WITH EXTENDED HALF-LIFE FACTOR CONCENTRATES IN HEMOPHILIA A PATIENTS MANAGED AT THE NATIONAL INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION

M. Nguyen[1,*], P. T. Tran[1], Q. T. Tran[1], B. D. Vu[1,1], T. H. Nguyen[1]
[1]Hemophilia Center, National Institute of Hematology and Blood Transfusion, Hanoi, Viet Nam

PO186

The Bone and Joint Health Assessment in Patients with Severe Hemophilia A at a single institution

J.-Y. Hou[1,*], H.-C. Liu[1], T.-C. Yeh[1], T.-H. Huang[1], C.-Z. Lew[1], C.-Y. Cheng[1]
[1]Division of Pediatric Hematology-Oncology, MacKay Children’s Hospital, Taipei, Taiwan, Province of China

PO187

Anthropometric and Biochemical Profiles of Paediatric Patients with Mild and Moderate Haemophilia

M. Hetman[1,*], G. Dobaczewski[1], E. Latos-Grazynska[1]
[1]Department of Paediatric Bone Marrow Transplantation, Oncology and Haematology, Wroclaw Medical University, Wrocław, Poland

PO188

Clinical characteristics of patients with mild and moderate paediatric haemophilia A and B: a multivariate analysis

M. Hetman[1,*], G. Dobaczewski[1], E. Latos-Grazynska[1]
[1]Department of Paediatric Bone Marrow Transplantation, Oncology and Haematology, Wroclaw Medical University, Wrocław, Poland

PO189

Unlocking Hope - Emicizumab in Acquired Hemophilia: Insights from an Indian Case Series

V. Lobo[1,*], S. Anandram [1], C. Ross[1], S. Rao[1], T. Alphonse[1], G. Vinister[1], C. HB [1], M. B[1], S. B[1], K. N [1], A. R [1], T. S [1]
[1]CLINICAL HEMATOLOGY, SAINT JOHNS MEDICAL COLLEGE, BANGALORE, India

PO190

Bleeding rates and related clinical outcomes before and after use of clotting factor concentrates in Malawi

F. Mkwenembera[1,2,*], Y. Mlombe[2,3]
[1]Haematology, Kamuzu Central Hospital, [2]Society of Haemophilia and Allied Disorders Malawi, [3]Haematology, Kamuzu University of Health Sciences , Lilongwe, Malawi

PO192

Management of patients with hemophilia undergoing percutaneous coronary intervention: pre and post-operative treatment

G. Sottilotta[1,*], E. Gonzalez[2], F. Luise[3], C. M. Rao[4]
[1]UOSD Microcitemie - Emostasi e Trombosi, Grande Ospedale Metropolitano, Reggio Calabria, Italy, [2]Acute Medical Surgery, University Hospital, Salt Lake City (UT), United States, [3]Laboratorio Analisi, [4]Cardiologia - UTIC, Grande Ospedale Metropolitano, Reggio Calabria, Italy

PO193

Clinical management of Hemophilia: A review of advances in gene therapy

P. Ashinze[1,*]
[1]Medicine , Faculty of Clinical Sciences, University of Ilorin , Ilorin, Nigeria

PO194

Cost Savings and Treatment Advancements in Hemophilia A Through Clinical Trial Participation: Insights from a Reference Center

N. Serrano-Garcia[1], M. Luque-Garrido[1], P. Tejuca-Gonzalez[1], C. Ortega de la Cruz[2], J.-C. del Río Valencia[2], F.-J. Lopez-Jaime[1,*]
[1]Unidad de Hemostasia y Trombosis, [2]Servicio de Farmacia, Hospital Universitario Regional de Málaga, Malaga, Spain

PO195

SINGLE EXPERIENCE ABOUT SWITCH TO EXTENDED HALF-LIFE FIX CONCENTRATES (EHL-FIX)

M. R, Lopez[1,*], R. I. Varela[1], M. E. L. Ansoar[1], C. R. Esteban[1], L. D. E. Jimenez[1], G. Cabirta Touzon[1], C. Albo Lopez[1]
[1]Hematology and Hemotherapy, Hospital Universitario Alvaro Cunqueiro, Vigo, Spain

PO196

Succesful Treatment of Type 3 Supracondylar Humerus Fracture in Haemophilia A: A Case Report And Literature Review

M. Soker[1,*], S. Yigit[2], V. H. Uzel[1]
[1]Pediatric Hematology and Oncology, [2]Orthopedics and traumatology, Dicle University, Diyarbakır, Türkiye

PO198

Single-center experience of rare coagulation disorders

C. Balkan[1,*], Z. Demirci[2], N. Abdullayeva[2], G. Saydam[2], F. Şahin[2]
[1]Pediatric Hematology Department, [2]Hematology Department, Ege University , Izmir, Türkiye

PO199

Tailored Treatment in Hemophilia B: Finding the Right Factor IX for Each Patient

A. Carril[1], E. M. Talegon[1,*], L. Eritzpokhoff[2], A. R. Cid[2], S. Haya[2], F. Ferrando[2], A. Blanquer[2], A. Moscardo[2], P. Bosch[2], S. Bonanad[2]
[1]Hemostasis and Thrombosis Unit, Hospital La Fe (the authors contributed equally), [2]Hemostasis and Thrombosis Unit, Hospital La Fe, Valencia, Spain

PO201

Perioperative Hemostasis with Extended half-life recombinant factors in Hemophilia: A Report from Tertiary Center of India

V. A. Bafna[1] on behalf of Department of Medicine, A. S. JADHAV[1,*] on behalf of DEPARTMENT OF MEDICINE, V. S. PATIL[1] on behalf of DEPARTMENT OF MEDICINE, A. A. Paritekar[1] on behalf of DEPARTMENT OF MEDICINE, S. M. kumbhojkar[2] on behalf of Department of Paediatrics
[1]MEDICINE, [2]paediatrics, RCSM CPR HOSPITAL , KOLHAPUR, India

PO202

The hemorrhagic profile of hemophiliacs with inhibitors Experience of CHU Oran

A. Cherif Hosni[1], Y. Rahal[1,*], M. Bensahli[1], R. Messaoudi[1]
[1]hematology, Oran university hospital, oran, Algeria

PO203

CLINICAL AND DEMOGRAPHIC CHARACTERISTICS OF PATIENTS WITH ACQUIRED HEMOPHILIA A- A SINGLE CENTRE STUDY

J. Bodrozic[1,2,*], P. Miljic[1,2], N. Suvajdzic-Vukovic[2,3], M. Mitrovic[2,3], D. Lekovic[2,3], D. Antic[2,3], S. Vlajin[3]
[1]Cabinet for hemophilia and other hemostatic disorders, Clinic of Hematology, University Clinical Center of Serbia, [2]Faculty of Medicine, University of Belgrade, [3]Clinic of Hematology, University Clinical Center of Serbia, Belgrade, Serbia

PO204

Inhibitors in haemophilia B: about recombinant Albumin-bound FIX: A clinical case

M. R, Lopez[1,*], R. Iglesias Varela[1], E. Lopez Ansoar[1], C. R. Esteban[1], L. Del Estal Jimenez[1], G. Cabirta Touzon[1], C. Albo Lopez[1]
[1]Hematology and Hemotherapy, Hospital Universitario Alvaro Cunqueiro, Vigo, Spain

PO205

Assessment of cardiovascular risk factors in patients with severe hemophilia A

M. S. Cruz[1,*], J. P. Ortíz[1], J. A. santillan[1]
[1]salta, Fundación de la hemofilia de Salta, salta, Argentina

PO206

CLINICAL AND LABORATORY ASSESSMENT OF EMICIZUMAB PROPHYLAXIS IN ADULT PATIENTS WITH HAEMOPHLIA A (PwHA)

A. Kouramba[1,*], I. Anastasopoulou[1], P. Christoforou[1], S. Gotsi[1], T. Pyrpyri[1], E. Kelaidis[1], O. Katsarou[1]
[1]Blood Transfusion Service and National Reference Center for Congenital Bleeding Disorders, ''Laiko'' General Hospital, Athens, Greece, Athens, Greece

PO207

Acquired hemophilia before and in Covid-19 pandemic: Single center experience

P. Dulíček[1,2,*], P. Sadílek[1] on behalf of Hemophilia center in University Hospital in Hradec Králové, E. Heinrich[1], E. Heinrich[1]
[1]Of Hematology, University Hospital, [2]Of Hematology, Medical Faculty, Hradec Králové, Czech Republic

PO208

Real-world quality of life data in patients with haemophilia A and haemophilic arthropathy after 1 year of emicizumab therapy

K. Rener[1,*], T. Sobotic[1], M. Urbancic[2], I. Preloznik Zupan[1]
[1]Haematology, UMC Ljubljana, [2]Clinum, Ljubljana, Slovenia

PO209

Prophylaxis with APCC in a Case of Haemophilia B with Inhibitors and Recurrent Iliopsoas Bleeding

A. Küpesiz[1,*], F. Tayfun Küpesiz[1]
[1]Pediatrics, Akdeniz University, Antalya, Türkiye

PO210

Quality of Life in Persons with Severe Haemophilia - insights from the WBDR registry from North East India

A. Dutta[1,*], E. Ayoub[2] on behalf of WBDR Group
[1]Department of Medicine, Assam Medical College and Hospital, Dibrugarh, India, [2]WFH, Montréal, Canada

PO211

Can surgery be performed without any bleeding with one extra dose of rFVIIIFc between prophylaxis days?

S. Aytac[1,*], S. Aydın[2], A. Simsek[3], T. Soyer[4], G. Simsek[5], O. Kuscu[6], H. Taylan Sekeroglu[7]
[1]Department of Pediatric Hematology, Hacettepe University Faculty of Medicine , Ankara, [2]Department of Pediatric Hematology and Oncology, Antalya Training and Research Hospital, Antalya , [3]Department of Pediatric Hematology and Oncology, Konya City Hospital, Konya, [4]Department of Pediatric Surgery, Hacettepe University Faculty of Medicine , Ankara, [5]Department of Surgery , Konya City Hospital, Konya, [6]Department of ENT , [7]Department of Ophthalmology , Hacettepe University Faculty of Medicine , Ankara, Türkiye

PO212
Prophylaxis in children with hemophilia at the Sétif pediatric center
M. Mouna[1,*]
[1]Medicine, CHU Setif Pediatric Center, Setif, Algeria

PO214
Anticoagulation and Anti-Aggregation Approaches in 2 Cases of severe haemophilia: Experience of Our Centre
J. Felix[1,*], C. Camara[1], F. Pires[1], E. Gonçalves[2], A. Pereira[1], F. Rodrigues[1], B. Freitas[2], C. Catarino[1]
[1]ULS Santa MAria, Lisbon, [2]Hospital Dr Nélio Mendonça, Funchal, Portugal

PO215
Case report of Emicizumab in young patient with acquired haemophilia
E. Millen[1,*], J. Hermans[1]
[1]Nottingham Haemophilia Comprehensive Care Centre, Nottingham, United Kingdom

PO216
EXPERIENCE WITH EMICIZUMAB IN PATIENTS WITH MODERATE-SEVERE HEMOPHILIA A IN OUR CENTER
C. Vaz Silva[1,*], B. Díaz Roldán[1], J. F. Domínguez Rodríguez[1], C. Gil Barroso[1]
[1]Haemophilia, Hospital Universitario Juan Ramón Jiménez, Huelva, Spain

PO217
Prevalence of hepatitis and human immunodeficiency virus in our population with hemophilia (PWH)
S. Herrero[1,*], A. Rodríguez [2], M. Nebro[3], A. Martín[4], S. Andrés [5], F. Panadero[6], I. Martínez[7], B. L. Díaz[8], A. Martínez[9], J. A. Perez [10], A. Del Rey [11], M. J. García [12], L. Núñez [13], A. Rodriguez[14], C. Cerveró[15]
[1]Hematology, HUG, Guadalajara, [2]Hematology, HUT, Toledo, [3]Hematology, HGUCiudad Real, Ciudad Real, [4]Rehabilitation, HGUAlbacete, Albacete, [5]Rehabilitation, HUG, Guadalajara, [6]Hematology, HGUAlbacete, Albacete, [7]Rehabilitation, HUT, Toledo, [8]Hematology, H.Valdepeñas, Valdepeñas, [9]Hematology, H.Santa Bárbara, Puertollano, [10]Radiology, HUG, Guadalajara, [11]Hematology, H.Hellín, Hellín, [12]Hematology, HVirgen del Prado, Talavera, [13]Hematology, H. De la Mancha Centro, Alcazar De San Juan, [14]Rehabilitation, HGUCiudad Real, Ciudad Real, [15]Hematology, H. Virgen de la Luz, Cuenca, Spain

PO218
SURGICAL RESECTION AND PERIOPERATIVE MANAGEMENT OF LARGE HAEMOPHILIC PSEUDOTUMORS: CASE REPORT
C. Doudakmanis[1], D. Prevezanos[1], A. Kouraba[2,*], F. Stavratis[1], P. Dorovinis[1], M. Keramida[1], A. Loizou[1], I. Lyberis[1], S. Kykalos[1], N. I. Nikiteas[1], G. Tsouroufl is[1]
[1]2nd Propaedeutic Department of Surgery, National and Kapodistrian University of Athens, [2]Blood Bank Department, Laiko General Hospital of Athens, Athens, Greece

PO219
Intracranial bleedings with initially suspected child abuse in patients with severe haemophilia: Two case reports.
R. Knöfler[1,*], J. Lohse[1], F. Boiti[1], O. Tiebel[2], R. Beck[3]
[1]Dept. of Pediatric Haemostaseology, [2]Dept. of Laboratory Medicine, [3]Dept. of Pediatric Surgery, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

PO220

Validation of the Dutch version of the PROMIS® Sexual Function and Satisfaction Measure in Dutch people with haemophilia and women with Von Willebrand disease

T. Van Gastel[1,2,3,*], L. Teela[1,2,4], M. Luijten[1,2,5], V. Lehmann[6], M. Peters[7], K. Fijnvandraat[7], L. Haverman[2,4,8]
[1] Emma Children's Hospital, Child and Adolescent Psychiatry & Psychosocial Care, Amsterdam UMC, location University of Amsterdam, [2]Child Development, Amsterdam Reproduction and Development, [3]Mental Health and Health Behaviors & Chronic Diseases, [4]Mental Health and Digital Health, [5]Mental Health and Methodology, Amsterdam Public Health, [6]Department of Medical Psychology, [7]Emma Children's Hospital, Paediatric Haematology, Amsterdam UMC, location University of Amsterdam, [8] Emma Children's Hospital, Child and Adolescent Psychiatry & Psychosocial Care, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands

PO221

Orthopantomographic data to assess bone density in haemophilia.

D. Johns[1,*]
[1]twins medicity, kudunji, India

PO222

Type 2N von Willebrand Disease: one disease, different phenotypes.

G. Baptista[1,2,*], M. Coutinho[1], N. Seidi[1], N. Pinho[1], M. Pereira[1], E. Cruz[1], S. Morais[1]
[1]Imuno-hemoterapia, Centro Hospitalar Universitário de Santo António, Porto, [2]Imuno-hemoterapia, Centro Hospitalar Universitário de Lisboa Central, Lisboa, Portugal

PO223

The role of genetics and the importance of a multidisciplinary approach in the diagnosis of Von Willebrand Disease – preliminary results in 194 patients of a Portuguese Centre

F. Pires[1,*], M. Oliveira[1], J. Felix[1], C. S. Pinto[2], P. Martinho[2], F. Rodrigues[1], A. Pereira[1], C. Catarino[1], T. Fidalgo[2]
[1]Hospital Santa Maria, ULS Santa Maria, Lisboa, [2]ULS Coimbra, Coimbra, Portugal

PO224

Reviewing the diagnosis of von Willebrand disease using new laboratory tests and recent consensus guidelines in paediatric patients attending the Paediatric Coagulation Centre at Children's Health Ireland at Crumlin

L. Devitt[1], B. Nolan[1,*] on behalf of Mairead Doyle, Kevin Ryan, Marie Lyons, Sara Byrne, Catriona Keenan, Saad Ahmed, Beatrice Nolan.
[1]Department of Haematology, Children's Health Ireland Crumlin, Dublin, Ireland

PO225

The gene conversions involving the amino acid Pro1266 appear to be common in the Italian von Willebrand disease (VWD) population and contribute to different VWD types.

L. Baronciani[1,*], P. Colpani[1], O. Seidizadeh[2], M. T. Pagliari[1], G. Cozzi[1], L. Pati[3], S. M. Siboni[1], F. Peyvandi[1,2]
[1]Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, [2]Department of Pathophysiology and Transplantation, [3]Department of Biosciences, Università degli Studi di Milano, Milan, Italy

PO226

The Clinical Application of a Novel Ristocetin-Independent Von Willebrand Activity Assay

S. Digiandomenico[1,*], R. Sidonio, [1], M. Brown[1], C. Maier[1]
[1]Emory University, Atlanta, United States

PO227

Diagnosis of type 2B VWD: a complex issue

M. Pereira[1], V. Almeida[1], R. Matos[1], M. D. L. Moreira[1], P. Freitas[1], M. Coutinho[1], E. Cruz[1,*], S. Morais[1]
[1]Centro de Referência de Coagulopatias Congénitas, Centro Hospitalar Universitário de Santo António, Porto, Portugal

PO228

Assessment of biological response to desmopressin in VWD patients: preliminary results

L. J. Mettis[1,*], T. Szanto[2,3], M. Pikta[4,5], K. Saks[6]
[1]Department of Hematology, North Estonia Medical Centre, Tallinn, Estonia, [2]Coagulation Disorders Unit, Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, [3]University of Helsinki, Helsinki, Finland, [4]Department of Laboratory Medicine, North Estonia Medical Centre, [5] Tallinn University of Technology, [6]Department of Hematology and Oncology, Tallinn Children's Hospital, Tallinn, Estonia

PO229

Effect of the polymorphic variant p.D1472H on the platelet-dependent VWF activity using VWF:GPIbR

O. Seidizadeh[1,*], L. Pati[2], L. Baronciani[3], P. Colpani[3], G. Cozzi[3], M. T. Pagliari[3], C. Novembrino[3], A. Cairo[3], E. Pappalardo[1], F. Peyvandi[1,3]
[1]Department of Pathophysiology and Transplantation, [2]Department of Biosciences, Università degli Studi di Milano, [3]Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy

PO230

Prevalence of Von Willebrand Disease Types Among Patients with Low Von Willebrand Factor Activity Based on Laboratory Profile and Genetic Studies

M. Ahmadinejad[1], B. Azari[1,*], R. Shamriz[1], M. Mojtabavi Naeini[1]
[1]Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran, Islamic Republic Of

PO231

Application of Von Willebrand Factor Propeptide in Identification of Type 1C Von Willebrand Disease Patients

B. Azari[1,*], M. Ahmadinejad[1], R. Shamriz[1], M. Mojtabavi Naeini[1]
[1]Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran, Islamic Republic Of

PO232

Clustered Referral of Family Members Suspected of Type 2B Von Willebrand Disease

R. Shamriz[1], M. Ahmadinejad[1], B. Azari[1,*], M. Mojtabavi Naeini[1]
[1]Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran, Islamic Republic Of

PO233

Presence of Subjects with Von Willebrand Factor Polymorphism p.D1472H among patients with low VWF:GPIbR levels

B. Azari[1,*], M. Ahmadinejad[1], R. Shamriz[1], M. Mojtabavi Naeini[1]
[1]Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran, Islamic Republic Of

PO234

A Case of Type 2N von Willebrand Disease Due to Homozygous p.Arg816Trp Mutation

E. Turkkan[1,*], B. Erturk[2]
[1]Pediatric Hematology, University of Health Science, Hamidiye Faculty of Medicine, Prof dr Cemil Tascioglu City Hospital, [2]Medical Genetics, Prof dr Cemil Tascioglu City Hospital, Istanbul, Türkiye

PO235

Familial Multiple Coagulation Factor Deficiencies (VWD/FVIID): A Study From Five Families

M. Ahmadinejad[1], F. Ramezani[1,*], M. Mojtabavi[1], R. Shamriz[1], E. Ghodratnia[1], S. Salarinejad[1], F. MohammadAli[1]
[1]Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran, Islamic Republic Of

PO237

Self-BAT and PBAC Scores in Adolescents From The General Dutch Population: Results From The Menstruation Education Calendar App.

A. de Vaan[1,*], H. Özcan[2,3], R. A. de Leeuw[2,3], K. P. van Galen[1]
[1]Center for Benign Haematology, Thrombosis and Haemostasis,van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, [2]Department of Obstetrics and Gynaecology, Amsterdam UMC, location Vrije University of Amsterdam,, [3]Amsterdam Reproduction and Development, Amsterdam, Netherlands

PO238

Predictors of von Willebrand factor antigen and activity, and factor VIII activity in patients with transfusion-dependent beta-thalassemia

M. Bordbar[1,*], S. Bordbar[2]
[1]Pediatric Hematology, [2]Shiraz Medical School, Shiraz University of Medical Sciences, Shiraz, Iran, Islamic Republic Of

PO240

Global Prevalence of platelet-type von Willebrand disease

O. Seidizadeh[1,*], A. Cairo[2], M. Othman[3], F. Peyvandi [1,2]
[1]Department of Pathophysiology and Transplantation, University of Milan, [2]Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, [3]Department of Biomedical & Molecular Sciences, Queen's University, Milan, Italy

PO241

Characterization of Acquired von Willebrand Syndrome: Association Between Bleeding Phenotype and Laboratory Parameters

A. Ciavarella[1,*], O. Seidizadeh[2], P. Colpani[1], G. Cozzi[1], A. Iurlo[3], M. T. Pagliari[1], S. M. Siboni[1], L. Baronciani[1], F. Peyvandi[1,2]

[1]Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, [2]Department of Pathophysiology and Transplantation, University of Milan, [3]Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

PO242

Increased prophylactic dosing frequency reduces bleeding in von Willebrand disease patients requiring more haemostatic coverage

R. F. Sidonio Jr[1,*] on behalf of WIL-31 study group
[1]Department of Pediatrics, Emory University School of Medicine, Atlanta, United States

PO243

Title: Health-related quality of life of French adults with von Willebrand disease: WiSH-QoL study results according to von Willebrand factor (VWF: RCo) activity levels.

A. Borel-Derlon[1,*], D. Desprez[2], F. Genre-Volot[3], H. Chambost[4], L. Ardillon[5], B. Pan-Petesch[6], N. Itzhar-Baïkian[7], M. Barthez-Toullec[8], M.-H. André-Bonnet[8], Y. Repessé[1], S. Susen[9], S. von Mackensen[10], J. Goudemand[9]
[1]Haemophilia treatment center, CHU Caen - CRMW, Caen, [2]Haemophilia treatment center, CHRU Strasbourg, Strasbourg, [3]Haemophilia treatment center, CHU Dijon, Dijon, [4]Haemophilia treatment center, AP-HM, Marseille, [5]Haemophilia treatment center, CHU Tours, Tours, [6]Haemophilia treatment center, CHU Brest, Brest, [7]Haematology Unit, CHU Lariboisière, Paris, [8]Clinical development and medical affairs, LFB Biotechnologies, Les Ulis, [9]Haematology Unit, CHU Lille - CRMW, Lille, France, [10]Medical Psychology Department, University Medical centre, Hamburg-Eppendorf, Germany

PO244

A new Desmopressin nasal spray provides a safe and effective treatment solution for people with VWD type 1 and non-severe hemophilia.

A. Gringeri[1,*], G. De Giorgi[2], J. H. Hval[3]
[1]Charta Foundation, Milano, [2]Hemorare, Pisa, Italy, [3]Staq Pharma, Denver, United States

PO245

The Significance of von Willebrand Factor Multimer analysis in the Clinical Classification of von Willebrand Disease: A Centre's Experience

P. Christoforou[1,*], I. Anastasopoulou[1], A. Kouraba[1], P. Katsiampoura[1], A. Zannou[1], T. Pyrpyri[1], O. Katsarou[1]
[1]Blood unit and National Reference Center for Congenital Bleeding Disorders, ''Laiko'' General Hospital, Athens, Greece

PO246

Postpartum Hemorrhage in Pregnant Women with and without Von Willebrand Disease: A Systematic Review and Meta-Analysis

S. Joshi[1,*], S. Kharel[1], S. Gurung[2]
[1]Maharajgunj Medical Campus, Institue of Medicine, Kathmandu, [2]Deparment of Physiology, Chitwan Medical College, Chitwan, Nepal

PO247

Regular prophylaxis with a 1:1 von Willebrand factor/Factor VIII concentrate is effective for reducing joint and muscle bleeds in children and adults with von Willebrand disease

A. Boban[1,2,*], R. F. Sidonio Jr[3], T. Lissitchkov[4], K. Vilchevska[5], C. Djambas Khayat[6]

[1]Department of Internal Medicine, University Hospital Centre Zagreb, [2]Zagreb University School of Medicine, Zagreb, Croatia, [3]Department of Pediatrics, Emory University School of Medicine, Atlanta, United States, [4]Specialized Hospital for Active Treatment of Haematological Diseases, Sofia, Bulgaria, [5]National Specialized Children's Hospital, Kyiv, Ukraine, [6]Hotel Dieu de France Hospital, Saint Joseph University,, Beirut, Lebanon

PO248

Evaluating Prophylaxis in von Willebrand Disease: Outcomes and Efficacy in Severe Cases

B. Zulfikar[1,*], B. Koc[1]
[1]Hereditary Bleeding Disorders Unit, Istanbul University Oncology Institute, Istanbul, Türkiye

PO249

Von Willebrand factor substitution for neuraxial anesthesia in women with persistent von Willebrand deficiency at term of pregnancy

Y. Mechelfekh[1,2,*], K. Kali[3], P. Noyel[4], A. Montmartin[5], M. Tuffigo[1,2], A. Butelet[6,7], B. Guillet[8,9], C. Falaise[10,11,12], N. Drillaud[13], M. Chirila-Hetsch[14], L. Macchi[15], P. Beurrier[16], B. Tardy[17,18,19]
[1]Laboratoire d'Hématologie, CHU d'Angers, [2]Univ Angers, Nantes Université, CHU Angers, Inserm, CNRS, CRCI2NA, F-49000, Angers, [3]INSERM CIC 1408 Laboratory of Hematology, [4]CHU de Saint-Etienne, Laboratoire d'Hématologie, [5]Inserm U1059, Sainbiose Dysfonction Vasculaire et Hémostase, Université de Lyon, Saint-Etienne, [6]Service d'hématologie biologique, Pôle de biologie, Hôpital Robert Debré, CHU de Reims, [7]Haemophilia Treatment Centre, University Hospital of Reims, Reims, [8]Haemophilia Treatment Center, Rennes University Hospital, [9]Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, [10]APHM, La Timone Children's Hospital, Department of pediatric hematology and oncology, [11]APHM, CHU Timone, Laboratory of Hematology, [12]APHM, CHU Timone, French national reference center for inherited platelet disorders (CRPP), Marseille, [13]Haemophilia Centre, Nantes University Hospital, Nantes, [14]Service d'Hématologie, Hôpital de Valence, Valence, [15]University of Poitiers, INSERM 1313, IRMETIST, F-86000 Poitiers, France; CHU de Poitiers, Laboratory of hematology, F-86000, Poitiers, [16]Hemophilia Treatment Center, Vascular and Coagulation Clinic, University Hospital Angers, Angers, [17]Centre de Ressources et de Compétence Maladies hémorragiques, CHU Saint-Etienne, Hôpital Nord, [18]Sainbiose, Inserm, U1059, Université Lyon, [19]Inserm, CIC 1408, CHU Saint-Etienne, Hôpital Nord, Saint-Etienne, France

PO250

von Willebrand factor (VWF:RCo) activity levels have an impact on health-related quality of life of adolescents with von Willebrand disease (VWD) and their family

J. Goudemand[1,*], C. Berger[2], F. Genre-Volot[3], S. Bayart[4], D. Desprez[5], S. Claeyssens[6], N. Itzhar-Baïkian[7], M. Barthez-Toullec[8], M.-H. André-Bonnet[8], Y. Repessé[9], S. Susen[1], S. von Mackensen[10], A. Borel-Derlon[9]
[1]Haematology Unit, CHU LILLE - CRMW, Lille, [2]Haemophilia treatment center, CHU Saint-Etienne, Saint-Etienne, [3]Haemophilia treatment center, CHU Dijon, Dijon, [4]Haemophilia treatment center, CHU Rennes, Rennes, [5]Haemophilia treatment center, CHRU Strasbourg, Strasbourg, [6]Haemophilia treatment center, CHU Toulouse, Toulouse, [7]Haematology Unit, CHU Lariboisière, Paris, [8]Clinical development and medical affairs, LFB Biotechnologies, Les Ulis, [9]Haemophilia treatment center, CHU Caen - CRMW, Caen, France, [10]Medical Psychology Department, University Medical centre, Hamburg-Eppendorf, Germany

PO251

Efficacy and Safety of Prophylaxis with a Plasma-derived von Willebrand Factor/Factor VIII Concentrate in Male and Female Patients with von Willebrand Disease

R. F. Sidonio Jr[1,*] on behalf of WIL-31 study group
[1]Department of Pediatrics, Emory University School of Medicine, Atlanta, United States

PO252

Exploring the potential of AI; Regarding efficiency in the treatment of VWD. an spanish simulation

M. R. Lopez[1,*], R. N. Vazquez[2], R. Salvado[3], R. O. Martinez[1], C. A. Lopez[1]
[1]Hematology and Hemotherapy, Hospital Universitario Alvaro Cunqueiro, EOXI Vigo, Vigo, [2]Hematology and Hemotherapy, Hospital Universitario Virgen del Rocio, Sevilla, Spain, [3]Serviço de Imuno-Hemoterapia, Centro de Referência de Coagulopatias Congénitas, Centro Hospitalar e Universitário de Coimbra, Coimbra, Coimbra, Portugal

PO253

GLOBAL NEED OF DESMOPRESSIN FOR PEOPLE WITH VON WILLEBRAND DISEASE AND HEMOPHILIA A

A. Gringeri[1,*], G. Castaman[2], F. Peyvandi[3,4], P. M. Mannucci[5]
[1]Charta Foundation, Milan, [2]Centre for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, [3]Department of Pathophysiology and Transplantation, Università degli Studi di Milano, [4]Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico, [5]Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico and University of Milan, Milan, Italy

PO254

Inducing Immune Tolerance in Severe Von Willebrand Disease Type 3

A. Carril[1], E. M. Talegon[2,*], L. Eritzpokhoff[3], S. Haya[3], A. R. Cid[3], B. Argiles[4], S. Izquierdo[4], A. Blanquer[3], F. Ferrando[3], A. Moscardo[3], P. Bosch[3], S. Bonanad[3]
[1]Unidad de Hemostasia y Trombosis, [2]Hemostasis and Thrombosis Unit, Hospital La Fe (authors contributed equally), [3]Hemostasis and Thrombosis Unit, [4]Pediatric Hematology , Hospital La Fe, Valencia, Spain

PO255

ANALYSIS OF VWF DOSIFICATION, FREQUENCY AND EFFICACY IN PROPHYLAXIS FROM DIFFERENT CLINICAL TRIALS

M. R, Lopez[1,*], R. N. Vazquez[2], E. L. Ansoar[1], R. O. Martinez[1], C. A. Lopez[1]
[1]Hematology and hemotherapy, Hospital Universitario Alvaro Cunqueiro, Vigo, [2]Hematology and hemotherapy, Hospital Universitario Virgen del Rocio, Sevilla, Spain

PO256

Efficacy of Prophylactic Emicizumab in Type III Von Willibrand Disease Patients: A Report of Two Cases.

O. F. Kashari[1,*], A. K. Almqaadi[1]
[1]Hematology, Alaziziyah Children Hospital, Jeddah, Saudi Arabia

PO257

Implementing prophylaxis in von Willebrand disease: reviewing the clinical case of a particular patient

I. Moreira[1,*], L. Costa[1], S. Silva[1], S. Teixeira[1], S. Fernandes[1], M. Carvalho[1], F. Araújo[1]
[1]Immunohemotherapy, Unidade Local de Saúde de São João, Porto, Portugal

PO258

Severe bleeding events in von Willebrand disease in Southern Tunisia

R. MALLEK[1], F. Kallel[1,*], F. MEGDICHE[2], M. CHARFI[1], I. FRIKHA[1], I. BEN AMOR [1], A. KOUBAA[1], M. MEDHAFFAR[1], C. KALLEL[2], M. ELLOUMI[1]
[1]Hematology, hedi chaker hospital, [2]hematology , HABIB BOURGUIBA HOSPITAL, SFAX, Tunisia

PO259

Occurrence of Type 1 von Willebrand disease and severe hemophilia B in the same family: Is it a coincidence or not?

Z. Kaya[1,*], S. Kirkiz Kayalı[1], E. Yılmaz[1], T. Atik[2]
[1]Pediatric Hematology, Gazi University Faculty of Medicine, Ankara, [2]Pediatric Genetics, Ege University Faculty of Medicine, İzmir, Türkiye

PO260

Use of thalidomide for refractory bleeding in von Willebrand disease.

O. Tsiamita[1,*], J. Collins[1], S. Sivapalaratnam[1,2], P. Raheja[1], O. O'Connor[1]
[1]Haemophilia, Barts Health NHS Trust, [2]Queen Mary University of London, London, United Kingdom

PO261

Rupture of ovarian cysts in willebrand disease, about 3 cases

S. S. Lakehal[1,*]
[1]EPH bouzidi lakhdar , Bordj bouarreridj, Algeria

PO262

Gastointestinal bleeding in people with von Willebrand disease in southern of Tunisia

F. Kallel[1,2,*], R. MALLEK[1], F. MEGDICHE[3], M. CHARFI [1], I. FRIKHA [1], H. GDOURA[4], I. BEN AMOR[1], A. KOUBAA[1], M. MEDHAFFAR[1], N. TAHRI[4], C. KALLEL[3], M. ELLOUMI[1]
[1]hematology, hedi chaker hospital, [2]HEMATOLOGY, FACULTY OF MEDECINE SFAX, [3]hematology, HABIB BOURGUIBA HOSPITAL, [4]GASTROLOGY, hedi chaker hospital, SFAX, Tunisia

PO263

A Rare Cause of Iron Deficiency Anemia: Type III Von Willebrand Disease and Angiodysplasia"

S. Karaman[1,*], Y. Yilmaz[1], G. Erbas[1], Z. Onal[2], S. Sahin[1], Z. Karakas[1], D. Tugcu[1], G. Tanyildiz[1], A. Unuvar[1]
[1]Pediatric Hematology Oncology Department, [2]Pediatric gastroenterology, Istanbul University Faculty of Medicine, Istanbul, Türkiye

PO264

Management of a hepatic laceration in a child with the Vicenza variant of Willebrand disease with Wilate® : Insights from an alsatian experience

E. Hammami[1,*], G. Bellon-serre [2], A. SPIEGEL-BOUHADID[2], I. Harzallah[1], O. Feugeas [3], D. Desprez[3]
[1]Hematology, [2]Pediatrics, Groupe Hospitalier Régional Mulhouse et Sud Alsace, Mulhouse, [3]CRC-MHC, Hôpitaux universitaires de strasbourg, Starsbourg, France

PO265

Single-center experience with treatment options of menorrhagia in patients with Von Willebrand Disease

C. Balkan[1,*], N. Ozdemir[1], C. Onder[1], D. Karapinar[1], K. Kavakli[1]
[1]Pediatric Hematology, Ege University Children's Hospital, Izmir, Türkiye

PO266

The Challenging Diagnosis of von Willebrand Disease Type 1C: a Clinical Case

B. Oliveira Rocha[1,*], S. Teixeira[1], M. Carvalho[1], S. Fernandes[1], I. Soares dos Santos[2], F. Araújo[1]
[1]Congenital Coagulopathies Reference Center, Unidade Local de Saúde de São João, EPE, Porto,
[2]Imunohemotherapy, Unidade Local de Saúde de Trás-os-Montes e Alto Douro, EPE, Vila Real, Portugal

PO267

Investigating the genetic profile of 527 cases with rare bleeding disorders

S. Mohsenian[1,*], O. Seidizadeh [1], A. Cairo[2], R. Palla[1], M. Menegati[2], F. Peyvandi[1,2]
[1]Department of Pathophysiology and Transplantation, Università degli Studi di Milano, [2]Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy

PO268

A rapid whole blood ATP secretion test can be used to exclude platelet dense granule deficiency

M. Zivkovic[1,*], R. E. Schutgens[1], V. van der Vegte[1], J. Lukasse[1], M. Roest[2], D. Huskens[2], A. S. de Moor[1], I. Kremer-Hovinga[1], R. T. Urbanus[1]
[1]Center for benign haematology, Van Creveldlkiniek, University Medical Center Utrecht, Utrecht, [2]Synapse Research Institute, Maastricht, Netherlands

PO269

COMPUTATIONAL MODELLING OF CARTILAGE DAMAGE IN HAEMOPHILIC ARTHROPATHY

V. S. M. Peddapeta[1,*], H. Fermor[2], G. de Boer[1], M. Mengoni[1]
[1]School of Mechanical Engineering, [2]School of Biomedical Sciences, University of Leeds, Leeds, United Kingdom

PO270

ATP-Release Identifies Platelet Function Disorders in Patients with Bleeding Disorder of Unknown Cause (BDUC) and Normal LTA Results

A. Monard[1,2,*], F. van Dellen[1], B. Brandt[1], D. Hellenbrand[3], P. Verhezen[3], E. Beckers[1], Y. Henskens[3], F. Heubel-Moenen[1]
[1]Hematology, MUMC+, [2]CARIM, Maastricht University, [3]Central Diagnostic Laboratory, MUMC+, Maastricht, Netherlands

PO271

Congenital fibrinogen disorders unraveled: Data from the Dutch RBiN study

B. Haisma[1,2,*], N. M. Blijlevens[1], M. H. Cnossen[3], P. L. den Exter[4], I. C. Kruis[5], K. Meijer[6], L. Nieuwenhuizen[7], N. V. Es[8], J. L. Saes[9], S. R. Rijpma[2,10], W. L. van Heerde[2,11], S. E. Schols[1,2]
[1]Department of Hematology, Radboud university medical center, [2]Hemophilia Treatment Center Nijmegen-Eindhoven-Maastricht, Nijmegen, [3]Department of Pediatric Hematology and Oncology, Erasmus MC Sophia Children's Hospital, University Medical Center Rotterdam, Rotterdam, [4]Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, [5]Netherlands Hemophilia Society, Nijkerk, [6]Department of Hematology, University Medical Center Groningen, Groningen, [7]Department of Hematology, Maxima Medical Center, Eindhoven, [8]Department of Vascular Medicine, Amsterdam University Medical Centers, Amsterdam, [9]Department of Benign Hematology, Van Creveldkliniek, University Medical Center Utrecht, Utrecht, [10]Department of Laboratory Medicine, Laboratory of Hematology, Radboud university medical center, [11]Enzyre BV, Noviotech Campus, Nijmegen, Netherlands

PO272

Exploring hemostasis in Chemotherapy-Induced Thrombocytopenia insights from NATEM-ROTEM and T-TAS01 analysis

N. Meskes[1,2], H. de Lil[3], F. Heubel-Moenen[1,*], Y. Henskens[2]
[1]Hematology, Internal Medicine, [2]Central Diagnostic Laboratory , Maastricht University Medical Centre, Maastricht, [3]Hematology, Internal Medicine, Máxima Medical Centre, Eindhoven, Netherlands

PO273

Characteristics of clinical phenotype and genotype in 114 patients with inherited fibrinogen disorders from Slovakia

T. Simurda[1,*], M. Drotarova[1], I. Skornova[1], K. M. Belakova[1], M. Brunclikova[1], Z. Lasabova[2], J. Zolkova[1], Z. Kolkova[3], D. Loderer[3], J. Sokol[1], J. Stasko[1]
[1]Department of Hematology and Transfusiology, [2]Department of Molecular Biology and Genomics, [3]Biomedical Center Martin, Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin and University Hospital in Martin, Martin, Slovakia

PO274

Congenital Factor X Deficiency: a report of a single-center experience

I. Krichen[1,*], F. Megdiche[1], Y. Fakhfakh[2], F. Ben Said[2], M. Hassairi[3], L. Gargouri[3], M. Elloumi[2], C. Kallel[1]
[1]Laboratory of Hematology, Habib Bourguiba Hospital, [2]Hedi Chaker Hospital, Clinical Hematology, [3]Hedi Chaker Hospital, Department of Pediatrics B, Sfax, Tunisia

PO275

Management of pregnancy and childbirth in Glanzmann Thrombasthenia: a scoping review

K. H. G. Rutten[1,*], R. E. G. Schutgens[1], R. d'Oiron[2,3], M. Fiore[4], G. Castaman[5], K. Gomez[6], K. P. M. van Galen[1] on behalf of Glanzmann Disease Working Group and Women and Girls with Bleeding Disorders Working Group
[1]Center for Benign Haematology, Thrombosis and Haemostasis, Van Creveldkliniek, University Medical Center Utrecht, Utrecht, Netherlands, [2]Centre de Référence de l'Hémophilie et des Maladies Hémorragiques Rares, Hôpital Bicêtre APHP , [3]INSERM Hémostase Inflammation Thrombose HITH U1176, Université Paris-Saclay, Le Kremlin-Bicêtre, [4]Haematology Laboratory, Reference Center for Inherited Platelet Disorders, University Hospital of Bordeaux, Pessac, France, [5]Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, Florence, Italy, [6]Haemophilia Centre and Thrombosis Unit, Royal Free, London NHS Foundation Trust, London, United Kingdom

PO276

Health related Quality of Life (HrQoL) in patients with Bleeding Disorder of Unknown Cause (BDUC)

A. Monard[1,2,*], S. Tegels[1], B. Brandt[1], I. Merry[1], F. Derikx[1], Y. Henskens[3], E. Beckers[1], F. Heubel-Moenen[1]
[1]Hematology, MUMC+, [2]CARIM, Maastricht University, [3]Central Diagnostic Laboratory, MUMC+, Maastricht, Netherlands

PO277

FXI deficiency beyond bleeding- is there a higher risk for allergic diseases?

R. S. Alesci[1,*], J. Verheyen[2,3], C. E. Dempfle[3], W. Miesbach[4], A. Huseynov[3,5]
[1]IMD blood coagulaation center Hochtaunus, Bad Homburg, [2]Institute of Immunogenetics, Kaiserslautern, [3]IMD blood coagulation centre Mannheim, Mannheim, [4]Frankfurt Haemophilia Centre, Goethe University Frankfurt Hospital, Frankfurt, [5]1. Dept of Medicine, University Medical Centre, Mannheim, Germany

PO278

Descriptive epidemiology of factor VII deficiency in south of Tunisia

I. Ben Amor[1,*], I. Krichen[2], I. frikha[1], I. Maaloul[3], O. Kraiem[4], T. Kammoun[5], C. Kallel[6], M. Elloumi[7]
[1]Hematology, Hedi Chaker, [2]Hematology, Habib Bourguiba, [3]Pediatric department, Hedi Chaker Hospital, [4]Hematology, Gabes Hospital, [5]Laboratory of Hematology, Hedi Chaker, [6]Laboratory of Hematology, Habib Bourguiba, [7]Clinical Hematology, Hedi Chaker, Sfax, Tunisia

PO279

Bethesda assay for detecting anti-ADAMTS13 antibodies

V. K. P. Yeung[1,*]
[1]Department of Pathology, Princess Margaret Hospital, Hong Kong, Hong Kong

PO280

Preparing girls with bleeding disorders for Menarche: development of an EAHAD patient information guide

D. Carbonero[1] on behalf of Women and Girls with Bleeding Disorder, R. Abdul-Kadir[2], K. van Galen[3,*], K. Gomez[4], M. Lavin[5], R. d'Oiron[6], G. Golan[7], P. Elfvinge[8] on behalf of Women and Girls + with Bleeding Disorders Working Group
[1]European Association for Haemophilia and Allied Disorders (EAHAD), Brussels, Belgium, [2]Department of O&G and Katharine Dormandy Haemophilia and thrombosis Centre , The Royal Free NHS Foundation Hospital , Institute for Women's Health, University College London, London, United Kingdom, [3]Center of Benign Haematology, Thrombosis and Haemostasis , Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands, [4]Haemophilia Centre and Thrombosis Unit, Royal Free London NHS Foundation Trust, London, United Kingdom, [5]Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, RCSI, Dublin National Coagulation Centre, St. James's Hospital, Dublin, Ireland, [6]Reference Centre for Hemophilia and Rare Bleeding Disorders, AP-HP, Bicêtre Hospital, University Paris-Saclay and UMR S1176 INSERM, Le Kremlin-Bicêtre, France, [7]Israel National Hemophilia Center, Sheba Medical Center, Ramat Gan, Israel, [8]Karolinska, Stockholm, Sweden

PO281

Molecular basis of congenital factor V deficiency in France: results of a large cohort of 217 families

M. Fretigny[1,*], C. Vinciguerra[1], Y. Jourdy[1]
[1]Groupe Hospitalier Est, Service d'Hématologie Biologique, Hospices Civils de Lyon, Bron, France

PO282

Platelet Storage Pool Defects (SPDs) in syndromic patients

M. Shahbazi[1,*], M. Ahmadinejad[2]
[1]Thalassemia & Hemoglobinopathy Research Center, Research Institute of Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, [2]Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran, Islamic Republic Of

PO283

Update on a Phase 3 Study of a Double Virus-Inactivated Human Antithrombin Concentrate During Surgery or Childbirth in Patients with Congenital Antithrombin Deficiency

C. M. Kessler[1], C. Ay[2], M. R. Guzman Fernandez[3], P. Simioni[4], M. Tarantino[5], A. Rodriguez[6], T.-E. Weisz[7], C. Solomon[8,*], Z. Oláh[9]
[1]Georgetown University Hospital, Washington, United States, [2]Medical University of Vienna, Vienna, Austria, [3]Ourense University Hospital, Ourense, Spain, [4]Universtity Hospital of Padua, Padua, Italy, [5]Bleeding & Clotting Disorders Institute, Peoria, [6]Octapharma, USA, Inc., New Jersey, United States, [7]Octapharma Pharmazeutika Produktionsgesellschaft mbH, Vienna, Austria, [8]Octapharma AG, Lachen, Switzerland, [9]University of Debrecen, Debrecen, Hungary

PO285

The proteomic landscape of platelets in Glanzmann thrombasthenia

M. Zivkovic[1,*], T. M. Shamorkina[2], M. W. Blaauwgeers[1], H. Post[2], A. J. Heck[2], R. E. Schutgens[1], R. T. Urbanus[1]

[1]Center for benign haematology, Van Creveldlkiniek, University Medical Center Utrecht, [2]Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands

PO286

Heavy Menstrual Bleeding: A Common Symptom in Women with Bleeding Disorder of Unknown Cause (BDUC)

A. Monard[1,2,*], S. Tegels[1], B. Brandt[1], I. Merry[1], F. Derikx[1], Y. Henskens[3], E. Beckers[1], F. Heubel-Moenen[1]
[1]Hematology, MUMC+, [2]CARIM, Maastricht University, [3]Central Diagnostic Laboratory, MUMC+, Maastricht, Netherlands

PO287

Bleeding Disorder of Unknown Cause, a report from a uni-center national referral coagulation lab

M. Ahmadinejad[1], M. Shahbazi[2,*]
[1]Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, [2]Thalassemia & Hemoglobinopathy Research Center, Research Institute of Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, Islamic Republic Of

PO288

ABNORMAL UTERINE BLEEDING AND HEMOCOAGULATIVE DISORDERS IN ADOLESCENCE: A CROSS-SECTIONAL STUDY

S. Iavarone[1], G. Ubertini[2], M. E. Amodeo[2], G. Di Felice[3], A. L. Montemari[3], M. Luciani[1,*]
[1]Onco-Hematology, Cell and Gene Therapy and Bone Marrow Transplant Clinic Area , [2]Unit of Endocrinology and Diabetology, [3]Clinical Laboratory Unit, Bambino Gesù Children's Hospital, Rome, Italy

PO289

Genetic Analysis and Functional Platelet Assessment of a Novel ABCG8 Mutation in a Patient with Sitosterolemia

J. A. Rodríguez Alén[1,*], M. D. L. O. Abío Calvete[1], A. Sánchez Fuentes[2], A. Marín-Quílez[2], P. L. Gómez-González[2], M. L. Lozano[2], J. Rivera[2] on behalf of Grupo Español de Alteraciones Plaquetarias Congénitas (GEAPC), N. R. Simón[1], J. M. Bastida[3] on behalf of Grupo Español de Alteraciones Plaquetarias Congénitas (GEAPC), J. Cuesta Tovar[1] on behalf of ISCIII-FEDER (PMP21/0005;PI23/00624;PI24/01458);Fundación Séneca (21920/PI/22);GRS2551/A/22,GRS2727/A1/23
[1]Servicio de Hematología, Hospital Universitario de Toledo, Toledo, [2]Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Pascual Parrilla, CIBERER-U765, Murcia, [3]Servicio de Hematología, Complejo Asistencial Universitario de Salamanca (CAUSA), Instituto de Investigación Biomédica de Salamanca (IBSAL), Universidad de Salamanca (USAL), Salamanca, Spain

PO290

Management of tooth extractions and full-mouth debridement in patients affected by Glanzmann Thrombasthenia: a retrospective observational study in University Hospital of Strasbourg

L. Pierre[1], M. Delarue[2], F. Bornert[2], M. Soell[2], F. Severac[3], O. Feugeas[1], D. Desprez[1,*]
[1]Haematology, CRC MHC, [2]Department of Oral Medicine and Surgery, [3]public health department, Strasbourg, France

PO291

Exploring Combined Congenital Deficiency of Coagulation Factors VII and XIII in Siblings

F. Megdiche[1,*], I. Frikha[2], I. Krichen[1], I. Ben Amor[2], R. Mallek[2], H. Charfi[2], M. Charfi[2], F. Kallel[2], M. Medhaffer[2], M. Elloumi[2], C. Kallel[1]
[1]Laboratory of Hematology, Habib Bourguiba Hospital, [2]Clinical Hematology, Hedi Chaker Hospital, Sfax, Tunisia

PO292

Management of Glanzmann Disease: Understanding Management of Anti-Platelet Antibodies via a European Survey

M. Fiore[1,2,*], R. Schutgens[3], M. Mathias[4], A. Artoni[5], R. Klamroth[6], R. d'Oiron[7,8] on behalf of the EAHAD Glanzmann Disease Working Group
[1]Department of Haematology, [2]French Reference Centre for Inherited Platelet Disorders, University Hospital of Bordeaux, Pessac, France, [3]Department of Benign Hematology, Thrombosis and Haemostasis, van Creveldkliniek, University Medical Center Utrecht and University Utrecht, Utrecht, Netherlands, [4]Haemophilia Comprehensive Care Centre, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom, [5]Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, [6]Department of Internal Medicine, Hemophilia Treatment Center, Vivantes Klinikum im Friedrichshain, Berlin, Germany, [7]Centre de Référence de l'Hémophilie et des Maladies Hémorragiques Rares, Hôpital Bicêtre AP-HP, [8] INSERM Hémostase Inflammation Thrombose HITH U1176, Université Paris-Saclay, Paris, France

PO293

Clinical significance of Immature Platelet Fraction above 30%: one year in Bicêtre hospital

C. Lavenu-Bombled[1,2,*], A. Sarthou[1], M. Jeday[1], S. Berrada[1], V. Coyaud[1], S. Barreau[1], A. Blandinieres[1,2]
[1]Service Hématologie Biologique CRC MHEMO, Hôpital Bicêtre APHP, [2]Inserm , UMR1176, Faculté Paris Saclay, Le Kremlin-Bicêtre , France

PO294

Insights on Acquired Factor VII Deficiency in Stem Cell Transplant Recipients: A Retrospective Study

M. T. Vieira[1,*], S. Ribeiro[1], A. Mascarenhas[1], C. Freitas[2], S. Pereira[2], R. Ramalho[3], R. Barreira[3], I. Ferreira[2], N. Miranda[2]
[1]Transfusion Medicine, Local Health Unit of São José, [2]Blood Marrow Transplant Unit, [3]Clinical Pathology, Portuguese Oncology Institute of Lisbon Francisco Gentil, Lisbon, Portugal

PO295

SURGICAL PROPHYLAXIS IN PATIENTS WITH RARE COAGULATION FACTOR DEFICIENCIES: EXPERIENCE FROM A SECOND-LEVEL HOSPITAL

C. Gil Barroso[1,*], B. Díaz Roldán[1], J. F. Domínguez Rodríguez[1], C. Vaz Silva[1], P. Pérez García[1]
[1]Hospital Juan Ramón Jiménez, Huelva, Spain

PO296

Acquired factor XI deficiency in paediatrics patients: A French series of four cases

A. Theron[1], J. AVOINE[2], C. GALEOTTI[2,*], A. HARROCHE[3], S. Azaenoush[4], Y. Huguenin[5], A. Blandinieres[6]
[1]Department of Paediatric hematology and oncology, Montpellier University Hospital, Montpellier University, Montpellier, [2]Reference center of hemophilia, Bicêtre University Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Saclay University,, Le Kremlin-bicêtre, [3]Reference Centre for Constitutional Haemorrhagic Diseases, Necker University Hospital, [4]Department of Paediatric hematology, Robert Debre Hospital, Assistance Publique-Hôpitaux de Paris, Paris, [5]Department of Paediatric hematology and oncology, Bordeaux University Hospital, Bordeaux,

[6]Department of hematology, Bicêtre University Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Saclay University,, Le Kremlin-bicêtre, France

PO297

clinical features of Factor XI deficiency: About 100 cases in southern Tunisia

F. Kallel Sarbeji[1,*], F. megdiche [2], M. CHARFI[1], I. FRIKHA[1], M. bahloul[3], I. KRICHEN[2], R. mallek [1], I. ben amor[1], A. koubaa[1], M. medhaffar[1], T. kammoun[3], C. kallel[2], M. elloumi [1]
[1]hematology department, HEDI CHAKER HOSPITAL, [2]hematology department, habib bourguiba hospital, [3]pediatric department , HEDI CHAKER HOSPITAL, SFAX , Tunisia

PO298

The importance of Romiplostim in Oncology Patients Affected by Chemotherapy-Induced Thrombocytopenia (CIT): positive impact on treatment delay and dose-reduction

U. Markovic[1], S. Grasso[1,*], D. Leotta[1], G. Giunta[1], A. Nardo[1], G. Novello [2], G. Giuffrida[1]
[1]Unità Operativa Semplice Malattie Rare Ematologiche, [2]Oncologia Medica, AOU Policlinico G.Rodolico- S.Marco, Catania, Italy

PO299

Successful subcutaneous infusion of plasmatic F VII - concentrate for bleeding prophylaxis

W. Eberl[1,*], M. Alrifai[2], S. Schmandt[3]
[1]Pediatrics, [2]Laboratory medicine, [3]Transfusion medicine, Klinikum Braunschweig, Braunschweig, Germany

PO300

A pathogenic variant in PTPN11 is linked to excessive bleeding after invasive procedures in a patient with BDUC

P. García-Jaén[1,2,*], C. Puerta-Vázquez[1], E. Zapata-Tapia[1], R. J. Malaver-Campos[1], C. Santos-Marcos[1], D. Clavo-Martín[1], A. Fernández-Sánchez[1], C. T. Fuentes-Morales[1], C. Prieto[1], M. D. L. Á. Sanz-Barbero[1], J. R. González-Porras[1,2], J. M. Bastida[1,2,3]
[1]Hematology, Complejo Asistencial Universitario de Salamanca, [2]Instituto de Investigación Biomédica de Salamanca (IBSAL), Universidad de Salamanca (USAL), Salamanca, [3]Grupo Español de Alteraciones Plaquetarias Congénitas (GEAPC), Spain, Spain

PO301

Molecular genetic diagnosis of Bernard Soulier syndrome in Iranian patients; reporting four novel mutations

E. Ghodratnia[1], S. Tabibian[2,*], M. Barati[3], M. Safa[1]
[1]Department of Hematology and Blood Banking, Iran University of Medical Science , [2]Blood Diseases Research Center , Iranain Comprehensive Hemophilia Care Center , [3]Department of Medical Biotechnology, Iran University of Medical Science , tehran , Iran, Islamic Republic Of

PO302

management of patients with Factor X deficiency

M. Bensadok[1,*], N. ferroudj[1], M. terchi[1], N. zidani[1], S. nekkal[1]
[1]hematology and blood bank , beni messous Hospital, Algeria

PO303

Destructive arthropathy due to hemarthrosis in a patient with Glanzmann thrombasthenia - “case report”

M. I. Sharif[1,*], H. Alzahrani[1]

[1]Department of Hematology , Stem Cell Transplant and Cellular Therapy , King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

PO304

Molecular and Clinical Profile of Rare Bleeding Disorders: A Single-center Retrospective Study

A. Ahmadfard Moghadam[1], A. R. Manafzadeh[2], S. S. Moazezi [3], F. Ramezan[3], D. Bashash[1], M. Hamidpour[4], S. Tabibian[3,*]
[1]Department of Hematology and Blood Banking,, Shahid Beheshti University of Medical Sciences, Tehran , Iran, Islamic Republic Of, [2]Department of Internal Medicine, Albert Szent-Györgyi Health Centre, University of Szeged,, Szeged, Hungary, [3]Blood Diseases Research Center (BDRC), Iranian Comprehensive Hemophilia Care Center, Iran University of Medical Sciences (IUMS),, [4]Hematopoietic Stem Cell Research Centre–Department of Hematology and Blood Banking, Shahid Beheshti University of Medical Sciences, Tehran , Iran, Islamic Republic Of

PO305

Efficacy and Safety of a New Human Fibrinogen Concentrate for Treatment of Bleeding Events in Patients with Congenital Fibrinogen Deficiency

C. Djambas Khayat[1], A. Khelif[2], W. Miesbach[3,*], H. Boehm[4], S. Aigner[4], S. Abraha[4], F. Bohlaender[4], J. Schuettrumpf[4,5] on behalf of On Behalf of the CFD Study Group
[1]Department of Pediatrics, Hotel Dieu de France Hospital Beirut, Saint Joseph University, Beirut, Lebanon, [2]Hospital Farhat Hached, Sousse, Tunisia, [3]Department of Hemostasis/Hemophilia Centre, Medical Clinic 2, University Hospital Frankfurt, Frankfurt, [4]Biotest AG, Dreieich, Germany, [5]Grifols, Barcelona, Spain

PO306

Girls and women with bleeding disease and endometriosis: an alsatian case-serie

E. Hammami[1,*], O. Feugeas [2], D. Desprez[2]
[1]hematology, GHRMSA, Mulhouse, [2]CRC-MHC, Hôpitaux Universitaires de Strasbourg, Strasbourg, France

PO307

Investigating familial multiple coagulation factor deficiencies : data from Southern Tunisia

I. FAKHFEKH[1], F. MEGDICHE[1], I. FRIKHA[2], I. KRICHEN[1], Y. FAKHFEKH[2], L. KHALIFA[2], F. KALLEL[2], N. SIALA[2], M. CHARFI[2,*], M. MEDHAFFAR[2], M. ELLOUMI[2], C. KALLEL[1]
[1]Laboratory of Hematology, Hospital University Habib Bourguiba, Sfax, Tunisia, [2]Department of clinical Hematology, Hospital University Hedi Chaker, Sfax, Tunisia, Sfax, Tunisia

PO308

Genetically confirmed 46 patients with inherited thrombocytopenia: A city experience from Türkiye

V. Gök[1,*], A. Özcan[1], F. T. Mutlu[2], E. Yılmaz[1], D. K. Göl[1], M. B. Mutlu[3], M. E. Doğan[4], A. Bişgin[5], M. Rohlfs[6], M. Dündar[7], Y. Özkul[7], C. Klein[6], M. Karakükcü[1], E. Ünal[1,8]
[1]Division of Pediatric Hematology and Oncology, Department of Pediatrics, Erciyes University, [2]Division of Pediatric Hematology and Oncology, Department of Pediatrics, Kayseri City Hospital, [3]DETAGEN Genetic Diseases Evaluation Center, [4]Department of Medical Genetics, Kayseri City Hospital, Kayseri, [5]Department of Medical Genetics, Çukurova University, Adana, Türkiye, [6]Division of Pediatric Hematology and Oncology, Department of Pediatrics, Dr von Hauner Children's Hospital, Ludwig Maximilians University, Munich, Germany, [7]Department of Medical Genetics, Erciyes University, Kayseri, [8]Pediatric Hematology and Oncology Clinic, Medical Point Hospital, Gaziantep, Türkiye

PO309

Dielmma between Thrombosis and Bleeding in Philadelphia-Negative Myeloproliferative Neoplasms

M. A. ELLOUMI[1], F. MEGDICHE[1], Y. FAKHFAKH[2], I. KRICHEN[1], I. BEN AMOR[2], I. BEN AYED[1], I. FRIKHA[2,*], L. KHALIFA[2], R. MALLEK[2], M. CHARFI[2], N. AJMI[3], M. ELLOUMI[2], C. KALLEL[1]
[1]Laboratory of Hematology, Hospital University Habib Bourguiba, [2]Department of clinical Hematology, Hospital University Hedi Chaker, [3]Free practice clinical hematologist, Sfax, Tunisia

PO310

GLANZMANN THROMBASTHENIA IN ADULTS AND CHILDREN IN GREECE

A. Michalopoulou[1,*], A. Kouramba[2], A. Dettoraki[1], P. Christoforou[2], S. Saslis[1], M. Gavalaki[2], O. Katsarou[2], H. Pergantou[1]
[1]Haemophilia Centre/Haemostasis and Thrombosis Unit, "Aghia Sophia" Children's Hospital, [2]Blood Transfusion Service and National Reference Center for Congenital Bleeding Disorders, ”Laiko” General Hospital, Athens, Greece

PO311

Severe Hypofibrinogenemia in a Patient with sysmetic sclerosis with pulmonary disease treated with Tocilizumab

C. RAULET-BUSSIAN[1,*], L. GOUBEAU[1], I. MARTIN-TOUTAIN[1,2], E. DE RAUCOURT[2], H. PAKTORIS[3], V. LAURENT[3], C. TRIDON[3], A. BRIZARD[3], G. LACAVE[3], C. Flaujac[1]
[1]78, Laboratoire de biologie médicale (secteur hémostase), Centre hospitalier de Versailles - Hôpital André Mignot,, [2]78, Centre de ressources et compétences maladies hémorragiques, Centre hospitalier de Versailles - Hôpital André Mignot, [3]78, Service de réanimation, Centre hospitalier de Versailles - Hôpital André Mignot, Le Chesnay-Rocquencourt, France

PO312

"Refractory Primary Immune Thrombocytopenia (ITP): A Diagnostic and Therapeutic Challenge."

L. Villarroya Martínez[1], L. Fernández Cuezva[1], R. González Resina[1], M. S. Ordás Miguélez[1], M. Herrero Gutiérrez[1], P. López Gómez[1], F. Cadenas Gota[1], R. Palacios Orellana[1], R. Monleón Gil[1], D. Lozada Poveda[1], L. Etxebarría Bahíllo[1], J. Obregón Membreño[1], J. M. Calvo Villas[2], N. Fernández Mosteirín[2,*]
[1]Hospital Universitario Miguel Servet, Zaragoza, Spain, [2]Hemostasia, Hospital Universitario Miguel Servet, Zaragoza, Spain

PO313

Severe Hereditary Factor XIII Deficiency and Brain Hemorrhage

C. Albayrak[1,*], D. Albayrak[2]
[1]Pediatric Hematology, Ondokuz Mayıs University, [2]Pediatric Hematology, Samsun Medicalpark Hospital, Samsun, Türkiye

PO314

A rare disease presenting with a rare coagulopathy: A rare disease

M. Abdelwahab[1,*], R. Mohsen[2]
[1]Pediatric Hematology, [2]Pediatric Hepatology, Cairo University Pediatric Hospital, Cairo, Egypt

PO315

Clinical spectrum and treatment outcomes of Rare Bleeding Disorders in Females: A two-center Experience in North Pakistan

M. Usman[1,2,*], N. Shahbaz[1], R. iftikhar[1], H. tariq[1], M. Gilani[1], M. Ali khan[1], M. khan[1], T. Zafar[3]

[1]Clinical hematolgy, Armed forces bone Marrow Transplant , [2]Hemophilia treatment center, rawalpindi, Pakistan, [3]Clinical hematolgy, Hemophilia treatment center, Rawalpindi, Pakistan

PO316

Cross talk between oxidative stress and redox potential of platelets in the pathogenesis of Immune thrombocytopenia; a new insight

A. Arshad[1,*], S. N. Mukry[2], T. Shamsi[1]
[1]Department of Hematology, [2]Department of Transplant Immunology and Applied Microbiology, National Institute of Blood Diseases and Bone Marrow Transplantation, Karachi, Pakistan

PO317

Hereditary fibrinogen deficiency: fatal outcome

E. Yakovleva[1,*], K. Sabirov[1], N. Zozulya[1], I. Iurev [1], O. Pshenichnicova[1], V. Surin[1]
[1]National Medical Research Center for Hematology, Moscow, Russian Federation

PO318

An Audit of the Diagnosis of Bleeding Disorder of Unknown Cause

C. J. Chan[1,*], E. Aradom[1], P. Chowdary[1], A. Drebes[1], B. Jradeh[1], A. Riddell[1], K. Gomez[1], P. Batty[1,2]
[1]Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital NHS Foundation Trust, [2]Cancer Institute, Department of Haematology, University College London, London, United Kingdom

PO319

Plasminogen deficiency and ligneous : two case reports

O. Benítez Hidalgo[1,*], J. Pamias Romero[2], N. Martin Begue[3], E. Sol Segarra[1], J. C. Juarez Giménez[4]
[1]Hemophilia Unit, [2]Maxillofacial and Oral Surgery, [3]ophthalmology Department, [4]Pharmacy Department, Hospital Vall d'Hebron, Barcelona, Spain

PO320

Ligth transmission aggregometry normal values: what about age and sex influence?

A. Dericquebourg[1], A. De-Wreede[1], C. Nougier[1], H. Rezigue[2,*]
[1]Hospices Civils de Lyon, [2]Hématologie biologique , Hopital Louis Pradel HCL LYON, Lyon, France

PO321

Glanzmann Thrombasthenia: challenges in the care of patients and outcomes

A. Salmi[1,*], N. Cherif[1], O. Gacem[1]
[1]pediatric hemato-oncology, the university hospital of beni messous algiers, algiers, Algeria

PO322

Management of pregnancy of a rare case of Glanzmann Thrombasthenia caused by two homozygous mutations in ITGB3 and ITGA2B

S. Hammer[1,2,*], K. Althaus[1,2], G. Uzun[1,2], S. Nowak-Harnau[2], G. Hoepner[2], T. Bakchoul[1,2]
[1]Institute for Clinical and Experimental Transfusion Medicine, [2]Center for Clinical Transfusion Medicine, University Hospital of Tuebingen, Tuebingen, Germany

PO323

Perioperative Management of Patients With Rare Factor Deficiency, Single-Center Experience

F. Şahin[1,*], Z. Demirci[1], N. Abdullayeva[1], A. Güneş[1], N. Soyer[1], G. Saydam[1]
[1]Ege Adult Hemophilia and Thrombosis Centers , Ege University, Izmir, Türkiye

PO324

MANAGING A PREGNANT WOMAN WITH GLANZMANN'S THROMBASTHENIA: A CLINICAL CHALLENGE

N. Ben Sayed[1,*], A. Rahal[1], G. Nourhene[1], R. belguecem[1], G. Monia[1], C. wafa[1], K. zahra[1], B. Ouni[2,3], Y. ben youssef[1], H. regaieg[4], A. khelif[4]
[1]Helatology departement, [2]Farhat Hached Hospital, [3]pharmacoloy departement, ibn jazzar medical college, [4]Hematology departement, Farhat Hached Hospital, sousse, Tunisia

PO325

Jugular thrombosis in context of severe FV deficiency

M. R, Lopez[1,*], R. Iglesias Varela[1], M. E. Lopez Ansoar[1], L. Del Estal Jimenez[1], C. R. Esteban[1], G. Cabirta Touzon[1], C. Albo Lopez[1]
[1]Hematology and Hemotherapy, Hospital Universitario Alvaro Cunqueiro, Vigo, Spain

PO326

Coexistence of Congenital Anomalies and Congenital Factor Deficiency: Coincidence or Predisposition? Single Center Report

M. Sezgin Evim[1,*], Y. Düzenli Kar[1], A. Meral Güneş[1]
[1]Pediatric Hematology , Uludag University , Bursa, Türkiye

PO327

Exploration of rare deficiencies in common pathway coagulation factors: a study in Southern Tunisia

F. Megdiche[1], I. Krichen[1], Y. Fakhfakh[2], I. Frikha[2], M. Charfi[2,*], F. Ben Said[2], M. Elloumi[2], C. Kallel[1]
[1]Laboratory of Hematology, Habib Bourguiba University Hospital, [2]Department of Clinical Hematology, Hedi Chaker University Hospital, Sfax, Tunisia

PO328

High risk of acquired rare bleeding disorders in elderly patients with concomitant hematological diseases: a single center experience

S. Pasca[1,*], P. Agostini[1], L. Novarese[1], P. Boccagni[1]
[1]Transfusion and Immunohematology, Azienda Provinciale Servizi Sanitari, Trento, Italy

PO329

The efficacy of therapeutic plasma exchange in combination with corticosteroid and rituximab for the treatment of refractory acquired hemophilia A

C. Chaiadisaksopha[1,*], P. Nirapan[1], P. Sinsakolwat[1], N. Hantrakun[1]
[1]Internal Medicine, Chiang Mai University, Chiang Mai, Thailand

PO330

Molecular study of IBD in women and girls in Tunisia

H. Elmahmoudi[1,*], C. Ouerdani[1], M. Gharbi[1], C. Jebali[1], A. Zaier[1], E. Gouider[1]
[1]Aziza othmana hospital, Tunis, Tunisia

PO331

Light transmission aggregometry is not suitable for monitoring hemostatic changes after platelet transfusion in Glanzmann thrombasthenia

K. H. G. Rutten[1,*], O. Tsiamita[2], R. T. Urbanus[1], S. Platton[2], M. Fiore[3], S. Sivapalaratnam[2,4], R. E. G. Schutgens[1] on behalf of Glanzmann Disease Working Group

[1]Center for Benign Haematology, Thrombosis and Haemostasis, Van Creveldkliniek, University Medical Center Utrecht, Utrecht, Netherlands, [2]Department of Clinical Haematology, Barts Health NHS Trust, The Royal London Hospital, London, United Kingdom, [3]Haematology Laboratory, Reference Center for Inherited Platelet Disorders, University Hospital of Bordeaux, Pessac, France, [4]Blizard Insititute and PHURI, Queen Mary University of London, London, United Kingdom

PO332

Acquired hemophilia A : A monocentric study

I. Frikha[1,*], I. Krichen[2], L. Khalifa[1], F. Kallel[1], I. Ben Amor[1], F. Megdiche[2], M. Charfi[1], Y. Fakhfakh[1], C. Kallel[3], M. Medhaffer[1], M. Elloumi[1]
[1]Clinical Hematology, Hedi Chaker Hospital, [2]Laboratory of hematology, Babib Bourguiba Hospital, [3]Laboratory of hematology, Hedi Chaker Hospital, Sfax, Tunisia

PO333

Recurrent bleeding episodes in a patient with an overdose of antivitamin K antagonist treatment: Beyond thrombosis in antiphospholipid syndrome.

C. Puerta Vázquez[1,*], A. P. Crisolino Pozas[2], P. García Jaén[1], V. Benito García[3], D. Clavo Martin[1], E. G. Zapata Tapia[1], D. Alonso Castronuño[1], A. Cerdán Morala[2], C. Prieto Carro[1], M. D. L. Á. Sanz Barbero[1], J. R. González Porras[1,4], J. M. Bastida Bermejo[1,4]
[1]Hematology, [2]Internal Medicine, [3]Clinical Analysis Laboratory, Complejo Asistencial Universitario de Salamanca, [4]Instituto de Investigación Biomédica de Salamanca (IBSAL), Universidad de Salamanca (USAL), Salamanca, Spain

PO334

A woman with Glanzmann's thrombasthenia and severe gingival bleeding was treated with local and systemic hemostatic therapies. Personalized therapy, dynamic rFVIIa dosing, and a multidisciplinary approach successfully controlled bleeding episodes.

R. González Resina[1], L. Fernández Cuezva[1], J. E. Obregón Membreño[1], M. Herrero Gutiérrez[1], M. S. Ordás Miguélez[1], P. E. López Gómez[2], L. Etxebarría Bahillo[1], L. Villarroya Martínez[1], R. Monleón Gil[1], F. Cadenas Gota[1], R. Palacios Orellana[1], D. F. Lozada Poveda[1], S. González López[1], J. Castañeda Fernández[1], P. Martínez Forga[1], J. M. Calvo Villas[1], N. Fernández Mosteirín[1,*]
[1]Hematología y Hemoterapia, Hospital Universitario Miguel Servet, Zaragoza, [2]Hematología y Hemoterapia, Hospital de Barbastro, Barbastro, Spain

PO335

Congenital factor 7 deficiency and surgery, about 3 cases

S. S. Lakehal[1,*]
[1]34, EPH Bouzidi lakhdar , bBordjbouarreridj, Algeria

PO336

Severe FV deficiency leading To Intracranial haemorrhage

R. Fenton[1,*], K. Forsyth [1], S. Platton[1], R. Barnard[1], S. Sivapalaratnam[1], S. Sharif[1], P. Raheja[1]
[1]Haemophilia comprehensive care centre , The Royal London Hospital , London , United Kingdom

PO337

Congenital "rare" bleeding disorders (RBDs) in Children: A Report of a Single-Center Experience

A. Salmi[1,*], N. Cherif[1], W. Messadi[1], O. Gacem[1]
[1]pediatric hematology and oncology, the university hospital of Beni Messous, Algiers, Algeria

PO338

Management of acquired factor X deficiency in a patient with multiple myeloma: a case study

F. Daniele[1,*], V. Rossi[1], C. Santoro[1], M. Gentile[2], E. Martino[2]
[1]UOS Patologie Della Coagulazione-Ematologia, Azienda Ospedaliera Cosenza, [2]UOC Ematologia, Azienda Ospedaliera Cosenza, Cosenza, Italy

PO339

Thrombosis in factor VII deficiency

J. Cabral[1,*], C. Calaza[1], M. Calheiros[1]
[1] Immunohemotherapy Service, ULS Braga, Braga, Portugal

PO340

Unusual Comorbid Conditions and Management of Two Siblings with Severe Factor XI Deficiencies: Spina Bifida and Legg-Calvé-Perthes

A. Kahraman[1], M. Yazol[2], G. Kayhan[3], H. Selek[4], M. Zinniroğlu[5], Z. Kaya[1,*]
[1]Pediatric Hematology, [2]Radiology, [3]Medical Genetics, [4]Orthopedics, [5]Physical Medicine and Rehabilitation, Gazi University Faculty of Medicine, Ankara, Türkiye

PO341

A Successful Surgery of Severe Scoliosis in a Child with Stormorken Syndrome: The first experience in the World

A. Unuvar[1,*], S. Sahin[1], Y. Yilmaz[1], N. Canbolat[2], A. K. Koltka[2], T. Akgul[3], S. Karaman[1]
[1]Division of Pediatric Hematology&Oncology, [2]Department of Anesthesiology, [3]Department of Orthopedics and Traumatology, Istanbul University, Istanbul School of Medicine, Istanbul, Türkiye

PO342

Acquired Hemophilia A: Case reports

N. Ferroudj[1,*], M. bensadok[1], M. terchi[1], N. zidani[1], S. nekkal[1]
[1]Hematology and blood bank, Beni Messous Hospital, Algeria

PO343

Bernard-Soulier syndrome, a rare bleeding disorder: experience of a single center in Algiers.

A. Salmi[1,*], N. Cherif[1], O. Gacem[1]
[1]pediatric hematology and oncology, The university hospital of Beni Messous, Algiers, Algeria

PO344

SLFN14 Gene Mutation-Related Platelet Disorder : A case report of normal platelet size.

S. Ahmed[1,*], A. Haroon[1], H. Alzahrani[1]
[1] Department of Hematology, Stem Cell Transplantation, and Cellular Therapy, Cancer Center of Excellence, King Faisal Specialist Hospital and Research Centre,, Riyadh, Saudi Arabia

PO345

Rare bleeding disorders: Diagnostic and therapeutic challenges

O. Grari[1,2,*], N. Douzi[1,2], N. Chahid[1,2], M. Slaoui[1], N. Trougouty [1], A. Berhili[1], A. Khermach[1,2], M. Bensalah[1,2], R. Seddik[1,2]
[1]Hematology, Mohammed VI University Hospital, [2]Faculty of Medicine and Pharmacy, Mohammed First University, Oujda, Morocco

PO346
ACQUIRED FXIII DEFICIENY SECONDARY TO A MYELODYSPLASTIC SYNDROME
N. Vilalta[1,*], G. Oñate[2], M. Triquell[1], M. Carrasco[1], J. Mateo[1]
[1]Hemostasis and Thrombosis Unit, [2]Hematology , Hospital de la Santa Creu i Sant Pau , Barcelona , Spain

PO347
Factor XIII deficiency- diagnose and treatment initiation
S. Hole[1,*], A. Halbrendt[1]
[1]Oslo University hospital, Center for rare disorders, Oslo, Norway

PO348
Duodenal Hematoma in A Child with Glanzmann thrombasthenia Causing Intestinal Obstruction
N. shams[1,*], S. Alavi[1], P. Eshghi[1], S. M. Aghapour[1], A. Zamani[1]
[1]Pediatric Congenital Hematologic Disorders Research Center, Research Institute for Children's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Islamic Republic Of

PO349
Inadequate investigation may fail to diagnose an underlying bleeding disorder in suspected NAI
K. Reynolds[1,*], J. Lancashire [1], J. Patel[1], J. Motwani[1]
[1]Haemostasis, Birmingham Children's Hospital, Birmingham, United Kingdom

PO350
Investigation of mutations in patients with Factor XIII Deficiency in southeast of Iran
M. naderi[1], S. Yaghoubi[2,*]
[1]Genetics of Non-communicable Disease Research Center, [2]Adolescents Health research center, Research institute of cellular and Molecular Science in Infectious Diseases, Zahedan University of Medical Sciences, Zahedan, Iran, Islamic Republic Of

PO351
Investigating the inhibitory level in patients with factor V deficiency as a Rare Bleeding Disorder in southeast Iran
M. naderi[1,*], S. Yaghoubi[2]
[1]Genetics of Non-communicable Disease Research Center, [2]Children and Adolescents Health research center, Research institute of cellular and Molecular Science in Infectious Diseases, Zahedan University of Medical Sciences, zahedan, Iran, Islamic Republic Of

PO352
Nurse Therapeutic Education Management for patients with non-acquired haemophilia treated with Emicizumab in France
C. CHENUEL[1,*], S. DELIENNE[2] on behalf of FIDEL'HEM Association (The French Association of Haemophilia Nurses)
[1]CHRU, Nancy, [2]CHU, Dijon, France

PO353
Experience of a Family and Transition Clinic in a Haemophilia Treatment Centre in the Netherlands
F. Yspeerd[1,*], M. Voskuilen[1], K. Bolhuis-van Dijken[1], M. Jansen[2], L. Hooimeijer[2], K. Meijer[1]
[1]Hematology, [2]Pediatric Hematology, University Medical Center Groningen, Groningen, Netherlands

PO354
Severe factor V - dated treatment modern demand
N. Larkin[1,*]
[1]National Coagulation Centre, St James Hospital, Dublin, Ireland

PO355
Knowledge and perspectives on haemophilia management and treatment: results of a Hospital-centre survey on haematology nurses.
L. Moralejo Cubero[1,*], C. Campoy Martínez[1], Y. Echarte Buil[1]
[1]Haematology, Hospital Universitario Miguel Servet, Zaragoza, Spain

PO356
Nursing care for patient with von Willebrand disease type 3 and complication of prostate cancer radiotherapy – a case report
B. Rakusic[1,*], J. Belev[1], E. Rankovic[1], A. Boban[1] on behalf of co authors: Josipa Belev, Ena Rankovic, Ana Boban
[1]DPT Hematology, UHC Zagreb, Zagreb, Croatia

PO357
Psychosocial care during novel therapies in haemophilia: a psychological framework
L. Haverman[1,2,3,*], L. Teela[1,2,3], G. O'Brien[4], P. Bučková[5], G. Golan[6], G. Rooney[7], K. Bartels[8], A. Torres-Ortuño[9], C. Burgess[10] on behalf of European Association for Haemophilia and Allied Disorders (EAHAD) psychosocial committee
[1]Child and Adolescent Psychiatry & Psychosocial Care, Amsterdam UMC location University of Amsterdam, Emma Children's Hospital, [2]Mental Health and Digital health, Amsterdam Public Health, [3]Child Development, Amsterdam Reproduction and Development, Amsterdam, Netherlands, [4]Royal Infirmary of Edinburgh, Haemophilia & Thrombosis Centre, Edinburgh, United Kingdom, [5]Department of Clinical Psychology, University Hospital Brno, Brno, Czech Republic, [6]Tel Aviv Medical University, Sheba Medical Centre, Tel Aviv, Israel, [7]St James's Hospital, The National Coagulation Centre, Dublin, United Kingdom, [8]University Hospitals Leuven, National Coordination Centre for Haemophilia, Leuven, Belgium, [9]Department of Psychiatry and Social Psychology, Facylty of Medicine, University of Murcia, Murcia, Spain, [10]a charity providing psychological support to the bleeding disorder community, Haemophilia and Bleeding Disorders Counselling Association, Cambridgeshire, United Kingdom

PO358
Psychosocial Impact of Bleeding Disorders on Women: A Cross-Sectional Study of Mental Health and Social Well-being
A. R. Sawal[1,*]
[1]HTC, Hemophilia Patients Welfare Society, Rawalpindi, Pakistan

PO359
Educational Needs of Health Care Providers regarding Women and Girls with Bleeding Disorders – an online survey
K. Van Galen[1,*], R. Kadir[2], N. Skouw-Rasmussen[3], R. d'Oiron[4], G. Golan[5], P. Elfvinge[6], S. Gouw[7], K. Gomez[8], D. Carbonero[9], M. Lavin[10] on behalf of Women and Girls+ with Bleeding Disorders Working Group
[1]Center of Benign Haematology, Thrombosis and Haemostasis, Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands, [2]obstetrics and gynaecology, Royal Free Hospital London, London, United Kingdom, [3]EHC, Brussels, Belgium, [4]Reference Centre for Hemophilia and Rare Bleeding Disorders, AP-HP, Bicêtre Hospital, University Paris-Saclay and UMR S1176 INSERM, Le Kremlin-Bicêtre, France,

[5]Israel National Hemophilia Center, Sheba Medical Center, Ramat Gan, Israel, [6]Karolinska, Stockholm, Sweden, [7]Pediatric Hematology, Amsterdam University Medical Center Amsterdam, Amsterdam, Netherlands, [8]Haemophilia Centre and Thrombosis Unit , Royal Free London, London, United Kingdom, [9]EAHAD, Brussels, Belgium, [10]National Coagulation Centre, Irish Centre for Vascular Biology, School of Pharmacy & Biomedical Sciences, RCSI , Dublin, Ireland

PO360

Enhancing Accessibility of Psychosocial Support for Patients with Hemophilia via Zoom, WhatsApp and Telemedicine

H. Landa[1,*], D. Bashari[1], R. Tiktinsky[1], T. Barazani Brutman[1], G. Kenet[1]
[1]The Israeli National Haemophilia and Thrombosis Institute, Sheba Tel HaShomer Medical Center,, Ramat Gan, Israel

PO361

Recommendations for Psychosocial Support During Gene Therapy: Results from an EAHAD Interdisciplinary Roundtable

L. Teela[1,2,3], G. O'Brien[4], P. Bučková[5], G. Golan[6], G. Rooney[7], K. Bartels[8], A. Torres-Ortuño[9], C. Burgess[10], L. Haverman[1,2,3,*] on behalf of European Association for Haemophilia and Allied Disorders (EAHAD) psychosocial committee
[1]Child and Adolescent Psychiatry & Psychosocial Care, Amsterdam UMC location University of Amsterdam, Emma Children's Hospital, [2]Mental Health and Digital health, Amsterdam Public Health, [3]Child Development, Amsterdam Reproduction and Development, Amsterdam, Netherlands, [4]Royal Infirmary of Edinburgh, Haemophilia & Thrombosis Centre, Edinburgh, United Kingdom, [5]Department of Clinical Psychology, University Hospital Brno, Brno, Czech Republic, [6]Tel Aviv Medical University, Sheba Medical Centre, Tel Aviv, Israel, [7]St James's Hospital, The National Coagulation Centre, Dublin, United Kingdom, [8]University Hospitals Leuven, National Coordination Centre for Haemophilia, Leuven, Belgium, [9]Department of Psychiatry and Social Psychology, Facylty of Medicine, University of Murcia, Murcia, Spain, [10]a charity providing psychological support to the bleeding disorder community, Haemophilia and Bleeding Disorders Counselling Association, Cambridgeshire, United Kingdom

PO362

Unmet Clinical and Psychosocial Needs in Women with Coagulopathies: Findings from a National Meeting

L. Quintas-Lorenzo[1,2,*], L. Pérez-González[3], L. Formariz-González[1,4], M. Sánchez-Ruiz[3], M. Ruiz-Madrid[1,5], D.-A. García-Diego[3,6]
[1]Women's Committee, Fedhemo - Spanish Hemophilia Federation, Madrid, [2]Agadhemo - Galician Hemophilia Asociation, Vigo, [3]Fedhemo - Spanish Hemophilia Federation, Madrid, [4]AHEVA - Biscay Hemophilia Asociation, Bilbao, [5]ASPHA - Andalucian Hemophilia Asociation, Malaga, [6]COCEMFE - Spanish Physical and Organic Disability Confederation, Madrid, Spain

PO363

The Impact of Social Stigma on Mental Health in Hemophilia Patients: A Mixed-Methods Study

A. R. Sawal[1,*]
[1]HTC, Hemophilia Patients Welfare Society, Rawalpindi, Pakistan

PO364

Biopsychosocial challenges of fathers with a child with severe hemophilia in Iranian culture: a qualitative phenomenological study

M. Niknam[1], A. Eshghi[1,2,*], A. Salimitoopghara[1], M. Firoozi[1], F. Maleki[1], B. Habibpanah[2], P. Eshghi[2]

[1]Department of Psychology, Faculty of Psychology and Education, University of Tehran, [2]Pediatric Congenital Hematologic Disorders Research Center, Research Institute for Children's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Islamic Republic Of

PO365

Post-Earthquake Challenges in the Management of Haemophilia Patients: A Situation Assessment

A. M. Demir[1], S. Aytaç[2,*], S. Karaman[3], M. Altunbaş[4]
[1]Hematology, Trakya University, Edirne, [2]Pediatric Hematology, Hacettepe University, Ankara, [3]Pediatric Hematology, İstanbul University, [4]Medical Affairs, Novo Nordisk, İstanbul, Türkiye

PO366

Exploring the concept of pain in children & adolescents with haemophilia

V. KOLIOPOULOU[1,*], A. MICHALOPOULOU[1], A.-M. TSILIA[2], G. GOULA[2], A. DETTORAKI[1], I. STAMATI[1], A. PAPANIKOLAOU[2], H. PERGANTOU[1]
[1]Haemophilia Centre / Haemostasis and Thrombosis Unit, [2]Department of Child and Adolescent Psychiatry, Athens University Medical School, "Aghia Sophia" Children's Hospital, Athens, Greece

PO367

Occupational Therapy - The Developing role of Occupational Therapy within Haemophilia Services Haemophilia Comprehensive Care Centre, Belfast Health & Social Care Trust

C. Forde[1,*], G. Benson[1]
[1]Haemophilia Comprehensive Care Centre, BHSCT, Belfast, United Kingdom

PO368

Autism spectrum disorders in children at a major UK hemophilia center

K. Reynolds[1,*], N. Lawson[1], J. Lancashire [1], J. Patel[1], J. Motwani[1]
[1]Haemostasis Department , Birmingham Children's Hospital, Birmingham, United Kingdom

PO369

Introduction to the UK PIVOT-VWD Study: A direct to community, cross-sectional study to capture and quantify the impact, voice and outcomes of VWD.

G. Morgan[1,*], K. Burt[2], J. Traunter[3], D. Morgan [2], H. Yarnall[2], S. Bristow[1]
[1]DHT.health , North West, [2]The Haemophilia Society, London, [3]The University of Hull, Hull, United Kingdom

PO370

Exploring unmet patient needs in haemophilia: a qualitative study on joint bleed treatment in the US

E. Mastroianni[1,*], C. Brink Scholz[2]
[1]Novo Nordisk A/S, Hillerød, [2]Novo Nordisk A/S, Zurich, Denmark

PO371

Health network to improve access to high-cost medicine for patients with hemophilia in the province of Salta, Argentina

M. S. Cruz[1,*], J. P. Ortiz [1], J. A. Santillan [1], A. Guzman[1]
[1]Fundacion de la Hemofilia de Salta, Salta, Argentina

PO373

Factors Associated with Health-Related Quality of Life in Obligate Carrier Women of Haemophilia

F. Manzano-Di Zeo[1], C. Sossa[1,*], A. Peña-Castellanos[1,2], M. Ochoa-Vera[1], M. Luna-González[1,2], M. T.-B. Tarazona-Bohórquez[1]
[1]Universidad Autónoma de Bucaramanga (UNAB), [2]Programa para el Tratamiento de Enfermedades Hemato-Oncológicas de Santader (PROTEHOS), Floridablanca, Colombia

PO374

Assessing the benefits of emicizumab prophylaxis for haemophilia A with inhibitors: Budget impact and cost utility analysis

H. Priyanka[1,*], D. Johns[1]
[1]twinsMedicity, Kudinji, India

PO375

Kinesiophobia in the parents of hemophilic patients

E. GÜLER KAZANCI[1,*], E. Kaya[2], T. DANDİNOGLU[2], G. R. AKSOY[1]
[1]Pediatric Hematology and Oncology , [2]Physical Medicine and Rehabilitation , Bursa City Hospital, Bursa, Türkiye

PO376

Loss of productivity and medical costs incurred with haemophilia Among Employees insured with large employer-Sponsored Insurance

H. Rozario[1,*], D. A. Johns[1]
[1]twins medicity, kuinji, India

PO377

Factors associated on quality of life in prophylaxis treatment in Thai hemophilia patients

B. Pongtanakul[1,*], N. Narkbunnam[1]
[1]Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

PO378

Remote Monitoring of Physical Function in Children with Haemophilia: Reliability of Telehealth for the Six-Minute Walk, Vertical Jump, and Triple Hop Tests

D. Stephensen[1,*], M. Bladen[2], H. Harbidge[3], T. Pellatt-Higgins[4], F. Hashem[4], E. Saloniki[5], C. Dodd[3], F. Sayers[6], N. Hubert[2], L. Crossley[7], L. Gueran[8], P. Fenlon[9], D. Hopper[10], E. Hope[10], K. Millar[11], R. Barnard[12], K. MacNeil[13]
[1]Faculty of Medicine, Health & Social Care, Canterbury Christ Church University, Canterbury, [2]Haemophilia Centre, Great Ormond Street Hospital for Children NHS Foundation Trust , London, [3]Haemophilia Centre, East Kent Hospitals University NHS Foundation Trust, [4]Centre for Health Services Studies, University of Kent, Canterbury, [5]Department of Applied Health Research, University College London, London, [6]Haemophilia Centre, Belfast City Hospital, Belfast, [7]Haemophilia Centre, University Hospital of Wales, Cardiff, [8]Haemophilia Centre, Oxford Children's Hospital, Oxford, [9]Haemophilia Centre, Sheffield Children's NHS Foundation Trust, Sheffield, [10]Haemophilia Centre, Royal Victoria Infirmary, Newcastle, [11]Haemophilia Centre, Bristol Royal Hospital for Children, Bristol, [12]Haemophilia Centre, Royal London Hospital, London, [13]Haemophilia Centre, Royal Hospital for Children, Glasgow, United Kingdom

PO379

A review of current MSK bleeding episodes in children with Severe Haemophilia A and B in a UK regional paediatric comprehensive care centre

K. Millar[1,*], A. Knott[1]

[1]Bristol Royal Hospital for Children, Bristol, United Kingdom

PO380

Relationship Between Upper Extremity Joint Health and Functional Status in Adults with Haemophilia

T. Poyraz Isleyen[1,2,*], E. Tarakcı[3], S. Koç Şenol[4], B. Zülfikar[4]
[1]Physical Therapy and Rehabilitation, Bahçeşehir University, [2]Institute of Graduate Studies, İstanbul University-Cerrahpasa, [3]Physical Therapy and Rehabilitation, İstanbul University-Cerrahpaşa, [4]Oncology Institute, Hereditary Bleed-ing Disorders Unit, İstanbul University, İstanbul, Türkiye

PO381

Case Study: Improved Gait of Hemophilia Patient with a
Total Hip Arthroplasty and Total Knee Arthroplasty using the CAREN Base Virtual Reality System

R. Tiktinsky[1,*], L. Landa[1], G. Kenet[1]
[1]The National Hemophilia and Thrombosis Center, Sheba Medical Center , Tel Hashomer, Ramat Gan, Israel

PO382

PHYSIOTHERAPY CLINIC for the musculoskeletal health of patients with haemophilia: A SINGLE CENTER EXPERIENCE

V. Begnozzi[1,*], E. A. Boccalandro[1], E. Privitera[2], M. Retucci[1], S. A. Sfregola[1], S. Arcudi[1], A. Giachi[1], L. P. Solimeno[1], R. Gualtierotti[1,3], F. Peyvandi[1,3]
[1] Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, [2]Dipartimento Professioni Sanitarie, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, [3]Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy

PO383

Reduced peak oxygen uptake with preserved pulmonary function in children with hemophilia versus healthy controls

A. Çakmak-Önal[1,*], F. Tan[2], E. Çalık-Kütükcü[1], S. Aytaç[3], H. Güney-Deniz[1]
[1]Faculty of Physical Therapy and Rehabilitation, Hacettepe University, Ankara, [2]Faculty of Health Sciences, Department of Physical Therapy and Rehabilitation, Atatürk University, Erzurum, [3]Faculty of Medicine, Pediatric Hematology, Hacettepe University, Ankara, Türkiye

PO384

The relationship between pain catastrophizing, physical activity level and balance confidence in adult people with hemophilia

S. Önal Aykar[1,2,*], Z. Demirci[1], F. Şahin[1]
[1]Ege Adult Hemophilia and Thrombosis Center, İzmir, [2]Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Aydın Adnan Menderes University , Aydın, Türkiye

PO385

An examination of barriers and facilitators to physical activity and sports participation in children and adolescents with haemophilia (in Ireland).

P. Loughnane[1,2,*], M. Kennedy[3], B. Nolan[1], J. Gormley[2]
[1]Children's Health Ireland at Crumlin, [2]Discipline of Physiotherapy, University of Dublin, Trinity College, Dublin, [3]Department of Health and Nutritional Sciences, Atlantic Technological University, Sligo, Ireland